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Foreword
The inspiration for this research was born in the 1990’s during my rotation as a trainee paediatrician 
attached to the teaching hospitals affiliated to the University of the Witwatersrand Medical 
School, Johannesburg, South Africa. 
The knowledge and concern then about C. trachomatis infections in pregnant women and new-
borns was superceded by other more prevalent infections like syphilis, tuberculosis and HIV. 
However, one particular patient drew my attention to C. trachomatis infection as an important 
pathogen requiring equal or increased attention. 
Despite full intervention a newborn on ventilatory support in the neonatal intensive care unit 
did not improve. Re-evaluation of the medical files, revealed that a conjunctivitis had been 
ignored in the history and initial examination. A subsequent nasopharyngeal swab from the 
newborn, and urine test from the mother, confirmed the diagnosis of a C. trachomatis infection. 
After appropriate treatment the newborn improved and could be taken off the ventilator. 
I discovered that obstetricians did not routinely test women for C. trachomatis and neither was 
it common protocol for paediatricians to test newborns and infants with respiratory tract infection 
for C. trachomatis. So, in a in a time, place and population with a high prevalence of syphilis in 
pregnant women and newborns and a rapidly increasing prevalence of HIV/AIDS, no attention 
was paid to another, easily treatable, sexually transmitted infection that could also cause severe 
disease in women and infants.
Wondering how often this preventable and treatable condition was being missed in our paediatric 
and obstetric population, I set out to find answers. Unwittingly, that was the beginning of this 
PhD thesis.  
Returning to practise in the Netherlands, it became clear that chlamydial screening for pregnant 
women and testing infants with conjunctival or respiratory tract infection for C. trachomatis was 
also not part of medical routine. I continued to research and this time to work towards a PhD.
9
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Abbreviations
AIDS acquired immune deficiency syndrome
ANC antenatal clinic
ATP adenosine triphosphate 
°C  degree Celsius 
CEA cost-effectiveness analysis 
CER cost-effectiveness ratio 
CI confidence interval
CPP chronic pelvic pain 
CT Chlamydia trachomatis
CTI+ Chlamydia trachomatis-positive infants 
CTI- Chlamydia trachomatis-negative infants 
CTM+ Chlamydia trachomatis-positive mothers
CTM- Chlamydia trachomatis-negative mothers
CS&T costs for screening and treatment 
DFA  direct fluorescent antibody test 
DNA deoxyribonucleic acid
EB  elementary body
EIA enzyme immunoassay 
ELISA enzyme-linked immunosorbent assay
FIR foetal inflammatory response 
FTA-ABS fluorescent treponemal antibody test 
GP general practitioner 
HC hybrid capture 
HELLP  haemolysis, elevated liver enzymes, low platelets 
HIV Human Immunodeficiency Virus
hMPV human Metapneumovirus 
hRSV human Respiratory syncytial virus 
LCR  ligase chain reaction
LGV  lymphogranuloma venereum 
LPS lipopolysaccharide 
MIF  micro-immunofluorescence 
MIR  maternal inflammatory response 
MOMP major outer membrane protein
NAAT  nucleic acid amplification technique
NASBA  nucleic acid sequence based amplification 
NO number 
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OR odds ratio
PAR  population attributable risk 
PCR polymerase chain reaction 
PF population fraction 
PI placental inflammation 
PID  pelvic inflammatory disease 
PROM premature rupture of membranes
QALY  quality-adjusted life year 
RB  reticulate body 
RNA ribonucleic acid
RPR rapid plasma reagin 
RR relative risk
SC savings on complications 
SD standard deviation 
SDA  strand displacement amplification 
SDS  standard deviation score
SGA small for gestational age 
STD sexually transmitted disease 
STI sexually transmitted infection 
TMA  transcription-mediated amplification 
TPHA Treponema pallidum haemagglutination assay 
WHO World Health Organisation 
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Background
Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) world-
wide. Chlamydia is responsible for a significant proportion of genitourinary tract infections in adult 
males and females, but like STIs in general, it is primarily a woman’s health care issue since the 
manifestations and consequences are more damaging to the reproductive health of women than of 
men [1]. Acute C. trachomatis infection is easy to treat, but the majority of chlamydial infections 
remain asymptomatic and untreated, and may lead to serious complications such as pelvic inflam-
matory disease (PID), ectopic pregnancy, infertility and chronic pelvic pain in women [2-5], as well 
as conjunctivitis and respiratory tract infection in infants [6, 7]. The health-economic impact of C. 
trachomatis infections may therefore be enormous. Vaccines are not yet available. Hence, health gain 
and financial benefits can only be achieved by active case finding and treatment of C. trachomatis 
infection, which can be done on an individual level or nationwide in a screening program.
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Chapter 1
Aims of this thesis
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This thesis concentrates on C. trachomatis infections in pregnant women and infants by evaluat-
ing the burden of disease, test methods, and the costs of prenatal screening in order to provide 
information for future discussions about the need for routine screening for C. trachomatis in 
pregnant women in the Netherlands. 
The specific aims and research questions were:
The assesment of the prevalence and risk factors during pregnancy
 1. What is the prevalence of C. trachomatis infection during pregnancy?
 2. What are risk factors for C. trachomatis infection in pregnant women?
The evaluation of complications of C. trachomatis infection during pregnancy
 3. Is C. trachomatis infection during pregnancy associated with increased risk for adverse 
  pregnancy outcomes such as stillbirth, premature birth and low birth weight?
 4. What is the rate of C. trachomatis transmission from women to neonates?
 5. Can we find evidence of vertical transmission by detection of C. trachomatis in infants 
  with neonatal conjunctivitis and respiratory disease?
The assesment of the feasibility of screening
 6. Is pooling of urine specimens a good method to improve cost-effectiveness of screening for 
 C. trachomatis during pregnancy?
 7. Is routine screening for C. trachomatis a cost-effective approach during pregnancy? 
The studies that were done in order to address the research questions are shown in figure 1.
16
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Figure 1 Studies presented in this thesis
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Epidemiology 
The World Health Organization estimated in 2001 that per year 92 million new cases of 
Chlamydia trachomatis infection occur worldwide [1]. This includes 5.2 million new cases of 
genital infection yearly in Western Europe of which around 2.9 million are in women, and 15.9 
million in Sub-Saharan Africa of which 8.2 million in women (Table I). Overall, there is an 
increasing trend in the chlamydia positivity rate in recent years, which may partly be due to the 
development of more sensitive laboratory tests, but also reflects a true increase in infections [2]. 
Global prevalence rates of C. trachomatis infection in asymptomatic nonpregnant women and 
pregnant women are similar and have been described to vary from 0-37% depending on the 
study population, setting and test methods used [3, 4]. Unexpectedly, high prevalences of up to 
17% have been documented for asymptomatic women in Europe [5]. 
Table 1 Estimated number of new cases of genital Chlamydia trachomatis infection 
 among adults, by gender and United Nation global region
Region New cases (million)
Males Females
North America 1.77 2.16
Western Europe 2.28 2.94
Australia & New Zealand 0.14 0.17
Latin America & Carribean 4.19 5.12
Sub-Saharan Africa 7.65 8.24
North Africa & Middle East 1.71 1.44
Eastern Europe & Central Asia 2.72 3.25
East Asia & Pacific 2.56 2.74
South & South East Asia 18.93 23.96
Overall 41.95 50.03
In the Netherlands approximately 60.000 new C. trachomatis infections are diagnosed annually 
with an increase in infections observed in recent years [6-8]. Of these infections 35.000 will be 
in women [9, 10]. The first nationwide screening study in the Netherlands showed a prevalence 
rate of 2.5% in women [11]. However, differences have been reported between regions ranging 
from 0.6% to 4.9% [11-14].
20
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Transmission
Since most C. trachomatis infections, up to 80% in women and 50% in men, remain asympto-
matic, a pool of individuals with subclinical infection continues to be responsible for the risk of 
transmission within the community [15]. Transmission among adults mainly occurs via sexual 
contact (horizontal transmission) and the transfer of infected secretions which primarily affect 
mucosal membranes such as the cervix, urethra, rectum, conjunctiva and pharynx. Transmission 
can also occur via genital-ocular auto-inoculation. 
The rate of transmission depends on the sexual behaviour within a community, the mean dura-
tion of infectiousness and the probability of transmission per sexual contact. Many risk factors 
have been associated with transmission of C. trachomatis infection. Young age and urban resi-
dence are the most consistent risk factors, but low socio-economic class, single marital status, 
ethnicity, and educational level have also been associated with chlamydial infection [16-18]. 
Behavioural factors that have been associated with increased risk for C. trachomatis transmission 
are first sexual contact at young age, multiple sexual contacts, intercourse with a recent new 
partner, other STIs, previous history of an STI, a partner with current or previous STIs, the use 
of oral contraceptives, lack of barrier contraceptives, and late antenatal clinic booking [17-19]. 
Overall, male-female and female-male transmission rates have been found to be similar being 68% [20].
Importantly, during passage through an infected birth canal C. trachomatis can be spread to 
newborns, who subsequently may become infected (vertical transmission) [21, 22]. The risk of 
vertical transmission is directly related to the prevalence of C. trachomatis infection in pregnant 
women and has been reported to be as high as 75% [22-24].
Microbiology
Chlamydia genus
Chlamydia trachomatis is a member of the family Chlamydiaceae, or Chlamydiales [25], which 
contain a single genus: Chlamydia. Chlamys, ‘mantle’, refers to the appearance of the intracyto-
plasmic inclusions in infected cells, which lie like a mantle around the host cell’s nucleus. 
Because of this appearance, chlamydiae were initially thought to be protozoa and described as 
‘mantled animals’. Later chlamydiae were classified as viruses because of their small size, and as 
parasites because of their obligate intracellular existence. At present chlamydiae are known as 
highly specialized gram-negative bacteria.  
Chlamydia species
Regularly, new members of the Chlamydiaceae are discovered. For humans the most important 
species are Chlamydia trachomatis and Chlamydia pneumoniae as well as Chlamydia psittaci, 
21
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although the latter is not a primary human pathogen [25-27]. The common characteristics of 
chlamydiae are a small genome size (1.1-1.2 million nucleotides), a deficiency in endogenous 
adenosine triphosphate (ATP) production, a characteristic bacterial double cell wall (inner and 
outer membrane) similar to other gram-negative bacteria with a lipopolysaccharide but absent 
peptidoglycan layer, the presence of RNA, DNA, and ribosomes, and the own protein and 
nucleic acids synthesis. The distinguishing characteristics between the three species C. trachomatis, 
C. pneumoniae and C. psittaci concern the host range, clinical expression, and antibiotic suscep-
tibility (due to folate biosynthesis), the staining characteristics (due to glycogen inclusions), inclusion 
morphology, shape of the elementary body, and limited DNA sequence homology.
Chlamydia trachomatis
C. trachomatis was the first Chlamydia species to be discovered and has been divided into sub-
groups based on antigenic variation in the major outer membrane proteins (MOMP) (serovars) 
and on clinical expression (biovars) (Table 3). Seventy percent of the non-lymphogranuloma 
venereum (LGV) STIs are due to serovars D, E and F, which are also responsible for neonatal 
disease. This thesis deals with urogenital and neonatal chlamydial infections, which are caused 
by serovars D through K.
Chlamydia trachomatis structure and pathophysiology
C. trachomatis has a distinctive two-phased life cycle (Figure I), in which it has two characteristic 
forms: an elementary body and a reticulate body [28]. The elementary body (EB) is a small (0.3-
0.4 mm), metabolically inactive but infectious form. EBs have a rigid, thick outer membrane 
Table 2 Distinguishing characteristics of Chlamydia species
C. trachomatis C. pneumoniae C. psittaci
host humans, mice humans rarely in humans,
birds, mammals,
clinical disease see page 34 pneumonia, asthma,
endocarditis, arthritis
pneumonia
folate biosynthesis yes no no
inclusion staining idodine+ iodine- iodine-
inclusion morphology oval, granular,
vacuolar
oval, dense variable, dense,
lucent 
elementary body shape coccoid pear-shaped coccoid
DNA homology 10 100 10
22
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that is composed primarily of lipopolysaccharide and proteins with extensive disulfide cross-
linking bonds among three cysteine proteins (MOMP, OmpB and OmpA), which make EBs 
resistant to the environmental conditions outside the host cells. The reticulate body (RB) is a 
larger (0.9 mm), intracellular metabolically active and replicating form, which is not infectious. 
RBs have a fragile membrane that lacks the cross-linking disulphide bonds.
The developmental cycle of C. trachomatis begins when infectious EBs attach to receptors on the 
surface of a suitable host cell (non-ciliated columnar cells and macrophages) and induce their 
own entry via receptor-mediated endocytosis. The ingested EBs reside within a membrane-
limited endosome and escape fusion and destruction by the host cells’ lysosomes by an unknown 
mechanism that may be based on its unique cell wall structure. The EBs enlarge, the DNA becomes 
less dense, ribosomes are produced that make the cytoplasm more granular, and transformation 
Table 3 Chlamydia trachomatis subgroups with presentation and distribution
Serovar Biovar Distribution
A, B, Ba, C trachoma Asia, Middle East, 
Africa, Australia
B, D, Da, E, F,
G, Ga, H, I, Ia, J, K
urogenital, neonatal,  
and ocular disease
worldwide
L1, L2, L2a, L3 LGV worldwide
Figure 1 Chlamydia trachomatis life cycle
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follows into metabolically active RBs (within 8 hours after infection). The RBs remain strictly 
intracellularly, synthesize mRNA and multiply via binary fission in the cytoplasm of the host 
cells while using the host cell’s ATP, sugars and amino acids for continued multiplication. This 
way the RBs form multiple intracellular microcolonies or inclusion bodies in the endosomes 
(12-30 hours). During the process chlamydiae protect the cells in an organism against destruction 
by the organism’s immune system. However, there is still a lack of consensus regarding the 
mechanisms involved in apoptosis inhibition by chlamydiae [29]. After a large number of fis-
sions, the RBs reorganize, condense and transform back into infectious EBs at which time an 
inclusion body contains up to 1000 infectious EBs (30-40 hours). Eventually, the nutrients of 
the host cell expend and the host cell releases the EBs by exocytosis, after which infection of 
other cells may take place (48-72 hours).
The infected cells produce and secrete inflammatory mediators, stimulate infiltration of poly-
morphonuclear cells and lymphocytes, and secrete growth factors, which leads to the formation 
of lymphoid follicles, chronic inflammation and even fibrotic changes. After an incubation 
period of 10 days (varying between 7 and 21 days) patients may present with a variety of clinical 
manifestations that result from the host inflammatory response and cell destruction. The host is 
assumed to have some sort of protective immune response to C. trachomatis since chlamydial 
infections have been found to be self-limiting in up to 45% of infected women [30, 31], and 
asymptomatic infection may last for months or even years [32, 33]. However, the acquisition of 
protective immunity due to previous infection remains unclear. This is especially so since it has 
been shown that recurrent infection increases the risk for complications [34, 35]. Due to its 
latent, insidious and potentially chronic character the severity and chronicity of chlamydial 
disease varies.
Diagnosis
Nucleic acid amplification techniques (NAATs) are the latest diagnostic methods and have 
replaced culture as the method of choice to diagnose chlamydial infection [36]. Hower, various 
laboratory tests, culture and non-culture methods, are available and may still be used to diag-
nose C. trachomatis infection (Table 4) [36-40]. The sensitivity of these tests depends on several 
factors: the nature of the disease and subsequent site of specimen collection, the quality of the 
specimen and transport medium, the intrinsic quality of the test and the precision with which 
the test is carried out. 
Specimen collection
Appropriate sites for specimen collection in women are the cervix, vulva or urethra, but in spe-
cific clinical disease rectal, nasopharyngeal or throat swabs may be the most suitable; also a 
24
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needle aspiration of the fallopian tube or a biopsy sample from the endometrium or inguinal 
bubo. Appropriate sites for specimen collection in infants are the conjunctiva, posterior 
nasopharynx, throat or tracheobronchial aspirates, and ear. In children only in case of suspected 
abuse vaginal, urethral or rectal specimens may be indicated. NAATs are not approved for these 
sites in children. However, recently NAATs on urines were shown to be adequate forensic tests, 
being more sensitive than culture and less invasive than swabs, and would reduce further trauma 
and discomfort for abused children [41].
When taking specimens one should remember that chlamydiae are obligate intracellular patho-
gens and that specimens should therefore contain epithelial cells from the involved sites rather 
than exudates. Purulent discharges are inappropriate for most tests and should be removed from 
the site before a sample is taken. A variety of swabs can be used to obtain specimens. However, 
toxicity related to material in swabs may be a problem. The tip of a swab should preferably be 
made of cotton or dacron, because these cause less inhibition than nylon or alginate tips. The 
shaft is best made of inert material such as plastic or metal instead of wood [38, 39]. A cytobrush 
appears to collect more cells than swabs and is prefered for endocervical specimens. 
Specimens taken for culture require a special transport medium such as a 2SP medium, which 
contains buffered salt, sucrose and antibiotics (vancomycin, gentamicin, amphotericin B and 
nystatin) that do not inhibit chlamydiae. Furthermore, specimens should be stored refrigerated 
at 4°C if inoculated in cell monolayers within 48 hours, or frozen at -70°C if stored for a longer 
period [38, 39]. Specimens for other tests should be handled according to the companies’ 
instructions for procedures to maintain the sensitivity and specificity of the test.
Diagnostic methods
Different diagnostic methods to detect C. trachomatis infection, advantages and disadvantages 
are shown in table 4 [37-42]:
1. Cytology
 Cell scrapings can be stained with iodine and examined for the presence of typical intracyto-
plasmic inclusion bodies. Since none of the other Chlamydia species contains glycogen, which 
stains with iodine, the finding of iodine-stained inclusion bodies is specific for C. trachomatis 
[43]. This method is not as sensitive as the other methods to diagnose C. trachomatis infection, 
but still exceeds 60% when diagnosing neonatal conjunctivitis. 
2. Culture
 Culture has been considered the gold standard for many years, and still is the method of 
choice for medico-legal issues and antibiotic susceptibility testing. Cell culture is the only 
method to detect viable organisms and therefore highly specific to diagnose C. trachomatis 
infection [37]. C. trachomatis is able to grow when specimens are brought to 37°C, inoculated 
onto the surface of confluent monolayers of susceptible cells (McCoy, Hela or BHK lines), 
centrifuged (to enhance ingestion of chlamydiae), and overlaid with a growth medium that 
25
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contains cyclohexamide to inhibit host cell metabolism and increase the number and size of 
inclusions [44, 45]. After 48-72 hours incubation of the infected cell monolayers, infected 
cells can be examined for growth of inclusion bodies, which may be microscopically visualised. 
Culture has several disadvantages (Table 4) and a low sensitivity for urine [46]. 
3. Antigen detection by enzyme immunoassay technique
 Enzyme immunoassay (EIA) techniques can be used to detect C. trachomatis [47]. The specimen 
is incubated with an antibody preparation to detect chlamydial lipopolysaccharide (LPS) on 
the membrane of EBs, after which an enzyme substrate is added to produce coloured particles 
that can be visualized microscopically or measured by spectrophotometry [48]. EIA has several 
disadvantages (Table 4) and is less sensitive than cultures and NAATs (40% to 75%); espe-
cially with samples that contain few organisms (asymptomatic infections). The specificity is 97%. 
4. Direct fluorescent antibody detection
 For the direct fluorescent antibody test (DFA) the specimen is smeared on a slide, air dried 
and fixed, and stained with fluorescein-labeled monoclonal antibodies that will bind to the 
major outer membrane proteins (MOMP) of EBs in specimens, which produces brightly 
fluorescing and morphologically distinctive particles for direct visualization by fluorescence 
microscopy [49]. DFA is highly specific (99%) compared to culture, but has several disadvantages 
(Table 4) and a sensitivity of 75% to 85% [50].
5. Serology
	 Serological tests are of limited value in diagnosing C. trachomatis infection in the individual, 
because antibodies may not occur in every case of uncomplicated infection and tests do not 
distinguish current from past infection (Table 4). However, serology may be used to detect 
chlamydial infection in newborns and in women with tubal factor infertility or LGV infection 
when aspirates are not obtainable [51-54]. Detection of IgG antibodies in newborns requires 
repeat testing to observe a rise in antibody titre. Detection of high titer (³32) anti-chlamydial 
IgM antibodies is indicative of recent infection and infection in newborns [55]. 
6. Nucleic Acid Amplification Techniques
 NAATs are based on the amplification and detection of specific DNA or RNA nucleic acid 
sequences unique to C. trachomatis in specimens. NAATs are using different target, probe or 
signal amplification technologies such as polymerase chain reaction (PCR), strand displace-
ment amplification (SDA), transcription-mediated amplification (TMA), nucleic acid 
sequence based amplification (NASBA), ligase chain reaction (LCR; now defunct), or hybrid 
capture (HC). NAATs are highly specific (99% to 100%) if cross contamination is avoided 
and have a high sensitivity of 90-95%, which is higher than in all other methods [46, 56-58]. 
Furthermore, NAATs can be used with non-invasive specimens such as urine or vulvovaginal 
swabs [42, 59], are (partially) automated and may be used for pooling of specimens, which 
makes them very useful for screening programs [60-62]. The main disadvantages of NAATs 
are the costs and the reduced performance if inhibitors (oestrogens, nitrates, crystals, blood) 
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are present in urine specimens [59, 63]. Furthermore, not all NAATs are equal in performance 
and some in house NAATs from several laboratories and for example the Cobas Amplicor do 
not detect strains with no plasmid or the Swedish new variant of C. trachomatis, for which 
Table 4 Diagnostic methods for Chlamydia trachomatis
Method Advantages Disadvantages
Diagnosis
NAATs:
• PCR
• SDA
• TDA
• high sensitivity
• suitable for urines and vulvo-vaginal swabs 
• validated for extragenital sites, including 
rectum
• automated
• expensive
• not licensed for extragenital sites
• less performance in presence of inhibitors
• false positive results in some settings
Cell culture • suitable for all specimen types
• only method to detect viable organisms
• special transport medium
• not automated
• labour intensive 
• requires expertise
• time consuming (3-7 days)
• subject to contamination
• low sensitivity for urine
• toxicity of certain swabs during pregnancy
• storage at -70°C if processing is delayed
EIA • inexpensive
• quick results
• rapid handling of large numbers of specimens
• can be accepted for point-of-care tests
• not appropriate for urines and  
self-collected swabs
• low sensitivity; especially in specimens with 
few organisms (40-70%)
• false positives: cross reaction with other 
chlamydiae and bacteria
DFA • suitable for all specimen types
• rapid turnaround time
• labour intensive
• time consuming
• not automated
• requires expertise
• low sensitivity for urine
Serology • suitable when other specimens are not obtain-
able
• not standardized
• no distinction between past and present 
infection
• need of acute and convalescent samples
• antibodies not always present in uncompli-
cated infections
Specimen collection
Clinician-obtained • ability to obtain good quality  
samples, which may increase  
sensitivity e.g. endocervical swab 
• less acceptable to some patients
• more expensive in staff time
Self-collected • more acceptable to some 
• less clinical facilities required
• self-collected vaginal swabs equivalent to 
clinician-obtained swabs
• may be less sensitive
NAATs: nucleic acid amplification techniques, PCR: polymerase chain reaction, SDA: strand displacement amplification, 
TMA: transcription-mediated amplification, EIA: Enzyme immunoassay, DFA: Direct fluorescent antibody test
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new dual target NAATs using real-time PCR have been developed [64, 65]. The most com-
monly used NAATs at the moment are the BD Probe Tec, Cobas Amplicor, Cobas TaqMan, 
and Aptima. 
Clinical manifestations
C. trachomatis infections in pregnant women
Pregnant women are a special group at risk for C. trachomatis infection. Pregnant women may 
develop chlamydial clinical disease like non-pregnant women, but are also at increased risk for 
post-partum PID and subsequent infertility (Table 5). Moreover, C. trachomatis infection during 
pregnancy may jeopardise the pregnancy. The majority, up to 80%, of pregnant and non-preg-
nant women, have no symptoms. Others have only mild symptoms or non-specific symptoms 
that easily escape medical attention [66]. Some of these infections may disappear spontaneously, 
others become overt cervicitis or urethritis or persist silently [67]. Cervicitis or urethritis may 
lead to non-specific and usually mild complaints like mucopurulent vaginal discharge, vaginal 
pruritis, intermenstrual or post-coital bleeding, dysuria or frequent micturation. 
Persisting ‘silent infections’ may remain local, but may also ascend to the upper genital tract 
where they can lead to symptomatic or asymptomatic inflammation of the endometrium, salp-
inges and abdominal cavity resulting in endometritis/chorioamnionitis, salpingitis and pelvic 
inflammatory disease (PID) [66, 68, 69]. Women with endometritis may present with low-
grade abdominal pain, cramping and intermenstrual bleeding. Salpingitis may lead to tubal 
scarring and subsequent subfertility or infertility or ectopic pregnancy [70, 71]. Women with 
PID may suffer from dyspareunia, pelvic pain, fever, chills, nausea and vomiting. However, usually 
the symptoms of PID are non-specific and may be missed. Further spread of infection in the 
abdominal cavity will lead to peritoneal inflammation and can result in a perihepatitis with 
hepatic capsular “violin string” adhesions, the Fitz Hugh Curtis syndrome, causing nausea and 
vomiting and right upper quadrant pain, as well as in perisplenitis, perinephritis, periappendicitis, 
perisigmoiditis and peritonitis [72-74]. Furthermore women may develop proctitis, inclusion 
conjunctivitis, and arthritis. Arthritis may in 1% of women occur isolated, as a so-called sexually 
acquired reactive arthritis, but may also be part of a Reiter’s syndrome, a triad of symptoms 
consisting of urethritis, conjunctivitis and polyarthritis with or without dermatitis and balanitis 
(in men) [75]. Lymphogranuloma venereum  has been described rarely in pregnant women [76, 77]. 
The effect of pregnancy on C. trachomatis infection
Various changes in pregnancy have been proposed to influence C. trachomatis infection [16]. 
First, cervical ectopy (related to oestrogen levels) has been associated with C. trachomatis infec-
tion and with pregnancy, and is supposed to increase shedding of C. trachomatis and/or increase 
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the risk of chlamydial infection. Second, pregnancy is physiologically immunosuppressive and 
alters the immune responses progressively with advancing gestation to a nadir at 32 weeks gestation, 
which may affect replication and shedding of C. trachomatis. Third, maternal antichlamydial 
antibodies cross the placenta after 5-6 weeks gestation and are found in breastmilk, which may 
be protective for neonates. However, if such protection occurs, then it is only partial since up to 
75% of neonates who are exposed to C. trachomatis at the time of delivery become infected [22, 24].
The effect of previous C. trachomatis infections on pregnancy 
Pelvic Inflammatory Disease 
Pelvic Inflammatory Disease (PID) is a consequence of a complex interaction of genetic, immu-
nological and bacterial virulence factors, set off by multimicrobial etiology including enteric 
organisms, Mycoplasma hominis and possibly Ureaplasma urealyticum, anaerobic bacteria, and 
sexually transmitted organisms such as Neisseria gonorrhoeae and C. trachomatis [78-82]. Com-
parison of PID studies is difficult because of the difference in clinical case definition in the 
absence of pathognomonic symptoms and signs, the absence of one simple accurate diagnostic 
test over time and the various pathogens that cause PID. The role of C. trachomatis in PID, 
however, has been well established but there are different opinions concerning the complication 
rate following C. trachomatis infection in PID. These are explained by differences in classification, 
incorrect diagnoses, and unjustified attribution of complications to chlamydial infections. The 
incidence of PID following C. trachomatis infection has been described to vary from 0% to 
40%, with the lowest rate in asymptomatic women and the highest in symptomatic women or 
women at higher risk for an ascending STI (e.g. symptomatic partner, co-infection with other 
STI, visitor STD clinic) [31, 35, 68, 82-92]. Recurrent chlamydial infections have been found 
to result in an increasing risk of PID after each infection, which may be as high as a four-fold 
increased risk of PID after two previous chlamydial infections and a six-fold increased risk after 
three or more infections [35, 68]. PID may result in chronic pelvic pain (18% to 30%), ectopic 
pregnancy, and tubal factor infertility. 
Ectopic pregnancy
Previous C. trachomatis infection has been associated with an increased risk for ectopic preg-
nancy in subsequent pregnancies as evidenced by serological studies, isolation of C. trachomatis 
from fallopian tubes, and detection of chlamydial DNA from cervical, endometrial or salpingec-
tomy tissues [93-97].The risk of a chlamydia-related PID leading to ectopic pregnancy, has been 
estimated to vary between 0% and 25% [34, 83, 91, 93, 98].The risk for ectopic pregnancy has 
been found to increase with increasing number of infections: two-fold after two previous 
chlamydial infections and five-fold after three or more infections respectively [35].
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Infertility
C. trachomatis is considered the most important cause of tubal obstruction leading to tubal 
infertility [99, 100]. IgG antibody testing for C. trachomatis has been proposed as a first screening 
test in combination with medical history taking to identify women with tubal factor subfertility 
[54, 101-103]. High rates of C. trachomatis infection, past and present, were found to be associ-
ated with infertility by many investigators [104-108]. Overall, the risk of chlamydia-related PID 
leading to infertility, has been estimated to vary between 0% and 20% [34, 71, 83, 108, 109].
The effect of C. trachomatis infection on pregnancy
In the first trimester
Spontaneous abortion
C. trachomatis has been associated with spontaneous (recurrent) abortions though not consist-
ently [110-116]. In one study 14 of 66 (21%) women from couples with spontaneous abortions 
consulting a reproductive medicine centre tested positive for C. trachomatis by direct immun-
ofluorescence compared to 23 of 59 (9%) women without spontaneous abortions and term 
pregnancies (P<0.05). The infection rate increased to 69% (P<0.001) when both partners of the 
couples were considered. In the same study, oocytes from hamsters were incubated with sperma-
tozoa from the infected partners and, using electron microscopy, the presence of C. trachomatis 
was demonstrated on the surface of and inside the oocytes [110]. Various models for studying 
the pathogenesis of chlamydia-related spontaneous abortions have been proposed, being either 
direct zygote infection or an immune response to heat shock proteins expressed by the zygote 
that is triggered by previous C. trachomatis infection, and reactivation of latent chlamydial infec-
tion or endometrial damage from past chlamydial infection [110, 114].
Induced abortion
Women undergoing surgical or medical termination of pregnancy have been reported to have 
C. trachomatis infection with prevalences as high as 17% [117-120]. If left untreated, up to 72% 
of C. trachomatis infected women with termination of pregnancy may develop PID, endometritis 
or salpingitis post-surgery, which risk has been shown to reduce drastically to 8% or even less 
with treatment [87, 120-124]. 
In the second and third trimester
Premature rupture of membranes, premature delivery, prematurity
C. trachomatis infection during pregnancy may influence pregnancy outcome and has been 
associated with chorioamnionitis, premature rupture of the membranes and premature delivery 
[125-144]. However, the literature regarding these effects of C. trachomatis infection on preg-
nancy outcome is conflicting, which seems primarily due to differences in study design, population 
and microbiological tests that were used [125-151]. While earlier studies based on serology and 
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cultures were at variance regarding premature delivery, there seems to be growing evidence with 
the use of the more recent NAATs that prematurity is associated with C. trachomatis infection 
[140-145]. 
Low birth weight
C. trachomatis infection during pregnancy has been associated with low birth weight [128, 132, 
133, 136, 152-155]. However, again the literature is contradictory and other studies could not 
confirm such an association [142, 145, 154, 156]. In some studies an association of C. trachomatis 
infection with low birth weight could only be confirmed in subgroups of women with elevated 
antichlamydial IgM antibodies [130, 157] .
Stillbirth
Between 10% and 25% of stillbirths in developed countries, and even more in developing countries, 
may be caused by infection [158]. C. trachomatis has been indicated to cause in utero infection 
in the fetus leading to stillbirth [127, 159]. Intrauterine chlamydial infection has been evi-
denced by infants with chlamydial infections who were born via caesarean section [160-164]. In 
cord blood of prematurely born neonates IgM antibodies to C. trachomatis can be detected, 
which is suggestive of fetal chlamydial infection [149]. This hypothesis was confirmed by studies 
in which 12%-16% of neonates born to chlamydia-positive women had anti-chlamydial anti-
bodies in their cord blood [165, 166]. 
Post-partum effects of C. trachomatis infections
C. trachomatis infection during pregnancy may continue after delivery and cause post-partum 
endometritis, salpingitis, or PID [167-169]. In contrast to early post-partum endometritis, 
which occurs within 48 hours after delivery and is mainly related to caesarean section, C. tracho-
matis usually causes late post-partum endometritis and develops between two days and six weeks 
after delivery [167, 170, 171]. Women are usually not seriously ill, but may present with sec-
ondary post-partum haemorrhage, with or without fever, lower abdominal pain, and vaginal 
discharge. C. trachomatis infection can spread into the fallopian tubes resulting in salpingitis 
increasing the risk for infertility or ectopic pregnancy.
The effect of C. trachomatis infections on newborns and infants
At the time of delivery, newborns may acquire C. trachomatis infections from pregnant women 
during passage through an infected birth canal. Hence, the occurrence of C. trachomatis infec-
tion in infants is directly related to the prevalence of maternal urogenital infections [163, 172]. 
Infants born by caesarean section are considered to be at lower risk of acquiring chlamydial 
infection [140]. However, several anecdotal reports of C. trachomatis infections in newborns 
after delivery by caesarean section, with and without premature rupture of the membranes, 
31
Chlamydia trachomatis infections in pregnant women and infants
Binnenwerk Chlamydia trachomatis.indb   31 6/16/10   12:39 PM
indicate that intrauterine infection can occur [161-163, 173-175]. The overall risk for infants 
born to women with untreated chlamydial infections is approximately 50-75%, with infection 
occurring at one or more anatomic sites [22]. 
Conjunctivitis
Neonatal conjunctivitis, also called inclusion conjunctivitis of the newborn, is the most com-
mon symptomatic disease and has been shown to occur in 20% to 50% of infected infants [22, 
24]. C. trachomatis has become the most frequent identifiable cause of neonatal conjunctivitis 
in many countries [176, 177]. The majority of chlamydial conjunctivitis cases resolve spontane-
ously during the first few months of life. However, untreated persistent infection can lead to 
acute discomfort and distress for both infant and mother. Infants usually present at the end of 
the first week until three months of age with tears, redness and swelling of one or both eyes and 
serosanguinous or mucopurulent discharge [178-182].  Although conjunctivitis may be quite 
severe, corneal ulceration or follicle formation rarely occur in infants and recovery is without 
visual impairment. Once neonatal conjunctivitis has been diagnosed, simultaneous silent infec-
tion of the respiratory tract should be suspected which in due time may cause acute or chronic 
respiratory disease [23, 178, 183].  
Upper respiratory tract infection
The nasopharynx is the most frequent site for perinatally acquired C. trachomatis infection and 
may be found in up to 70% of infants born to chlamydia-positive women [22]. Nasopharyngeal 
infection is usually asymptomatic and self-limited, but may cause rhinitis as part of the prodromal 
phase of chlamydial pneumonia [184-186]. However, isolated cases of chlamydial rhinitis 
neonatorum have been described in infants between two weeks and three months of age pre-
senting with a running nose, sneezing, nasal obstruction and epistaxis that may be complicated 
with apnoeic episodes [187-189]. Nasopharyngeal infection may be preceeded by conjunctivitis 
suggesting that conjunctivas are portals of entry and that the nasopharynx is infected by a 
‘spillover’ effect [23, 190]. However, nasopharyngeal infection has also been described in infants 
with pneumonia without evidence of conjunctivitis suggesting that infection occurs in its own 
right in the respiratory tract [184]. Though nasopharyngeal infection is usually self-limited, 
infection may also persist for periods of up to one year [183]. 
There are sporadic reports of C. trachomatis being cultured from infants with acute otitis media, 
otitis media with effusion and chronic otitis media, suggesting that chlamydial infection may be 
a potential cause of otitis media in early infancy [186, 191, 192]. 
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Lower respiratory tract infection
C. trachomatis pneumonia occurs in 5% to 20% of exposed infants [21, 22]. Chlamydial pneumonia 
has a characteristic presentation with an insidious onset between 3 and 12 weeks of age. Infants 
are usually afebrile with mild tachypnoea and a distinctive pertussis-like, non-productive staccato 
paroxysmal cough but without a post-tussic inspiratory whoop. The coughing spells may result 
in cyanosis and emesis. If left untreated, the cough may take weeks to clear and can run a long 
and intermittent course. Chest auscultation reveals vesicular breath sounds and crepitations, 
with no or minimal wheezing. Chest X-rays are not distinctive and show hyper-expansion with 
bilateral, diffuse interstitial and patchy alveolar infiltrates [22, 24, 186, 193]. Serum immu-
noglobulins are consistently elevated and mild absolute eosinophilia (> 300 cells/mm3) may be 
present. Nasopharyngeal aspirates usually test positive for C. trachomatis. Respiratory failure has 
been described with chlamydial infection, but is relatively uncommon and mainly described in 
premature infants. 
In premature neonates C. trachomatis pneumonia has been described to present differently. C. 
trachomatis has been detected in the pharynx, trachea, and lungs as early as within 48 hours after 
birth in premature neonates [164, 174, 175]. Initially, the clinical presentation has been 
described as resembling the idiopathic respiratory distress syndrome and may improve. However, 
newborns may develop apnoeic spells and feeding problems, and may go on to need ventilatory 
support [164, 173, 194]. In contrast to X-rays in full-term neonates, in premature neonates 
lung hypoexpansion and hypotransparency have been reported with a fine reticular pattern, 
bilateral opacifications and cystic interstitial emphysema [173]. 
An association has been suggested between C. trachomatis lower respiratory tract infection in 
infancy and bronchial hyperresponsiveness and asthma. However, the literature regarding such 
associations is sparse [195, 196].
Infection at other sites
C. trachomatis has been detected in the rectum and vagina of newborns. Usually, there is a late 
appearance of infection at these sites, which raises the question whether it is the result of direct 
infection at birth or rather spread from the respiratory tract [21, 197]. Since untreated perinatally 
aquired chlamydial infection may persist for years, C. trachomatis may still be detected in the 
urogenital tract of children [198, 199]. Chlamydial detection in children, however, should 
always raise the suspicion of sexual abuse [200, 201], and require, in view of the medico-legal 
aspects, a thorough anamnesis, physical examination and appropriate microbiological analysis 
[41, 202-204].
33
Chlamydia trachomatis infections in pregnant women and infants
Binnenwerk Chlamydia trachomatis.indb   33 6/16/10   12:39 PM
Treatment
C. trachomatis spends most of its life inside epithelial cells, as previously described. The meta-
bolically active RB is likely to be the primary target of antibiotics, which act by inhibition of 
protein synthesis, growth and division of RBs, DNA-gyrase activity, or cell wall biosynthesis. 
Table 5 Clinical spectrum of Chlamydia trachomatis infection in women and infants
Women Pregnant women Newborns
cervicitis cervicitis 
urethritis urethritis 
bartholinitis bartholinitis
endometritis chorioamnionitis
salpingitis salpingitis
pyosalpinx pyosalpinx
ovarian abscess ovarian abscess
perihepatitis perihepatitis
perisplenitis* perisplenitis*
perinephritis * perinephritis*
periappendicitis* periappendicitis*
perisigmoiditis* perisigmoiditis*
peritonitis peritonitis
abortion intra-uterine death*
ectopic pregnancy 
stillbirth dysmaturity*
premature rupture membranes
premature labor
premature delivery prematurity*
postpartum endometritis
postpartum salpingitis
proctitis proctitis
conjunctivitis conjunctivitis conjunctivitis
reactive arthritis reactive arthritis
pharyngitis pharyngitis pharyngitis
rhinitis
pneumonia
otitis media
infection of rectum*
infection of vagina*
*rare complication of C. trachomatis or not proven
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These processes occur inside the inclusions within the host cells, which is why pharmacotherapy 
requires the use of antibiotics that are able to gain acces to and exhibit activity in intracellular 
sites. The 72-hour life cycle and the asynchronous nature of chlamydial infection requires the 
maintenance of adequate antibiotic concentrations in tissues for longer periods.  
Treatment in adults
To prevent recurrent transmission within partnerships, it is important that management of 
chlamydial infection is based on similtaneous treatment of infected women and their sexual 
partners [205]. Table 6 shows the current treatment choices for C. trachomatis infection as rec-
ommended by the CDC [206, 207]. Single-dose treatment with azithromycin has been a sig-
nificant development in the management of chlamydial infection. Azithromycin concentrates 
extensively within cells and has a long tissue half-life, which makes it suitable for a single dose 
regimen. A seven-day course of doxycycline is the recommended alternative with a similar cure 
rate [208], but other macrolides, quinolones, sulfonamides, rifampicin and clindamycin also 
have activity against C. trachomatis. Antibiotic resistance has only rarely been described for 
chlamydial infection 
Treatment in pregnant women
In most countries there is agreement that both symptomatic and asymptomatic chlamydia-
positive pregnant women should be treated considering the possibility of complications. However, 
for pregnant women therapeutic options are more restricted due to the fetus. The teratogenic 
and embryopathic effects of tetracyclines on bone growth and dentition, the interference of 
doxycycline and quinolones with normal skeletal growth, the growth retardation and postnatal 
hemorrhage in neonates due to rifampicin, and the increased risk that sulfonamides have in 
bringing about neural tube, cardiovascular and urinary tract defects or adverse pregnancy out-
comes has been described in humans or animal studies [209-213]. The current alternatives for 
treatment of chlamydial infection in pregnant women include multi-day treatment with eryth-
romycin, amoxycillin or clindamycin, or single dose treatment with azithromycin [214, 215]. 
In recent years, more data and clinical experience have become available to support the efficacy, 
safety and tolerability of azithromycin in pregnant women [206]. Azithromycin has been shown 
to be similar or better in treatment success compared to erythromycin and amoxicillin, and to 
cause similar or less total adverse events and gastrointestinal side effects (nausea, diarrhoea, 
abdominal pain), which resolve spontaneously [216-221]. Azithromycin may be more costly, 
but the price is decreasing and its single dose regimen will increase compliance, which makes it 
increasingly more cost-effective [215]. 
Erythromycin used to be the first choice to treat chlamydial infection during pregnancy. Eryth-
romycin has been shown to be similar or less efficacious than azithromycin, but the long treatment 
period, multiple dosing regime, and gastrointestinal side effects decrease compliance significantly 
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[217, 218]. In addition, the use of erythromycin in pregnant women and infants has been asso-
ciated with an increased risk for maternal hepatotoxicity  and infantile pyloric stenosis [222-
224].
Amoxicillin has similar or less efficacy, similar or more reported side effects, and similar or less 
compliance than azithromycin [216-218, 221]. In addition, amoxicillin also requires a long 
treatment period and multiple dosing regime, and may precipitate hypersensitivity reactions 
[225]. Therefore, amoxicilin is less convenient for pregnant women than azithromycin, but is 
still a recommended alternative during pregnancy and first choice in some countries, including 
the Netherlands. 
Clindamycin may be another alternative but is more expensive than azithromycin, has gastroin-
testinal side effects similar to erythromycin and may cause pseudomembranous enterocolitis 
[215, 226]. 
Treatment in infants 
Systemic treatment has been demonstrated to be more effective than topical application of anti-
biotics to treat chlamydial neonatal conjunctivitis, and infection at other sites [227]. Official 
guidelines for neonatal chlamydial infection at present recommend systemic treatment with 
erythromycin (Table 6) [207, 227]. However, erythromycin in neonates and infants has been 
shown to cause gastrointestinal side effects, increase the risk for hypertrophic pyloric stenosis, 
and to have drug interactions with theophylline, carbamazepine, warfarin, cyclosporin and dig-
oxin [223, 228]. In addition, a 20% treatment failure rate has been described, which may 
require multiple courses of therapy [182, 229, 230]. Single-dose azithromycin might be an 
alternative for the treatment of neonatal chlamydial infection. However, although single-dose 
azithromycin is being used in paediatric endemic trachoma [231, 232], only one study has been 
published regarding the use of azithromycin in neonatal inclusion conjunctivitis [233]. Single 
Table 6 Treatment in uncomplicated Chlamydia trachomatis infections
First choice Alternative
women Azithromycin po
1 g in single dose 
Doxycycline po
100 mg bid X 7 days
partners Azithromycin po
1 g in single dose 
Doxycycline po
100 mg bid X 7 days
pregnant women Azithromycin po
1 g in single dose
Amoxicillin po
500 mg tid x 7 days
infants Erythromycin po
12.5 mg/kg qid x 14 days
Azithromycin po
20 mg/kg daily x 3 days
PO: orally
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dose treatment (20 mg/kg) was compared to a three-dose regimen (20 mg/kg once daily for 
three days) and the authors concluded that the efficacy of the latter regimen was similar to 
erythromycin treatment, but that modification of the concentration of azithromycin might improve 
efficacy even further. More data on the tolerability and efficacy of azithromycin and other new 
oral macrolides such as clarithromycin or roxithromycin, for infants are still needed [234]. 
Prevention
C. trachomatis prophylaxis
Previously, ocular prophylaxis with 1% silver nitrate ophthalmic drops, 0.5% erythromycin 
ophthalmic ointment, 1% tetracycline ointment and 2.5% povidone-iodine (betadine) solution 
have been used attempting to prevent chlamydial disease in newborns and infants. However, 
topical prophylaxis may prevent some chlamydial neonatal conjunctivitis, but complete irradi-
cation of chlamydial conjunctivitis and prevention of subsequent chlamydial infection at other 
sites cannot be achieved [235, 236]. 
C. trachomatis screening
By definition screening is a public health service in which members of a defined population, 
who do not necessarily perceive they are at risk of or are already affected by a disease or its com-
plications, are asked a question or offered a test to identify those individuals who are more likely 
to be helped than harmed by further tests or treatment to reduce the risk of a disease or its com-
plications [237]. 
The above seems applicable to C. trachomatis infection in pregnant women suggesting a good 
potential for C. trachomatis screening during pregnancy. However, in order to decide whether 
screening for C. trachomatis infection in pregnant women would be a good policy to serve public 
health we should consider the 10 screening criteria as described by Wilson and Jungner [238]. 
These state that (1) there should be knowledge about the disease, which means that the disease 
should be acknowledged as an important problem, that the natural course of the disease should 
be adequately understood, and that there should be a recognisable latent or early symptomatic 
stage. (2) There should be knowledge about the test, which includes that a test should be suit-
able for examination, acceptable to a population, and case finding should be a continuous process 
instead of an occasional action. (3) Treatment for the disease should be acceptable for patients 
with recognized disease, should be readily available and there should be an agreed policy con-
cerning whom to treat. (4) The costs of case finding should be economically balanced in relation 
to possible expenditures on medicale care as a whole.
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Pregnant women as a target population for C. trachomatis screening
The natural history of C. trachomatis infection is largely known, although infection in pregnant 
women is not yet completely understood. C. trachomatis is infection is sexually transmitted, 
which means that pregnant women by definition belong to the population at risk for chlamydial 
disease. Up to 80% of women are asymptomatic. Hence, they will not seek medical care or 
perceive themselves as being at risk and may easily be missed while they may already be affected 
by chlamydial infection or its complications. C. trachomatis infection in pregnant women may 
therefore be an important problem for women and infants, but the extent of the health problem 
can vary between different populations. Chlamydial infection has been shown to occur in 
between 0.6% and 4.9% of sexually active women in the Netherlands and may be assumed to 
be similar among pregnant women [11-13]. Some of these women will develop PID, ectopic 
pregnancies and become subfertile or infertile [9, 10]. By offering pregnant women a test, 
infected women can be identified and treated to reduce the risk of chlamydial disease and its 
complications. Moreover, detection and treatment of chlamydia-positive women will reduce the 
risk of chlamydial infection and complications for their offspring, and also for their partners. An 
advantage of screening during pregnancy may be that most pregnant women, at least in the 
developed world and in increasing numbers also in the developing world, spontaneously seek 
antenatal care. Such visits offer a good opportunity to include a C. trachomatis test as part of a 
routine antenatal care program, as is done by some members of the European Union and other 
countries [207, 239, 240]. 
Tests for C. trachomatis infection during pregnancy
Various test methods for C. trachomatis were described before. The high sensitivity and automa-
tion of the more recent NAATs make these tests suitable for screening. In addition, NAATs have 
a high performance while using non-invasive specimens such as first-void urines or self-obtained 
vulval or vaginal swabs, which will lower the threshold for women to participate in screening 
[42, 241, 242]. Urines are well-accepted specimens by the majority of women and are mainly 
used for screening at present [242, 243]. Bacterial loads are generally lower in urines, which may 
have an adverse effect on NAATs and produce a lower detection rate in urines than in clinician-
obtained swabs [243-245]. NAAT results in urines have also been shown to be inferior when 
urines are from asymptomatic women [57, 244, 246], and when pooling of urine specimens has 
been applied [62, 247, 248]. In contrast, others have described similar sensitivity with pooling 
compared to individual testing [60, 61]. To date limited data are available regarding NAAT 
performance on urines from pregnant women, especially while pooling urines. 
Acceptable treatment against C. trachomatis infection for pregnant women
Efficacious antibiotics available to treat C. trachomatis infection in pregnancy have been 
described on page 36. Single dose treatment with azithromycin will increase compliance and is 
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readily available in most countries and is now recommended by the CDC [206, 207, 240]. 
However, in some countries the drug of choice is still under debate, this being the case in the 
Netherlands, where amoxicillin is still advised [249, 250].
Cost-effectiveness of screening  
Apart from the target population, availability of non-invasive sampling, high quality testing and 
effective treatment, the cost-effectiveness of screening is the other important issue to address in 
order to assess the implementation of a C. trachomatis screening program [251-255]. From a 
health economic point of view, the costs of detecting chlamydia-positive individuals during a 
screening program should be in balance with the possible expenditures on medical care as a 
whole. Previous reports regarding C. trachomatis screening in family planning clinics showed 
that screening was cost-effective, but queried the relative merits of total screening versus selec-
tive screening and the best diagnostic test method to be used [256, 257]. Screening programs 
are generally considered to be cost-effective if the prevalence of C. trachomatis infection is higher 
than 3 to 6% [42, 255, 258-260]. This was also concluded from a Dutch study regarding ante-
natal screening for asymptomatic C. trachomatis infection in pregnancy [259]. However, at that 
time no actual data were available concerning pregnant women and pregnancy outcome in the 
Netherlands. 
Psychosocial consequences of screening
Screening women for C. trachomatis infection, and other STIs, with subsequently a positive test 
result may lead to negative feelings such as guilt, shame, stigmatisation, a negative effect on 
womens’ self-esteem, a sense of responsibility, self-recrimination, awareness of their body and 
sexuality, anxiety for partner notification and distrust within a relationship, and uncertainty 
about future reproductive health [261-263]. The literature regarding the psychosocial conse-
quences of chlamydial screening is limited, especially in pregnant women. During pregnancy 
such emotions may even weigh more heavily, especially because a diagnosis of chlamydial infec-
tion would commonly be unexpected and because women may have an additional feeling of 
responsibility for and uncertainty about the consequences for the health of the fetus. Before 
implementing a screening program, the impact of diagnostic communication and retesting after 
treatment of infection as well as possible psychosocial consequences are important aspects to be 
taken into account [263, 264].
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Abstract
Objective The study was conducted to assess the prevalence of sexually transmitted infections in 
pregnant urban South African women and to determine associations with demographic and socio-
economic characteristics, and clinical symptoms.
Methods Pregnant urban South African women presenting for delivery to the Johannesburg 
Hospital were eligible for the study. Data concerning maternal health, socio-economic circum-
stances and life style risk factors were obtained through questionnaires. Results of serological 
testing for HIV and syphilis and delivery characteristics were obtained from obstetric or antenatal 
clinic records. At inclusion a urine specimen was obtained and blood was taken for serology. 
Results Overall, 48% of 766 women carried one or more sexually transmitted infection during 
their pregnancy. Infection with HIV, Treponema pallidum, Chlamydia trachomatis and Neisseria 
gonorrhoeae was detected in 18%, 23%, 12% and 9% of women, respectively. Rates of detection 
of HIV, active syphilis and chlamydial infection, were found to be age-dependent. Predictive 
factors for infection included lack of antenatal care, multiple pregnancies, being unmarried, 
unemployed status and lack of a regular monthly income.
Conclusions The prevalence of sexually transmitted infections was extremely high among these 
pregnant urban South African women. Not elicited symptoms, but differences in demographic 
and socio-economic characteristics were associated with infection.
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Introduction
Worldwide, sexually transmitted infections (STIs) remain a significant public health problem 
with a disproportionate burden of the complications of infection affecting women of reproduc-
tive age and their infants. STIs do not only cause acute and chronic illness in these women, but 
may also jeopardise procreation by inducing infertility and pregnancy loss, while significantly 
contributing to perinatal morbidity and mortality [1, 2]. In addition, conventional STIs have 
been shown to increase both the risk of acquisition of HIV and increase the rates of shedding of 
HIV in persons already dually infected. In turn, HIV infection may alter the presentation and 
clinical course of conventional STIs [3-5]. The World Health Organization has estimated an 
incidence of 340 million new cases of curable STDs among adults in 1999 [1]. In South Africa, 
STIs are endemic but have increased in number with the emergence of the HIV/AIDS epidemic 
and have a rate of approximately 5,000-15,000 cases per 100,000 [6, 7]. In this study, we have 
determined the prevalence of selected STIs in a group of pregnant urban South African women 
presenting for delivery. A special focus was made on HIV, syphilis, chlamydial and gonococcal 
infections since these can be transmitted vertically from mother to child. We have also attempted 
to identify demographic factors that indicate increased risk of maternal infection. 
Methods
Patients
The study was undertaken in the Department of Obstetrics and Gynaecology at the Johannes-
burg Hospital, South Africa, which is the major academic hospital that provides primary and 
secondary care for the population of Johannesburg as well as tertiary care for the whole of the 
Gauteng province. The hospital serves a population covering all socio-economic classes and 
races, but most obstetric patients are of lower socio-economic status. At the time of the study 
black women constituted 96% of all deliveries. In order to avoid confounding factors and 
because the number of women in other groups (white, coloured, Indian) were too small, the 
study focused on black women. Some pregnant women seek antenatal care while others attend 
clinics at the hospital, or are referred as a result of complications. Women were not approached 
for inclusion in the study if they required emergency caesarean section after presentation to the 
obstetric ward, had an (incomplete) abortion, or were fully dilated upon arrival. Overall, 935 
consecutive black pregnant women delivering at the hospital between October 1996 and January 
1997 were considered eligible for inclusion in the study. Most women spoke English; otherwise 
the study was explained in their home language. Women were excluded if complete microbio-
logical and serological STI results were not available either as a result of refusal of testing or 
failure to trace results, if urine could not be obtained before delivery, or because specimen bottles 
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were empty on arrival in the laboratory. Eventually, the data generated in 766 cases were 
 analyzed.
Data collection
In each case, a female doctor or nurse administered a questionnaire. Data were collected con-
cerning maternal health and socio-economic circumstances, including maternal age, parity and 
gravidity, antenatal clinic attendance, underlying disease and substance abuse, as well as marital 
status (traditional western or African style), number of sexual partners, employment and residen-
tial area. Socio-economic information such as medical insurance status and a regular monthly 
income of the women’s household was obtained from a computerized outpatient record system, 
which was also used to verify employment status and location of residence. Results of serological 
testing for HIV and syphilis were obtained from obstetric or antenatal clinic records, if available, 
or as a result of testing on admission to the study. Subsequently, following delivery, information 
about the mode of delivery, gestational age, birth weight and gender of the newborn were 
obtained from obstetric and neonatal records.
Laboratory methods
If testing had not been performed prior to entry into the study, women were asked to provide a 
venous blood sample to test for syphilis and HIV (following pre-test and post-test counselling 
guidelines). Maternal HIV status was determined using two different HIV ELISA tests: the 
third generation HIV1/2 test (Abbott Laboratories, North Chicago, USA) and the Access 
HIV1/2 test (Sanofi Diagnostics Pasteur S.A., Marnes la Coquette, France). Screening for syphilis 
was undertaken using the rapid plasma reagin (RPR) test (Immutrep, Omega Diagnostics, 
Alloa, Scotland) and the Treponema pallidum haemagglutination assay (TPHA). Positive reactions 
were confirmed by a fluorescent treponemal antibody test (FTA-ABS). For the purpose of this 
study, active infections were defined as follows: (1) a positive TPHA with a positive RPR titre 
greater or equal to 1:4 with or without a positive FTA-ABS or (2) a positive TPHA with a 
positive RPR titre equal to 1:2 with a positive FTA-ABS IgM. Fresh, first-void urine specimens 
were tested for chlamydial and gonococcal infection using the Ligase Chain Reaction (LCx, 
Abbott Laboratories, Abbott Park, IL, USA).
Statistical methods
Percentages and continuous variables were compared between groups using the Mann-Whitney 
test or Chi-square/Fisher’s exact test. Multivariate analyses for putative risk factors for the presence 
of any STI were performed using logistic regression. After adjusting for age, the association 
between various STIs was investigated using the Mantel-Haenszel procedure. P=0.05 (two-sided) 
was considered the limit of significance.
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Consent
The study was approved by the Committee for Research on Human Subjects of the Witwatersrand 
University, Johannesburg, South Africa and written informed consent was obtained from all participants.
Results
A total of 766 pregnant women were screened for all four STIs (HIV, syphilis, chlamydial and 
gonococcal infection). Overall, 366 (48%) women were found to be infected with at least one 
STI at the time of sampling; 35% had one STI and 13% had mixed infections (11% with two, 
1% with three and a single woman with all four). Patient characteristics for the total group as 
well as differences in characteristics between women with and without an STI are shown in table 1. 
Although the median age of the study subjects was 26 years, the youngest was 13 and only a 
third of women were primigravida. The majority was unmarried (70%) and had received ante-
natal care (93%) during the current pregnancy. A minority reported underlying diseases such as 
diabetes, hypertension, or renal disease. Substance abuse was rare. Almost one-third stated they 
were employed, but several unemployed participants reported a regular monthly income for 
their household. Only four women had private medical insurance. After inclusion into the 
study, 20% of women delivered by caesarean section. 
Table 1 Characteristics of the total population, and women with and without an STI 
Characteristics women
Total
n=766
No STI 
n=400
Any STI
n=366 P-value
age 26 (13-44) 26 (15-44) 26 (13-44) 0.60
parity 1.2 (1.3) 1.1 (1.3) 1.3 (1.2) 0.004
pregnancy 2.4 (1.3) 2.3 (1.3) 2.5 (1.3) 0.001
antenatal care 709 (93) 378 (95) 331 (90) 0.04
vaginal delivery 621 (81) 318 (80) 303 (83) 0.30
husband 229 (30) 136 (34) 93 (25) 0.01
employment 251 (33) 143 (36) 108 (30) 0.08
regular income 295 (39) 167 (42) 128 (35) 0.05
underlying disease 81 (11) 42 (11) 39 (11) 1.00
alcohol use 14 (2) 6 (2) 8 (2) 0.60
tobacco use 9 (1) 5 (1) 4 (1) 1.00
STI: sexually transmitted infection, n: number
Age given in median (range); parity, gravidity in means (SD); others in number of patients (%)
61
STIs in pregnant urban SA women
Binnenwerk Chlamydia trachomatis.indb   61 6/16/10   12:39 PM
Between women with and without an STI no difference was found in age distribution, rates of 
caesarean section, presence of an underlying disease or substance abuse. However, univariate 
analyses showed a significant difference between the two groups in respect of parity (P=0.004), 
gravidity (P=0.001), rates of attendance for antenatal care (P=0.04) as well as marital status 
(P=0.01) and the availability of a regular monthly income (P=0.05). Differences in employment 
status also tended towards significance (P=0.08). Women with an STI did not report more 
genitourinary symptoms during the three-month period prior to delivery than those without an 
STI. In addition, pregnancy outcome reflected by gestational age (P=0.70) and birth weight 
(P=0.20) were similar for both groups as were rates of neonatal admission. Neonatal death was 
recorded twice as often among newborns born to women with an STI: 14 (4%), compared to 8 
(2%) of those born to uninfected women. However, this difference was not found to be significant 
(P=0.33).
Associations between demographic characteristics and the presence of any STI when employing 
multivariate analyses were: history of two or more pregnancies (with no difference between 
women with two, three or more pregnancies), being single, and unemployed (Table 2). The lack 
of antenatal clinic attendance (univariate analysis P=0.04) tended towards significance (P=0.07). 
Grouping the women according to the number of associated factors present (two or more pregnancies, 
single marital status, no employment and lack of antenatal care), it was noted that the STI 
prevalence in women with no factor present was 13%, while the prevalence rate was 75% in 
those with four factors present (Figure 1).
Table 2 Multivariate analysis of risk factors for an STI in pregnant women
Risk factor Odds ratio* (95% CI) P-value
age
• group 2: 20-24 years 0.8 (0.4-1.5) 0.44
• group 3: 25-29 years 0.8 (0.4-1.5) 0.42
• group 4: ≥ 30 years 0.7 (0.4-1.5) 0.38
no antenatal care 1.7 (1.0-3.0) 0.07
partner ≥ 1 boyfriend 1.8 (1.3-2.5) <0.001
no employment 1.4 (1.0-1.9) 0.05
pregnancy ≥ 2 2.2 (1.5-3.3) <0.001
STI: sexually transmitted infection
* Reference categories are age group 1 < 20 years, antenatal care, husband, employment and first pregnancy respectively
62
Chapter 3
Binnenwerk Chlamydia trachomatis.indb   62 6/16/10   12:39 PM
Of the 366 women with an STI, 141 tested positive for HIV (18%), 176 for active syphilis (23%), 
and 92 and 65 for Chlamydia trachomatis (12%) and Neisseria gonorrhoeae (9%), respectively. 
None of the women reported specific treatment for chlamydial infection in the 3 months prior 
to delivery. However, among the women who tested negative for C. trachomatis, 32/674 (5%) 
reported receiving antibiotics for reasons other than chlamydial infection but which may have 
affected chlamydial status, compared to 1/92 (1%) of the chlamydia-positive women who 
received such antibiotics (P=0.17).
On evaluation of the STIs separately, rates of detection of HIV, active syphilis and chlamydial 
infection, were found to be age-dependent (Figure 2). Rates of HIV seropositivity were signifi-
cantly higher among women under 30 years of age (21%) than among women 30 years and 
older (12%) (P=0.04). For syphilis, a significant trend was noted with the lowest prevalence 
among the youngest women (14%) and a higher rate in older women (30%) (P=0.01). In con-
trast, an equally significant trend, but in the opposite direction, was observed for chlamydial 
infection with a highest prevalence (22%) in younger women and a lower rate of infection (5%) 
being detected among women in the older group (P<0.001). The prevalence for gonococcal 
infection was found to be highest in women less than 20 years (13%), but was not age-dependent 
(P=0.61). 
Rates of reported genitourinary symptoms during the three-month period prior to delivery were 
unrelated to the STIs demonstrated. Gestational age and birth weight as well as neonatal admission 
and neonatal death did not differ between STI groups. However, neonates born to women with 
Figure 1 Prevalence of an STI according to number of risk factors (multiple pregnancies, single, 
 lack of employment and lack of antenatal care)
  Numbers of patients per category shown in bars
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serological evidence of active syphilis that were untreated, were born at a significantly lower 
gestational age (P=0.001) than those born to women treated for the disease. There was also a 
trend towards lower birth weight (P=0.08). Rates of neonatal admission and death were three 
times higher in the untreated syphilis group than in the treated group (19% versus 6%), but this 
difference was not found to be significant owing to few patients in the untreated group. And 
although 9% of newborns born to women positive for gonorrhoea alone died in this study, no 
statistical association between maternal gonococcal infection and neonatal death could be demon-
strated. Overall, 132 different residential areas were reported, but no significant association of 
maternal carriage of individual STIs with residential area could be demonstrated.
With increasing age of the women, a significant trend was observed for an increase in antenatal 
clinic attendance (P=0.04), as was an association with multiple pregnancies (P<0.001), being 
employed (P<0.001), the availability of a regular monthly income (P<0.001), and a decrease in 
single marital status (P<0.001). Women who did not receive antenatal care were more likely to 
be seropositive for HIV (P=0.004) and positive for gonococcal infection than their counterparts 
who had attended antenatal clinics (P=0.05). In all age groups a significant association could be 
shown between HIV seropositivity and active syphilis (P<0.001, age-adjusted OR=2.3), as well 
as between gonococcal and chlamydial infection in women less 20 years of age (P=0.01).
Figure 2 Prevalence of HIV, syphilis, chlamydia and gonorrhoea by age group
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Discussion
The prevalence of sexually transmitted infections (nearly 50% positive for at least one STI) was 
extremely high among the group of pregnant urban black South African women who presented 
for delivery in this study. Other South African reports have also shown high STI rates in preg-
nant women with varying rates recorded for individual STIs [8, 9]. HIV, syphilis, chlamydial 
and gonococcal rates detected in this study were 18%, 23%, 12% and 9%, respectively. The 
highest HIV prevalence was shown in young women in their late teens (19%) and early twenties 
(22%) with a significant decline after age 30. A similar age distribution has been shown else-
where and can be explained in part by the natural course of HIV infection [10, 11]. The pre-
sented high rate of syphilis infections has been observed by others in Africa while previous 
South African studies demonstrated rates ranging from 7% to 20% among antenatal clinic 
attendees [8, 12, 13], up to 31% among unbooked pregnant women [14]. The prevalence of 
active syphilis recorded here may still prove to be an underestimation because complicated 
deliveries taken directly to the operating theatre were not included in our study as were women 
with foetal loss early in pregnancy, and the risk of perinatal mortality among neonates born to 
women with syphilis is known to be at least twice that of those without [15-17]. Chlamydial 
infection rates also vary widely in South Africa [8, 9, 12, 18, 19]. In our study chlamydial infec-
tion was the most prevalent STI in women less than 20 years (22%) and thereafter decreased 
significantly with age. This is not surprising since increased sexual activity with multiple partners 
and unprotected sex is known to occur more in younger age groups. Gonorrhoea was the least 
prevalent STI, but the rate detected was consistent with those previously recorded in South 
Africa [8, 12, 18, 20]. Gonorrhoea was also most prevalent in women less than 20 years of age 
(13%), but no significant differences were recorded between age groups. 
The WHO recommends a syndromic approach to the management of STIs in developing coun-
tries [21]. However, in this study the typical symptoms for an STI appeared to be insufficiently 
sensitive and specific to be used to estimate the risk for an STI. This is not surprising since 
60-70% of chlamydial and gonococcal infections in women are known to be asymptomatic and 
detection and subsequent treatment of latent syphilis is routinely achieved by comprehensive 
antenatal screening [22, 23]. Additionally, urogenital symptoms can be so non-specific that they 
may not be recognized as part of a disease process but regarded as part of a pregnancy and con-
sequently not reported, or they may be due to other infections for which no diagnostic test was 
performed. Similar studies have also indicated a poor correlation between reported symptoms 
and STIs during pregnancy [8, 24, 25].
However, univariate and multivariate regression analyses showed significant demographic and 
socio-economic risk factors (two or more pregnancies, single marital status, unemployed status, 
lack of regular income and antenatal care) associated with STIs. These data can be used to predict 
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risk for an STI among women late in pregnancy since we showed retrospectively that the presence 
of an STI increased from 13% in women with no risk factors to 75% in those with four risk 
factors. Figure 2 indicates that young women under 25 years of age are mainly at risk for STIs, 
which is not surprising since single, poor women are more likely to have numerous sexual partners 
and therefore to be at increased risk for STIs [26].
STIs have generally been accepted as major factors for HIV transmission and this study con-
firms a significant association between active syphilis in women of all ages with positive HIV 
status, but not with either chlamydial or gonococcal infection [3, 27]. Co-infection of chlamydia 
with gonorrhoea was frequently recorded in women less than 20 years of age.
Nearly half the women studied carried an STI, of which 18% tested positive for HIV. Therefore 
the majority of STIs could be managed appropriately had proper diagnostic testing been avail-
able at the antenatal clinic. Antenatal clinic attendance (at least one attendance in our study) 
was much higher than WHO estimates [27, 28], but women under 20 years (84%) were less 
likely to seek antenatal care than older women (92%-95%). Although a difference between early 
and late booking was not recorded, a significant difference in the presence of STIs between 
women with and without antenatal care could still be observed; especially for HIV infection and 
gonorrhoea. Since 1994, free health care for pregnant women has been available in South Africa 
and it has clearly been shown that health benefits can be obtained by educating young women 
about the importance of antenatal care, the risks of unprotected sex, and by encouraging early 
booking for delivery [29].
Serological screening for syphilis among antenatal clinic attendees as recommended by the 
WHO and Centers for Disease Control and Prevention is offered freely to all women in South 
Africa [30]. Early detection of syphilis using the RPR test is inexpensive, simple to perform and 
facilitates immediate and appropriate treatment to significantly prevent adverse pregnancy out-
come, postnatal morbidity and mortality [31]. Our study confirmed other reports indicating 
that a positive RPR and TPHA as such are not associated with increased risk for prematurity or 
low birth weight except if these women are left untreated [19].  Routine serological testing of 
pregnant women for syphilis at antenatal clinics may act as an appropriate entry point for ini-
tiation of on-site rapid HIV testing, which could sub sequently lead to increased awareness of 
serostatus and optimising opportunities for STI/HIV  prevention as well as reducing vertical 
transmission of HIV by providing anti-retrovirals during labour and postpartum as well as 
choices with regard to infant feeding [27, 32, 33]. At the time of the study, HIV treatment was 
in most South African clinics not available and no medication was given to prevent transmission 
of infection to newborns. This situation has changed considerably, but the opportunity of linking 
serological testing for HIV and routine syphilis screening has not been fully exploited. At 
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present, HIV testing is readily available throughout South Africa as is anti-retroviral treatment. 
Positive women should be treated as soon as possible with active follow-up of the women, their 
newborns and partners.
Asymptomatic chlamydial and gonococcal infections may also result in neonatal infection, 
complicated pregnancy outcome, post-partum pelvic inflammatory disease and transmission to 
sexual partners [19, 34, 35] In our study, a syndromic approach, based on elicited symptoms, 
failed to discriminate between infected and uninfected women, and routine screening by culture 
or nucleic acid amplified tests would prove too expensive and time consuming while currently 
available rapid tests lack sensitivity [36]. However, without testing for chlamydia and gonorrhoea, 
21% of infections would have remained undiagnosed and therefore would not have been treated.
Overall, this study confirms the high rates of infection with HIV, T. pallidum, C. trachomatis 
and N. gonorrhoeae among pregnant women in this urban South African community. Further-
more, we have shown that a risk assessment approach based on socio-demographic factors could 
prove more effective than provision of mass treatment or dependence on syndromic management 
principles in women who are largely asymptomatic. This population would therefore benefit 
from basic approaches to decrease the burden of STIs such as provision of information on STIs 
including the recognition of subtle symptoms associated with chlamydial and gonococcal infec-
tions, the importance of safe sex and antenatal care, and the offer of HIV testing in addition to 
routine serological screening for syphilis. Since treatment of syphilis and chlamydial and gono-
coccal infections is one of the most cost-effective health interventions available in developing 
countries in terms of cost per healthy life-year saved, additional screening for chlamydial and 
gonococcal infection would be desirable at least for women at highest risk. However, if screening 
were not feasible, combined treatment with a single dose of azithromycin and ceftriaxone for 
high-risk women and treatment of their partner may be a safe and cost-effective strategy to 
reduce the burden of both chlamydial and gonococcal infections. 
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Abstract
Objective The aim of this study was to determine the rate of C. trachomatis transmission from 
mother to infant in a setting where tetracycline eye prophylaxis is routinely provided, and to 
assess the postnatal consequences of chlamydial carriage during pregnancy for mother and child. 
Methods Pregnant urban South African women presenting for delivery to the Johannesburg 
Hospital were eligible for the study. At inclusion a urine specimen was obtained to test for C. 
trachomatis and N. gonorrhoeae, and blood (-results) were obtained for HIV and syphilis. At 
follow-up six weeks post-delivery, maternal and neonatal health were assessed via standardized 
questionnaires, a full physical examination for infants and urogenital examination for women, 
and a venous blood sample, chest X-ray and conjunctival and nasopharyngeal swabs of infants. 
Results A total of 77 chlamydia-positive women and their newborns were followed-up. The 
chlamydial transmission rate from mother to infant was found to be 30%. C trachomatis was 
detected in the conjunctivae of 39% and in the nasopharynx of 83% of these infants. Postnatal 
genitourinary symptoms were found in 52% and signs in 78% of chlamydia-positive mothers 
with 18% developing post-partum pelvic inflammatory disease. 
Conclusions C. trachomatis infection was transmitted from mothers to infants despite the use of 
tetracycline eye prophylaxis. Eye prophylaxis appeared to prevent overt ocular, but not nasopha-
ryngeal infection. Postnatal maternal genitourinary symptoms and signs, in combination with 
symptoms and signs in the infant, should alert clinicians to the possibility of neonatal and 
maternal complications of chlamydial infection.
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Introduction
Chlamydial urogenital infection during pregnancy has been well documented as a cause of acute 
and chronic maternal illness including extra-uterine pregnancy, infertility and pregnancy loss, as 
well as perinatal morbidity and mortality [1-4]. Previous studies undertaken in South Africa 
have indicated maternal chlamydial infection rates varying between 4.7% and 13% among 
antenatal clinic attendees [5-10], and a vertical transmission rate of approximately 50% has 
been documented in a study in which no ocular prophylaxis for neonatal conjunctivitis was 
employed [11]. In this study we endeavoured to determine the rate of chlamydial transmission 
from mother to infant in a setting where tetracycline eye prophylaxis is routinely provided, 
using chlamydial culture and nucleic acid amplification techniques. In addition we explored the 
relationship between maternal chlamydial infection and post-partum maternal symptomatology.
Methods
Patients
Black women presenting for delivery at the Johannesburg Hospital, South Africa, between 
October 1996 and January 1997 were considered for inclusion in the present study. Methods of 
testing for genital tract pathogens at the time of delivery and rates of infection in relation to 
demographic risk factors and subsequent pregnancy outcome have been described elsewhere 
[12]. Women received cefoxitin as antimicrobial prophylaxis before caesarean sections. Imme-
diately following delivery, newborns received a ribbon of 1% tetracycline eye ointment in each 
eye as routine prophylaxis against ophthalmia neonatorum. All women (and newborns) were 
given a follow-up appointment six weeks post-delivery together with verbal and written infor-
mation about the study and a copy of the consent form. 
At follow-up, the initial population was separated into chlamydia-positive (CTM+) and chlamydia-
negative women (CTM-) on the basis of the urinary nucleic acid amplification test results at 
delivery. Matching of mothers and their infants was done according to the following parameters: 
maternal age (± 2 years), antenatal clinic attendance (ANC), HIV and syphilis serological status, 
mode of delivery and neonatal gender and birth weight (± 250 grams). Subsequently, the char-
acteristics of infants of CTM+ were compared to infants of CTM-, as were the characteristics of 
chlamydia-positive infants (CTI+) of CTM+ compared to those of chlamydia-negative infants 
(CTI-) of CTM+. 
CTM+, who did not return for scheduled follow-up visits, were traced by telephone at home, 
work or another private number, by letter in English, Zulu, and Sotho, or, if all else failed, by a 
home visit by the principal investigator. The same procedure was followed to trace CTM- 
matched controls, but this required no more than a telephonic approach since more controls 
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were suitable for each CTM+. As a result of the uncertainty regarding return for scheduled fol-
low-up, it was necessary to record the data of CTM+ and infants at the time of follow-up, and 
subsequently search for a match either among CTM- and infant pairs, which had already 
returned for their appointment, or from those still to return. The latest follow-up to be accepted 
for inclusion was 12 weeks after delivery.
All CTI+ were treated with erythromycin 50 mg/kg/day orally divided into four doses for 14 
days. Mothers were given instructions for the treatment of their infants. In addition, a prescrip-
tion for erythromycin 500 mg orally four times a day for 7 days was provided for their own 
treatment, and they and their partners were referred to the sexually transmitted diseases clinic 
for follow-up.
Data collection
A female doctor or experienced nurse confidentially administered a questionnaire pre-delivery 
and at the six week follow-up. House staff and the principal investigator cared for all cases and 
controls and all treatment and diagnostic procedures (including those not related to C. trachomatis 
infection) were conducted at their discretion. Data concerning pre-delivery maternal health and 
socio-economic circumstances in relation to the presence of any sexually transmitted infection 
(STI) and isolated C. trachomatis, N. gonorrhoeae, HIV and syphilis have been reported elsewhere 
[12]. The maternal follow-up questionnaire included information on urogenital complaints, 
unscheduled visits to a doctor or clinic and the intercurrent use of antibiotics. The questionnaire 
regarding infant characteristics included information about eye, and respiratory problems, 
unscheduled visits to a doctor or clinic, use of antibiotic treatment and breastfeeding. In all 
cases, mothers underwent a urogenital examination and infants a full physical examination 
including weight measurement. From the infants, conjunctival and nasopharyngeal swabs were 
collected for chlamydial culture and ligase chain reaction (LCR), a venous blood sample to 
determine the presence of an eosinophilia and detection and quantitation of specific anti-
chlamydial antibodies, and a chest X-ray.
Laboratory methods
Eye specimens for isolation and detection of C. trachomatis were obtained by stroking the 
everted lower palpebral conjunctiva with a sterile dacron swab. Specimens for culture were 
immersed in a 2SP medium, transported on ice and subsequently frozen at -70ºC. Attempts to 
isolate C. trachomatis were made in monolayers of cycloheximide-treated McCoy cells [13]. 
Specimens for LCR testing were placed in a commercial transport medium, transported on ice, 
frozen at -70ºC, and processed according to the manufacturer’s instructions as for genital speci-
mens (LCx, Abbott Laboratories, Abbott Park, Il, USA). Nasopharyngeal swabs for isolation 
and LCR were obtained by stroking the nasopharynx while rotating the swab 360°, placed in a 
transport medium, stored and processed for isolation of C. trachomatis by culture or LCR as 
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described above. LCR testing has been studied less frequent than PCR, but is used and has been 
proven to be more sensitive than cell culture in pharyngeal specimens [14-16]. A two ml blood 
sample was taken to perform a full blood count by standard methods from which absolute eosinophil 
values were calculated using a cut-off value of 300/mm³ [17], and to measure specific IgG anti-
bodies to C. trachomatis using a cut-off value of 16. Type-specific antibody to C. trachomatis was 
detected and quantified by means of the modified micro-immunofluorescence method [18]. 
Radiological methods
In order to prevent bias, two radiologists who were blinded to maternal and infant chlamydial 
status evaluated infant chest X-rays [17]. Radiographic characteristics for clinical comparison 
were scored for hyperinflation, consolidation, broncho-alveolar markings, interstitial markings, 
lymphnodes, and a final conclusion was recorded as normal or abnormal.
Statistical methods
Percentages and continuous variables were compared between groups using the Mann-Whitney 
test or Chi-square/Fisher’s exact test or McNemar test. P=0.05 (two-sided) was considered the 
limit of significance.
Ethical considerations
The study was approved by the Committee for Research on Human Subjects of the Witwatersrand 
University, Johannesburg, and written informed consent was obtained from all participants.
Figure 1 Study population of mothers and infants
  CTM+ = chlamydia-positive mothers, CTM- = chlamydia-negative mothers 
  CTI+ = chlamydia-positive infants, CTI- = chlamydia-negative infant
766 pregnant women
674 CTM-
65 CTM-
matched
65 CTM+
matched
65 infants
matched
65 infants
matched
92 CTM+
23 CTI+
54 CTI-
77 CTM+
at follow up
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Results
During the study period 766 pregnant women were screened for HIV, syphilis, C. trachomatis 
and N. gonorrhoeae and rates of infection detected were 18%, 23%, 12% and 9%, respectively. 
Chlamydia-positive mothers (CTM+) (with or without another STI) were found to be signifi-
cantly younger (24.4 ± 4.8 years) than chlamydia-negative mothers (CTM-) (27.0 ± 5.7 years, 
P<0.001), had fewer previous pregnancies (2.0±1.0 versus 2.4±1.3, P=0.05), and tested less 
often positive for syphilis (14% versus 24%, P=0.03). No significant difference between the two 
groups was detected regarding HIV (17% versus 19%) or gonococcal status (12% versus 8%), 
ANC attendance (90% versus 93%), rate of caesarean section (12% versus 20%), and gestational 
age or birth weight of the newborns. No significant differences in rates of urinary, cervical or 
uterine symptoms were reported at the time of delivery.
Seventy-seven of the initial 92 CTM+ (84%) were available for follow-up (Figure 1). LCR and/
or culture testing for C. trachomatis were positive in 23 of their infants reflecting an overall rate 
of concordance of 30% (Table 1). Nineteen infants of these infants (83%) had a positive 
nasopharyngeal and nine (39%) had a positive conjunctival test. Five infants (22%) were colo-
nised in both sites. All conjunctival cultures were negative. Nasopharyngeal specimens were 
positive in 13 of 23 infants (57%) by LCR and in 9 of 20 infants (45%) by culture. Three 
nasopharyngeal cultures were contaminated with other bacteria and were therefore not evaluable.
After matching CTM+ with CTM- and their infants, 65 mother-infant pairs were available for 
comparison owing either to failure of CTM+ or CTM- to return for follow-up or lack of matching 
Table 1 Patterns of detection of C. trachomatis by culture and LCR in conjunctival and
 nasopharyngeal specimens obtained from infants at follow-up
Number of specimens Nasopharyngeal culture Nasopharyngeal LCR Conjunctival LCR
1 + + +
2 + + _
2 + _ +
2 + _ _
2 _ + +
2 _ + _
2 _ _ +
2 NE* + +
2 NE* + _
2 NE* - +
Total 23 9/20 (45%) 13/23 (57%) 9/23 (39%)
*NE = not evaluable, + = positive, - = negative, eye cultures were negative
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controls. When comparing the two groups with regards to matching criteria, the maternal age 
was 25±5 years, gestational age 37±1week, parity1±1, gravidity 2±1, ANC 94% and 98%, rate 
of vaginal deliveries 88%, and the HIV and syphilis seropositivity rates were 9% and 8% respectively. 
Matching for gonococcal status was not performed, but seven CTM+ (11%) and two CTM- 
(3%) were found to harbour N. gonorrhoeae. Urine was collected after rupture of the membranes 
from 18% and 23% of CTM+ and CTM-, respectively. 
A comparison between CTM+ and CTM- for symptoms reported at the time of delivery for the 
three-month period prior to delivery is shown in table 2. One CTM+ had fever while one 
mother in each group reported urinary frequency. None received specific treatment for chlamydial 
infection, but one CTM+ and two CTM- received antibiotics for other diagnoses that could be 
effective against the organism.
At the follow-up visit (Table 2), CTM+ had significantly more urogenital symptoms (34 versus 
one; P<0.001) and signs (51 versus 13; P<0.001) than CTM-. Chlamydial infection was found 
to be strongly associated with symptoms of dysuria, vaginal discharge and lower abdominal 
pain. Post-coital bleeding was only reported in CTM+ and the association with chlamydial 
infection tended towards significance. Altogether, 16 CTM+ had one complaint, 12 had two, 
five had three and one woman had four complaints. One CTM+ reported joint pains. In both 
groups, eight women reported a previous diagnosis for which treatment had been provided during 
their pregnancy (urinary tract infection, vaginal discharge, and vaginal candidiasis). Examination 
Table 2 Association of Chlamydia trachomatis infection with maternal symptoms and signs
CTM+
N=65 (%)
CTM-
N=65 (%)
P-value
Symptoms at delivery
dysuria 0 8 (12) 0.008
vaginal discharge 12 (18) 13 (20) 1.00
post-coital bleeding 2 (3) 2 (3) 1.00
lower abdominal pain 8 (12) 7 (11) 1.00
Symptoms at follow-up
dysuria 8 (12) 0 0.008
vaginal discharge 27 (42) 0 <0.001
post-coital bleeding 5 (8) 0 0.06
lower abdominal pain 19 (30) 1 (2) <0.001
Signs at follow-up
vaginal discharge 49 (75) 13 (20) <0.001
bleeding 6 (9) 0 0.03
cervical excitation tenderness 12 (18) 1 (2) 0.003
CTM+ = chlamydia-positive mothers, CTM- = chlamydia-negative mothers
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of the women also showed a significant association of chlamydial infection with signs of lower 
and upper genital tract disease: 36 CTM+ having one sign, 14 having two and one three signs 
compared to 12 CTM- with one sign and one with two signs.
At follow-up, the weight of infants born to CTM+ was significantly lower than that of infants 
to CTM- as was the age. Subsequent calculation of weight gain per week showed no significant 
difference between groups (Table 3). Comparison of infant groups showed no significant difference 
for intercurrent visits to a clinic or doctor, or intercurrent treatment. Infants of CTM+ had 
more frequent eye and respiratory problems, presented more frequently with nasal obstruction 
or sneezing than those born to CTM-, and were significantly more often exclusively breastfed. 
On examination, bronchial breathing or crepitations were not detected, and wheezing was doc-
umented in only one infant of a CTM+. Sneezing or nasal obstruction was documented much 
more frequently in infants of CTM+, as were higher respiratory rates and intercostal recession. 
Table 3 Differences between infants born to chlamydia-positive and chlamydia-negative womens
CTM+
N=65 (%)
CTM-
N=65 (%)
P-value
History 
birth weight (grams ± SD) 3155 ± 476 3180 ± 454 0.06
eye problems 19 (29) 7 (11) 0.08
nasal problems 32 (49) 15 (23) 0.005
chest problems 19 (29) 10 (15) 0.08
exclusively breastfed 28 (43) 13 (20) 0.05
Examination 
FU weight (grams ± SD) 5600 ± 1005 6027 ± 1072 0.006
FU age (weeks ± SD) 10.2 ± 3.2 12.2 ± 2.7 0.001
weight gain (grams/week) 246 ± 72 238 ± 73 0.68
conjunctivitis 2 (3) 2 (3) 1.00
nasal obstruction/sneezing 37 (57) 7 (11) <0.001
respiratory rate (mean ± SD) 56 ± 11 45 ± 5 <0.001
intercostal recession 21 (32) 4 (6)  <0.001
Laboratory results 
eye LCR 8/65 (12) 0 0.008
nasopharyngeal LCR 12/65 (18) 0 <0.001
eye culture 0 0 -
nasopharyngeal culture 7/58 (12) 0 0.02
MIF titre ≥ 16 19/65 (29) 3/65 (5) 0.001
eosinophil count ≥ 300/mm³ 32/65 (49) 30/65 (46) 0.90
CTM+ = chlamydia-positive mothers, CTM- = chlamydia-negative mothers, FU = follow-up
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The latter signs, however, were not associated with significant differences in eosinophil counts 
or radiographic chest X-ray changes. Chest X-rays showed similar rates of hyperinflation and 
atelectases, and no hilar lymphadenopathy, consolidation or pleural effusion in both groups.
Although overall 23 infants were found to be chlamydia positive, in the nested case control 
analysis, 19 CTI+ born to 65 CTM+ (29%) were compared with matched infants of CTM-. 
Chlamydia was not detected in specimens from infants of CTM-. Among the 19 infected new-
borns, eight (42%) had a positive conjunctival LCR and 12 (63%) a positive nasopharyngeal 
LCR while seven of 16 evaluable nasopharyngeal cultures (43%) were positive. Evidence of infec-
tion on the basis of elevated specific chlamydial IgG titres was significantly different between 
infant groups: 19 infants of CTM+ (29%) compared to three infants of CTM- (5%) had ele-
vated anti-chlamydia antibody titres (Table 3). However, only nine of these 19 infants were in 
the group of 19 CTI+ detected by LCR or culture.
Subsequently, the characteristics of CTM+ of 23 CTI+ were compared to CTM+ of 54 CTI-. 
No significant differences were found with respect to maternal age, parity, gravidity, ANC 
attendance, gestational age, rate of vaginal deliveries, marital status, regular monthly income or 
employment. In addition, rates of maternal symptoms and signs were similar both at delivery 
and at follow-up. More CTM+ of CTI+ tested positive for HIV (13% versus 9%), syphilis 
(13% versus 11%) and gonorrhoea (13% versus 11%) compared to CTM+ of CTI-, but these 
differences were not significant. No mother had received previous treatment for chlamydial 
infection, but one CTM+ of a CTI- received antibiotics that should treat chlamydial infection. 
The only significant difference was that urine was more often obtained after rupture of the 
membranes from seven mothers of 23 CTI+ (30%) compared to six mothers of 54 (11%) CTI- 
(P=0.05). All except one CTI+ were delivered vaginally. No difference between groups was 
reported for unscheduled visits to a clinic or for intercurrent treatment. More CTI+ were exclu-
sively breastfed: 13/23 (57%) versus 18/54 (33%); (P=0.08). CTI+ had a lower birthweight and 
lower weight at follow-up, but these differences were not significant. The weight gain per week 
was also similar in both groups as were rates of reported symptoms and signs, eosinophil counts 
and chest X-ray changes. CTI+ had more atelectases, 3 of 22 (14%) versus 1 of 53 (2%) 
(P=0.07), and hyperinflation, 9 of 22 (41%) versus 16 of 53 (30%) (P=0.43), compared to 
CTI-. Hilar lymphadenopathy, consolidation or pleural effusion was not seen in either group. 
However, specific anti-chlamydial antibodies were significantly elevated in 12 of 23 (52%) 
CTI+ compared to 10 of 54 (19%) CTI- (P=0.005). 
Discussion
The high rates of sexually transmitted infection detected during the course of this study are 
consistent with similar studies conducted in South Africa and elsewhere on the African continent 
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[5, 19, 20]. The correlation of maternal infection with demographic and other factors has been 
described elsewhere [12]. The follow-up rate (84%) of chlamydia-positive women (CTM+) and 
controls (CTM-) was higher than generally known from African follow-up clinics and offered 
the opportunity to compare groups of women and infants [21, 22]. In this paper we endeavoured 
to determine the risks and consequences of maternal chlamydial infection during pregnancy 
both to the mother following delivery and to her newborn. The overall transmission rate in our 
study (30%) was lower than reported by others [23-25], but similar to studies in which ocular 
prophylaxis was given at delivery to protect newborns against acquisition of neonatal chlamydial 
or gonococcal conjunctivitis [26-28]. 
It is remarkable that despite the use of tetracycline ocular prophylaxis, C. trachomatis-specific 
DNA was still detected in the conjunctivae of 39% of CTI+ at follow-up, but no cases of isolation-
positive chlamydial conjunctival infection could be detected. While culture is able to detect 
only viable organisms, LCR is capable of detecting both viable and non-viable organisms. This 
implies that, in the absence of culture positive conjunctival samples, a positive LCR result in a 
newborn may be the result of contamination of the conjunctivae by C. trachomatis from the 
maternal cervico-vaginal fluid during delivery. We would assume, however, that a positive LCR 
result from a specimen obtained six to twelve weeks after birth indicates detection of infection 
in the infant rather than maternal contamination. 
It is clear that the use of tetracycline eye prophylaxis decreased the bacterial load significantly 
and that overt chlamydial conjunctival infection can be prevented. However, it is also clear that 
complete eradication of chlamydial colonisation is not achieved [27, 29]. This underlines once 
again the need for systemic treatment to prevent late ocular infection or its recurrence. 
The nasopharynx was the most frequent site where chlamydial infection was detected in infants. 
The finding that chlamydial cultures and LCR tests were both positive in a high proportion of 
infants actually indicates that direct transmission of infection to the nasopharynx occurred 
rather than contamination of the nasopharynx with chlamydial DNA via the conjunctivae. 
These findings also indicate that the use of prophylactic tetracycline eye ointment has no apparent 
influence on nasopharyngeal colonization and the possible development of chlamydial neonatal 
pneumonia [26]. Ocular prophylaxis may therefore only reduce the index of suspicion of 
chlamydial infection in the newborn since fewer infants will present with overt conjunctivitis as 
an indicator that other sites may be infected. Subsequently, without a history of neonatal con-
junctivitis, infection at other sites may remain unnoticed and may cause sequelae later in life 
such as chronic lung disease and hyperreactive airways [3, 30]. Therefore systemic treatment 
should be used to treat chlamydial infection in infants rather than antibiotic prophylaxis [31, 32].
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Minor symptoms in infants such as sneezing and nasal obstruction, and increased respiratory 
rates and intercostal recession were associated with antenatal chlamydial infection in their mothers. 
The significant difference in respiratory rates between groups may in part be due to the differ-
ence in age at follow-up. However, nasal obstruction and intercostal recession are not age-
related and are therefore more likely to reflect evidence of chlamydial nasopharyngeal infection. 
The increased respiratory rates and recession in infants in this study may be more related to 
nasal obstruction as a result of relatively early manifestation of upper respiratory chlamydial 
infection rather than to established chlamydial pulmonary disease since chest X-ray findings did 
not support a diagnosis of pneumonia. Newborns are obligatory nasal breathers. Oral respira-
tion is usually acquired by two months, but may take up to six months of age to develop fully 
[33]. Chlamydial infection, or another infection for which no test was performed in this study, 
may therefore be more likely to cause obstructive nasopharyngeal disease leading to increased 
respiratory rates or recession [34, 35]. The classical radiological changes described in cases of 
chlamydial neonatal pneumonia and the detection of an eosinophilia on haematological exami-
nation proved either non-specific or relatively insensitive in our hands and may again be due to 
the presentation of early respiratory disease [17, 36]. Chest X-rays are therefore not indicated as 
a screening tool and should only be used if there is a clinical indication of pneumonia. Likewise, 
detection of an eosinophilia appeared unhelpful at this stage. In contrast, significantly more 
elevated titres of anti-chlamydial antibody were found in infants born to CTM+ compared to 
infants born to CTM- as well as in CTI+ compared to CTI- both born to CTM+. Only single 
blood samples were obtained and therefore a significant rise in antibody titres could not be 
detected. These single elevated anti-chlamydial antibody titres may be associated with infection 
in the newborn, but may also reflect passive transfer of maternal antibody to the child. Single 
serological sampling is therefore not useful in establishing a diagnosis. However, sequential 
sampling for the detection of a rise in anti-chlamydial antibody titres remains useful. 
We found that significantly more infants born to CTM+ were exclusively breastfed and that, 
although not statistically significant, more CTI+ were exclusively breastfed than CTI-. An asso-
ciation of chlamydial infection in the infant with breastfeeding has been recorded in a previous 
study [23], suggesting the  possibility of postpartum transmission as a result of more intimate 
handling of the infant by the mother. 
In this study significant differences between CTM+ and CTM- were detected in respect of post-
partum urogenital symptom rates. On follow-up examination, chlamydial infection was associated 
with post-partum vaginal discharge, bleeding and cervical excitation tenderness [37-39]. Most 
symptoms and signs are probably due to chlamydial infection, but the findings may in part be 
confounded by gonococcal infection in some CTM+ and CTM-.
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In conclusion, we have shown that chlamydial infection in pregnant women places the newborn 
at risk and that topical antibiotic prophylaxis at birth is insufficient to prevent chlamydial infection 
in the infant.  Furthermore, a careful examination of both mothers and infants at follow-up and 
the finding of maternal symptoms or signs of genital tract disease should alert clinicians to the 
possibility of chlamydial infection in the infant. Likewise, the finding of conjunctivitis and/or 
respiratory tract infection in the infant should alert physicians to the possibility of asympto-
matic maternal post-partum chlamydial infection of the genital tract, which requires prompt 
treatment with systemic antibiotics. The long-term implications of these inapparent infections 
for both infant and child health, and maternal fertility in developing societies remain areas in 
need of further study. Meanwhile consideration should be given to the possible implementation 
of antenatal screening for chlamydial infection in this high-risk population during the last 
month of pregnancy. 
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Abstract
Background C. trachomatis infection is the most prevalent bacterial sexually transmitted infection 
and may influence pregnancy outcome.
Objective This study was conducted to assess the effect of chlamydial infection during preg-
nancy on premature delivery and birthweight. 
Methods Pregnant women attending a participating midwifery practice or antenatal clinic 
between February 2003 and January 2005 were eligible for the study. From 4,055 women self-
administered questionnaires and urine samples, tested by PCR, were analysed for C. trachomatis 
infection. Pregnancy outcomes were obtained from midwives and hospital registries. Gestational 
ages and birthweights were analysed for 3,913 newborns. 
Results The C. trachomatis prevalence was 3.9%, but varied by age and socio-economic back-
ground. Chlamydial infection was, after adjustment for potential confounders, associated with 
preterm delivery before 32 weeks (OR 4.35 [95% CI 1.3-15.2]) and 35 weeks gestation (OR 
2.66 [95% CI 1.1-6.5]), but not with low birthweight. Of all deliveries before 32 weeks and 35 
weeks gestation 14.9% [95% CI 4.5-39.5] and 7.4% [95% CI 2.5-20.1] was attributable to C. 
trachomatis infection.
Conclusion C. trachomatis infection contributes significantly to early premature delivery and 
should be considered a public health problem, especially in young women and others at increased 
risk of C. trachomatis infection. 
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Introduction
Chlamydia trachomatis is an important cause of sexually transmitted infections (STIs) in women, 
which may lead to pelvic inflammatory disease, tubal infertility, ectopic pregnancy, and chronic 
abdominal pain [1-4]. C. trachomatis infection during pregnancy may in addition influence 
pregnancy outcomes leading to premature rupture of membranes, prematurity, low birthweight 
and perinatal mortality, and cause neonatal conjunctival and respiratory infection [5-7]. The 
literature regarding these detrimental effects of C. trachomatis infection on pregnancy outcome, 
however, yields conflicting results that seem primarily due to differences in study design, popu-
lation and microbiological tests employed [8-24]. 
Screening for C. trachomatis in pregnant women has revealed prevalence rates varying from 0% 
to 37% and various associated risk factors including, in particular, age and socio-economic 
status [25-27].
In the Netherlands, a C. trachomatis prevalence of 2.5% was reported in women [28]. However, 
prenatal screening for C. trachomatis is not routine obstetrical practice in the Netherlands and 
data on pregnant women and pregnancy outcome are lacking. 
The objective of this study was to assess the prevalence of C. trachomatis infection in pregnant 
women and to investigate the association of chlamydial infection with the risks of preterm delivery 
and low birthweight or being small for gestational age. 
Methods
Design
This Chlamydia trachomatis study was embedded in the Generation R Study, which is a popu-
lation-based, non-interventional, prospective cohort study designed to identify early environ-
mental and genetic determinants of growth, development and health of children, starting from 
foetal life until adolescence [29, 30]. Pregnant women, who attended one of the participating 
midwifery practices or antenatal clinics and who were expected to deliver in Rotterdam, were 
eligible for the study. Regular health care workers (midwives, obstetricians) informed the women 
about the study. Most women spoke Dutch, otherwise the study was explained and question-
naires were provided in their native language. Enrolment was scheduled in early pregnancy 
(gestational age < 18 weeks) at the first routine foetal ultrasound examination, but was allowed 
until delivery. Women who were scheduled for termination of pregnancy and women with a 
pregnancy resulting in miscarriage or perinatal death prior to or at the first ultrasound were not 
included in the study. The Generation R study started in 2002 [29]. Inclusion for the Chlamydia 
sub-study was between February 2003 and January 2005.
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Risk factors
Data were obtained using confidentially administered standardized questionnaires at the time of 
inclusion. Questions that were not answered were registered as missing data. Maternal age was 
defined as age at enrolment of the study. Ethnicity was defined according to the classification of 
Statistics Netherlands [30]. Most women were Dutch (49%), Surinamese (9%), Turkish (9%) 
or Moroccan (7%). Educational levels of participating women were defined in groups by highest 
attained education (primary school, secondary school, higher education). Marital status was 
defined as married if married or living together in partnership. Further information was obtained 
regarding gravidity, number of sexual partners in the year prior to pregnancy, history of an STI, 
and the use of cigarettes, alcohol and drugs. 
Microbiological diagnosis
Women provided a first-void urine specimen to test for C. trachomatis at enrolment. Urines were 
stored at 4°C, transported the same or following working day, and processed within 24 hours of 
receipt by the laboratory. DNA was isolated from pooled urine specimens using the MagNA 
Pure LC Bacterial DNA isolation Kit III (Roche Molecular Systems, Inc, Alameda, USA) and 
amplified by polymerase chain reaction (PCR) (Cobas Amplicor, Roche Molecular Diagnostics, 
Branchburg USA) [31]. In brief, pools were made of five individual urines by adding 200 µl of 
each of the urines into one tube. From each pool the full 1000 µl were taken, and centrifuged 
for 10 minutes. Subsequently, 900 µl were removed and the pellet was resuspended in 100 µl of 
the remaining supernatant, mixed with 130 µl lysis buffer and 20 µl proteinase K, incubated for 
10 minutes and thereafter denatured for 10 minutes. Finally, DNA was isolated in the automated 
MagNA Pure LC using a sample volume of 250 µl and an elution volume of 100 µl. Then, 25 
µl was used for PCR. Urines from positive pools were individually re-tested and reported as 
negative or positive.
Pregnancy outcomes
Information about pregnancy outcomes (miscarriage, perinatal death, gestational age, birthweight) 
was obtained postnatally from midwives and hospital registries. Gestational age was established 
by foetal ultrasound examination. Preterm birth was defined as delivery at a gestational age of 
less than 37 weeks with subgroups of gestational ages less than 32 weeks and less than 35 weeks. 
Low birthweight was defined below 2500 grams. Birthweight measurements were converted 
into gestational age adjusted standard deviation scores (SDSs) [32]. Small for gestational age 
(SGA) was defined as birthweight less than 2 SDS below the mean for gestation. 
Ethical aspects
The C. trachomatis study was embedded within the framework of the Generation R Study, 
which is a population-based prospective cohort study designed to identify environmental and 
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genetic causes of normal and abnormal growth, development and health from fetal life until 
young adulthood [29, 30]. Both studies were approved by the Medical Ethical Committee for 
Research on Human Subjects of the Erasmus University Medical Centre, Rotterdam. Written 
informed consent was obtained from all participants. Generation R provided the data anony-
mously to protect the privacy of participants.
Data analysis
Associations of C. trachomatis infection during pregnancy with socio-economic and life style 
risk factors of women were assessed using multiple logistic regression models. Unequivocal con-
founders were selected based on previous studies. Associations were studied for each risk factor 
while adjusting for all other risk factors and for the confounders alcohol, drugs and smoking. 
We imputated the missing data in other risk factors and confounders with multiple imputa-
tions. Preterm birth was analysed using multiple logistic regression models. We adjusted for 
maternal age, ethnicity, gravidity, education, and smoking).
The Kaplan-Meier procedure was used to illustrate the proportion of women who delivered at 
given gestational ages. The Breslow test was used to calculate the significance of the difference 
between gestational ages at delivery of chlamydia-positive and chlamydia-negative women in 
the Kaplan-Meier procedure.
The proportion of preterm delivery attributable to C. trachomatis infection in women in the 
total population was assessed using the population attributable risk (PAR) [33]. The PAR was 
calculated with the observed relative risk (RR) and the population fraction with chlamydial 
infection (PF), using the formula: 
PAR = [(RR – 1)PF] / [1 + (RR – 1)PF].
Birthweight as a continuous variable was analysed using multiple linear regression models. Low 
birthweight and SGA were analysed using multiple logistic regression models. The latter regressions 
were adjusted for known determinants of low birthweight (maternal age, ethnicity, gravidity), 
socio-economic status and life style related variables (education, smoking). 
Measures of association are presented with 95% confidence intervals (CI).
Statistical analysis was performed using the Statistical Package of Social Sciences version 11.0 
for Windows (SPSS Inc, Chicago, IL, USA). Data imputation was done with the MI procedure 
in SAS 9.13.
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Results
Population for analysis 
During the study period 5,167 pregnant women were enrolled in the overall Generation R 
study (Figure 1), of whom 4,676 women (90%) provided a urine sample and were enrolled in 
the Chlamydia sub-study. Of these, 621 urines could not be matched to the respective question-
naires in the database. Urine samples and data from 4,055 women were used to analyse the 
prevalence and risk factors for C. trachomatis infection. Half the women were included within 
the first 14 weeks of their pregnancy, 95% within 22 weeks.
Prevalence 
C. trachomatis infection was detected in 157 of 4,055 (3.9%) women. Age-specific prevalences 
were 13.5% in women age 20 years or less, 6.7% between 21 and 25 years, 3.3% between 26 
Figure 1 Profile of the Generation R sub-study on Chlamydia trachomatis
Enrolment in Generation R Study 
n=5,167 women
February 2003-January 2005 
Not enrolled in C. trachomatis study (n=491):
urine samples not available
Enrolment in C. trachomatis study
n=4,676 women
February 2003-January 2005
Excluded (n=621):
urine samples not matching to questionnaires
n=4,055
Data on C. trachomatis infection and 
questionnaire for analysis of prevalence 
and risk factors
Excluded (n=142):
twin pregnancies (n=34)
loss to follow-up (n=28) 
miscarriage (n=11) 
perinatal death (n=51)
missing gestational age or birthweight (n=18)
n=3,913
Data on C. trachomatis infection,
gestational age and birthweight for 
analysis of prematurity, low birthweight 
and SGA
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Table 1 Socio-economic and lifestyle risk factors of Chlamydia trachomatis infection in 
 pregnant women
Chlamydia trachomatis infection
Negative Positive Crude Adjusted
Risk factors n=3,898 n=157 (%) OR (95% CI) OR (95% CI)#
Age groups (n=4,055)
< 21 years 217 34 (13.5) 9.4 (5.6-15.8)** 1.8 (1.2-2.6)**
21-25 years 741 53 (6.7) 4.3 (2.7-6.8)** 1.3 (1.0-1.7)
26-30 years 1,194 41 (3.3) 2.1 (1.3-3.4)** 0.9 (0.7, 1.2)
> 30 years 1,746 29 (1.6) 1.00 1.00
Ethnicity (n=3,730)
Dutch 1,748 33 (1.8) 1.00 1.00
Cape Verdean 149 18 (10.8) 6.4 (3.5-11.6)** 1.5 (0.9-2.5)
Antillean 109 21 (16.2) 10.2 (5.7-18.2)** 2.3 (1.4-3.7)**
Surinamese 310 31 (9.1) 5.3 (3.2-8.8)** 1.4 (1.0-2.1)
Moroccan/Turkish 610 14 (2.2) 1.2 (0.7-2.3) 0.5 (0.3-0.9)*
other (non-) western 668 19 (2.8) 1.5 (0.9-2.7) 0.7 (0.4-1.1)
Education (n=3,656)
primary school 389 24 (5.8) 3.3 (1.9-5.8)** 1.3 (0.9-1.8)
secondary school 1,573 79 (4.8) 2.7 (1.8-4.2)** 0.9 (0.7-1.2)
higher education 1,562 29 (1.8) 1.00 1.00
Marital status (n=3,648)
not married 479 65 (11.9) 5.9 (4.1-8.4)** 1.6 (1.3-2.0)** 
married 3,034 70 (2.3) 1.00 1.00
Gravidity >1 (n=4,011)
no 1,719 81 (4.5) 1.00 1.00
yes 2,138 73 (3.3) 0.7 (0.5-1.0) 0.9 (0.7-1.0)
Multiple sexual partners in year prior to pregnancy (n=3,289)
no 2,918 99 (3.3) 1.00 1.00
yes 251 21 (7.7) 2.5 (1.5-4.0)** 1.2 (0.7-2.2)
History of STI (n=3,313)
no 2,778 100 (3.5) 1.00 1.00
yes 370 25 (6.3) 1.9 (1.2-3.0)** 1.4 (0.7-2.5)
do not know 38 2 (5.0) 1.5 (0.4-6.2) 0.8 (0.3-2.2)
Values are frequencies and odds ratios (95% CI), *P<0.05, **P<0.01
#Adjusted for all other risk factors, use of drugs, alcohol and smoking with multiple imputation of missing data in the 
other factors
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and 30 years and 1.6% in women over 30 years. The prevalence was highest in Antillean 
(16.2%), Cape Verdean (10.8%) or Surinamese (9.1%) women, and in women with low education 
(5.8%), single marital status (11.9%), first pregnancies (4.5%), multiple sexual partners in the 
past year (7.7%) or a history of an STI (6.3%) (Table 1). 
Women with missing data on ethnicity, education and smoking had higher rates of chlamydial 
infection than women with these data recorded: 6.5% versus 3.6% (P=0.01), 6.3% versus 3.6% 
(P=0.01) and 4.8% versus 3.4% (P=0.04), respectively. Women with missing data on marital 
status, gravidity, multiple sexual partners, history of an STI, use of alcohol or drugs did not have 
significant higher rates of chlamydial infection than women with these data recorded. 
Risk factors 
In the unadjusted analysis age below 30 years, Antillean, Cape Verdean and Surinamese ethnicity, 
education, single marital status, multiple sexual partners in the year prior to pregnancy and history 
Table 2 Pregnancy outcomes of women and their association with Chlamydia trachomatis infection
Chlamydia trachomatis infection  
Outcomes Negative Positive Percentage positive (95% CI) P-value *
All outcomes (n=4,055)
all women enrolled 3,898 157 3.9 (3.3-4.5)
Live pregnancy outcomes (n=4,055)
live singleton birth 3,780 151 3.8 (3.2-4.4) 1.0 (reference)
live twin birth 30 4 11.8 (0.3-21.9) 0.05
lost to follow up 26 2 7.1 (0.0-17.3) 0.29
Adverse pregnancy outcomes
Demise (n=4,055)
miscarriage 11 0 0 1.00
perinatal death 51 0 0 0.27
Gestational age ** (n=3,913)
term, ≥ 37 weeks 3,583 140 3.8 (3.2-4.4) 1.0 (reference)
prematurity, < 37 weeks 180 10 5.3 (2.1-8.5) 0.33
prematurity, < 35 weeks 57 7 10.9 (3.1-18.8) 0.01
prematurity, < 32 weeks 18 4 18.2 (0.7-36.7) 0.01
Birthweight ** (n=3,913)
≥ 2500 gram 3,589 140 3.8 (3.1-4.4) 1.0 (reference)
< 2500 gram 174 10 5.4 (2.1-8.7) 0.25
* P-value (Chi-square or Fishers exact test) for comparison of C. trachomatis prevalence with respective outcome 
categories of live singleton birth, gestational age ≥ 37 weeks, and birthweight ≥ 2500 gram
** Including live singleton birth outcomes only
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of an STI were significantly associated with C. trachomatis infection (Table 1). In the adjusted 
analysis age below 21 years, Antillean ethnicity and single marital status remained risk factors 
for C. trachomatis infection; other maternal factors were not independently associated. Moroccan 
or Turkish women had a lower risk for C. trachomatis infection. 
Pregnancy outcomes
Pregnancy outcomes are shown in table 2. Of the 4,055 pregnancies 3,931 resulted in live singleton 
births and 34 in live twins. Women who gave birth to twins were more often chlamydia-positive 
than women who had singletons (P=0.05). Miscarriage (n=11) and perinatal death (33 stillbirth, 
18 neonatal death) occurred in 1.5% pregnancies. These adverse events were not associated with 
C. trachomatis infection during pregnancy. Preterm delivery occurred in 190 women (4.9%) of 
which prematurity before 32 weeks (0.6%) and 35 weeks (1.6%) of gestation was significantly 
associated with C. trachomatis infection (Table 2). No significant association was observed with 
low birthweight. 
After exclusion of women who were lost to follow up, or who had twin pregnancies, a miscarriage 
or perinatal death, the effect of C. trachomatis infection on gestational age and birthweight was 
further analysed for 3,913 women and neonates.
Gestational age. The distribution of gestational ages according to the chlamydial status of women 
is shown in a Kaplan-Meier plot (Figure 2). Regarding premature delivery, chlamydia-positive 
women had a significantly shorter duration of gestation (P Breslow=0.02). 
Figure 2 Kaplan-Meier analysis of gestational age at delivery in women with and without 
 Chlamydia trachomatis infection
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Unadjusted analysis (Table 3) showed that chlamydia-positive women had a significantly higher 
risk of preterm delivery before 32 weeks compared to delivery at term (OR 5.7 [95% CI 1.9-
17.0]). After adjustment for the potential confounders maternal age, ethnicity, education, gravidity, 
and smoking a significant four-fold increased risk (OR 4.4 [95% CI 1.3-15.2]) of chlamydia-
positive women for preterm delivery before 32 weeks remained. Chlamydia-positive women 
also had a significantly higher risk of preterm delivery before 35 weeks (OR 3.1 [95% CI 1.4-7.0]), 
which also remained significant after adjustment for the above-stated confounders (OR 2.7 
Table 3 Risk for preterm delivery among women with Chlamydia trachomatis infection
Risk for preterm delivery
< 32 weeks
n=22
< 35 weeks
n=64
< 37 weeks
n=190
Unadjusted odds ratio
C. trachomatis infection 5.7 (1.9-17.0)** 3.1 (1.4-7.0)** 1.4 (0.7-2.8)
Adjusted odds ratio
C. trachomatis infection 4.4 (1.3-15.2) * 2.7 (1.1-6.5) * 1.2 (0.6-2.4)
Analyses are done versus delivery ≥ 37 weeks (n=3,724)
#Adjusted for maternal age, ethnicity, education, gravidity and smoking with multiple imputation
Values are odds ratios (95% confidence interval), *P<0.05, **P<0.01
Figure 3 Birthweight standard deviation scores versus gestational ages of neonates born to 
 women with and without Chlamydia trachomatis infection
96
Chapter 5
Binnenwerk Chlamydia trachomatis.indb   96 6/16/10   12:39 PM
[95% CI 1.1-6.5]). Chlamydia-positive women did not have an increased risk of preterm delivery 
before 37 weeks. 
The fraction of all premature deliveries before 32 weeks gestation attributable to C. trachomatis 
infection in women was 14.9% (95% CI 4.5-39.5). The PAR of C. trachomatis infection for 
preterm delivery before 35 weeks gestation was 7.4% (95% CI 2.5-20.1).
Birthweight. Crude analysis of the difference in birthweight (in grams) between neonates born 
to chlamydia-positive and chlamydia-negative women showed a significant difference (-114 
grams [95% CI -206, -23]), which disappeared after adjustment for the potential confounders 
gestational age, maternal age, ethnicity, education, gravidity and smoking (-20 grams [95% CI 
-98, 58]). A comparison of low birthweight (n=184) among neonates born to chlamydia-positive 
and chlamydia-negative women also showed no significant difference, neither in the unadjusted 
analysis (OR 1.5 [95% CI 0.8-2.8]) nor in the adjusted analysis (OR 1.0, [0.4-2.2]). Analysis 
of the correlation between birthweights of neonates, expressed in SDSs, and their gestational 
ages according to the maternal Chlamydia status is demonstrated in figure 3. This figure suggests 
that neonates born to chlamydia-positive women had, on average, a lower birthweight SDS, 
especially when prematurely born. However, this difference in birthweight SDSs between 
neonates born to chlamydia-positive and chlamydia-negative women did not reach statistical 
significance, also not after stratification by gestational ages (Table 4). Furthermore, neonates 
Table 4 Differences in birthweight between neonates born to women with and without
 Chlamydia trachomatis infection
Number
(%)
Mean birth weight 
SDS 
Difference in birthweight SDS*
Gestational age Unadjusted Adjusted
< 32 weeks (n=22)
C. trachomatis – 18 (82) 0.83 
C. trachomatis + 4 (18) –0.72 –1.54 (–3.6-0.5) –1.43 (–4.6-1.7)
< 35 weeks (n=64)
C. trachomatis – 57 (89) 0.13 
C. trachomatis + 7 (11) –0.87 –0.99 (–2.2-0.2) –0.79 (–2.2-0.7)
< 37 weeks (n=190)
C. trachomatis – 180 (95) –0.26 
C. trachomatis + 10 (5) –0.85 –0.59 (–1.4-0.2) –0.38 (–1.2-0.4)
≥ 37 weeks (n=3,723)
C. trachomatis – 3,583 (96) –0.08 
C. trachomatis + 140 (4) –0.19 –0.10 (–0.3-0.1) –0.12 (–0.1-0.3)
SDS: standard deviation score
# Adjusted for maternal age, ethnicity, education, gravidity and smoking
Difference and 95% confidence interval calculated with linear regression analysis
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born to chlamydia-positive women were not more often SGA than neonates born to chlamydia-
negative women, 3.3% versus 3.6% respectively (P=0.88).
Discussion
This study provides evidence that C. trachomatis infection during pregnancy is associated with 
preterm delivery, but not with low birthweight or being small for gestational age. Young age, 
Antillean ethnicity and single marital status were independent risk factors for C. trachomatis 
infection in pregnant women.
The strength of this study is its population-based, non-interventional and prospective design 
with a large number of well-described participants, adjustments for many potential confounders, use 
of a highly sensitive microbiological test method and near perfect follow-up until delivery (97%). 
A potential weakness is that the Generation R cohort is slightly skewed towards a relatively 
affluent and healthy study population [30]. However, we do not expect this to effect our results 
since the present study was designed to assess the effects of C. trachomatis infection on preg-
nancy outcomes in a non-hospital based, low risk population. Another weakness could be that 
not all women initially enrolled in the Generation R study could be tested for C. trachomatis. 
We had a non-response of 9.5% (491 women) for the Chlamydia study. This may in part be 
true non-response, but is more likely due to a change in the Generation R routine with a later 
start of the inclusion of urine collections for the Chlamydia study. Another 12.0% (621 women) 
had to be excluded because their urines could not be matched to the respective questionnaires 
in the database. This was due to logistical problems in the pilot phase of the Chlamydia study. 
However, all risk factors were similarly distributed among tested and untested women and no 
differences were found in median gestational age and mean birthweight (39.8 weeks versus 39.8 
weeks; p=0.84, 3408 grams versus 3407 grams; p=0.92). Furthermore, our numbers were too 
small to properly assess an association of C. trachomatis infection with miscarriage or perinatal 
death. Of all enrolled women with C. trachomatis results, 62 (1.5%) had a miscarriage or peri-
natal death. Data on gestational age and birthweight were not available for women with these 
adverse pregnancy outcomes, but likely is that these women delivered relatively more often 
prematurely. None of these women tested positive for C. trachomatis. Theoretically, our effect 
estimates for the associations of chlamydial infection with gestational age and birthweight could 
be biased and exaggerated when these associations would differ between all fetuses and fetal 
'survivors'. This would be the case if C. trachomatis infection would have a `protective` effect on 
early fetal death. However, this is most unlikely [8, 20].
98
Chapter 5
Binnenwerk Chlamydia trachomatis.indb   98 6/16/10   12:39 PM
Previous studies of associations between maternal chlamydial infection and subsequent sponta-
neous preterm delivery produced mixed results. Most of these studies were small compared to 
our study (less than 1,000 women included) and were published 10 to over 20 years ago. Early 
studies were often based on serology, which does not reliably distinguish current from past 
infection [9, 11, 14, 15]. One case-control study found an association between the presence of 
IgM anti-chlamydial antibody, but not IgG antibody, and preterm delivery [11]. Studies using 
cervical culture for C. trachomatis at that time also yielded conflicting results [9, 10, 13, 14]. 
More recently, sensitive DNA amplification techniques have been used to screen pregnant 
women for C. trachomatis [21-24]. One case-control study, nested in a large USA study among 
2,929 pregnant women, used this methodology and reported a two- to three-fold increased risk 
of preterm delivery before 35 weeks gestation [21]. Interestingly, the same study group reported 
later that C. trachomatis infection in midterm pregnancy was not associated with an increased 
risk of preterm delivery among 2,470 women enrolled in an antibiotic treatment trial for bacte-
rial vaginosis or Trichomonas vaginalis infection [23]. Since all women were infected and bacte-
rial vaginosis itself may induce preterm delivery [10, 34], the findings of the latter study cannot 
be extrapolated to the population at large. In a prospective South-African study among low-risk 
pregnant women [22], chlamydia-positive women (cases, n=40) had a relative risk of 2.20 for 
preterm delivery before 37 weeks gestation (controls, n=303). In this study women were also 
tested for Syphilis, Gonorrhoea and bacterial vaginosis, which were found not to be associated 
with preterm delivery. Another population-based retrospective cohort study in the USA found 
that C. trachomatis infected pregnant women (cases, n=851) had a relative risk of only 1.50 for 
preterm delivery before 37 weeks gestation (controls, n=3,404) [24]. However, the true effect of 
C. trachomatis infection on pregnancy outcomes cannot be ascertained from that study since all 
women were screened and, when positive, treated for C. trachomatis in the first trimester of their 
pregnancy. In contrast, our study is prospective, non-interventional and population-based 
(n=4,055), which makes that our findings better estimate the effect of C. trachomatis infection 
on pregnancy and are more predictive for the population as a whole. 
Preterm birth represents a major problem for obstetrics and neonatology due to its increasing 
frequency and accompanying socio-economic impact. We found chlamydial infection to be 
associated with preterm delivery before 32 weeks and before 35 weeks gestation. The association 
was much stronger for 32 weeks than for 35 weeks gestation indicating that C. trachomatis infection 
contributes relatively more to early than to late prematurity. For such an important issue, a four-
fold increased risk of preterm delivery before 32 weeks gestation implies that a considerable 
proportion (14.9% in our cohort) of preterm deliveries before 32 weeks gestation is attributable 
to chlamydial infection in pregnancy. Despite a considerable confidence interval around the 
estimate, this would classify C. trachomatis among the important infective risk factors of early 
prematurity. The attributable fraction (7.4%) remained significant for preterm delivery before 
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35 weeks. It should be noted, however, that the number and proportion of premature deliveries 
attributable to chlamydial infection highly depends upon the C. trachomatis prevalence in a 
given population, and that some confounding as a result of  co-infection by other genital patho-
gens cannot be excluded. Furthermore, we did not correct for a previous history of termination 
of pregnancy in these women since this potential confounder was only recently established [35]. 
Finally, we had no information concerning the use of (macrolide) antibiotics during pregnancy, but 
suggest that such use would mitigate, rather than exaggerate, the detrimental effect of C. tracho-
matis infection on pregnancy outcome. Furthermore, pregnant women are not routinely tested 
and treated for Ureaplasma urealyticum or Mycoplasma genitalium in the Netherlands; neither 
are women with premature rupture of the membranes routinely treated with antibiotics.
Extrapolation of our findings to the Netherlands, where approximately 3,000 neonates are born 
before 32 weeks gestation annually [36], showed that C. trachomatis infection in pregnancy 
contributes approximately 450 cases to this burden; for deliveries before 35 weeks gestation 
these numbers are 7,100 and 525, respectively. Our finding of an association between C. trachomatis 
infection with premature delivery may be useful in a cost-benefit analysis of C. trachomatis 
screening during pregnancy, especially among women with increased risk for infection. 
Interestingly, C. trachomatis infection was more prevalent among women who had twins than 
among women who had singletons, a finding not reported before. Since C. trachomatis infection 
is associated with infertility and assisted conception for infertility is associated with twin preg-
nancies, an explanation for our findings may be that chlamydia-positive women were not treated 
effectively during their infertility work-up or that they were reinfected. This observation war-
rants further study into medical histories of women with twin deliveries versus women with 
singletons. 
The major risk factors we found are amongst the many previously described including young 
age, urban residence, low socio-economic class, specific ethnic groups, single marital status and 
recent changes in sexual partnerships or sexual promiscuity [9, 25, 37, 38]. Adolescents are at 
highest risk of infection, which was also observed in this study [27]. Urban residence has been 
described to be of importance, which effect we could not evaluate since all participating women 
resided in Rotterdam. The risk factors we describe are similar to those reported in another 
Dutch community-based study [28, 39]. Importantly, on global scale C. trachomatis prevalences 
vary widely [25], which will directly affect the incidence of complications attributable to this 
infection, including preterm delivery.
One may question the design of our study since women screened and found positive for C. 
trachomatis infection were not treated. The design of our study would face ethical barriers in 
those countries that have national guidelines or directives advocating C. trachomatis screening 
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and treatment in routine antenatal care, and would be impossible to perform [40, 41]. However, 
in most countries of the European Union, including the Netherlands, screening and treatment 
of chlamydial infection during pregnancy remains controversial and is currently not recom-
mended in routine antenatal care [42, 43]. Our study provides novel data that may well have an 
impact on the future antenatal screening strategy in the Netherlands and elsewhere. In addition, 
the main study, the Generation R study, was designed as a non-interventional follow-up study 
[29, 30]. All following substudies, including ours, had to fit into this overall design. Further-
more, Generation R provided the data anonymously to protect the privacy of participants. We, 
therefore, had no access to names or addresses of chlamydia-positive women. 
In conclusion, C. trachomatis urogenital infection in pregnant women increases the risk of preterm 
delivery, especially early prematurity, such that a significant proportion of preterm deliveries can 
be attributed to this infection. In order to improve birth outcomes, health systems should consider 
additional focus on C. trachomatis infection, especially in young women and others at increased 
risk of C. trachomatis infection.
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Abstract
Objective To evaluate the relationship between the presence of Chlamydia trachomatis and signs 
of placental inflammation in women who delivered at 32 weeks gestation or less. 
Study Design Placental histology and clinical data were prospectively obtained from 304 
women and newborns at the Erasmus MC. C. trachomatis testing of placentas was done retro-
spectively using PCR.
Results C. trachomatis was detected in 76 (25%) placentas. Histological evidence of placental 
inflammation was present in 123 (40%) placentas: in 41/76 (54%) placentas with C. trachomatis 
versus 82/228 (36%) placentas without C. trachomatis infection (OR 2.1, 95% CI 1.2-3.5). C. 
trachomatis infection correlated with the progression (P=0.003) and intensity (P=0.002) of pla-
cental inflammation on the maternal side, but not on the foetal side. 
Conclusion C. trachomatis DNA was detected in the placenta of 25% of women with early 
premature delivery, and was associated with histopathological signs of placental inflammation. 
Figure 1 Histological signs of placental inflammation
 (a) necrotizing chorioamnionitis (maternal stage 3): degenerating subamnionic neutrophilic granulocytes and 
thickened amnionic basement membrane in placental membranes, (b) no maternal inflammation, (c) 
umbilical vasculitis (foetal stage 2): neutrophilic granulocytes infiltrate the smooth muscle of the umbilical 
arteries, (d) no foetal inflammation
A
C
B
D
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Introduction
Preterm birth is the main cause of perinatal morbidity and mortality worldwide accounting for 
60%-80% of deaths of infants born without congenital abnormalities [1]. Preterm labor is asso-
ciated with placental inflammation, especially with acute chorioamnionitis [2, 3]. Many studies 
associated clinical and histological chorioamnionitis with acute neonatal morbidity and mortality 
and, at least to some degree, also with neurological impairments and chronic lung disease [4-8].
Chlamydia trachomatis is the most common bacterial sexually transmitted infection worldwide, 
including in the Netherlands [9]. Starting as cervicitis, chlamydial infection may ascend and 
infect the placenta or amniotic fluid, which may subsequently lead to premature delivery. The 
literature regarding the association of maternal C. trachomatis infection with premature delivery, 
however, is conflicting due to differences in study design, population and microbiological test 
methods [10-18]. 
The aims of this study were to detect C. trachomatis infection in placentas of women with early 
preterm delivery and to associate C. trachomatis infection with histological signs of placental 
inflammation. In addition, we studied the association of C. trachomatis infection with delivery 
characteristics and neonatal outcome in this selected cohort of women. 
Methods
Patients and Design
The chorioamnionitis study, during which the placentas were collected that we used in the current 
Chlamydia trachomatis study, was prospective, observational, and non-interventional. Pregnant 
women, who delivered live newborns between May 2001 and February 2003 at the Erasmus 
MC-Sophia, Rotterdam, The Netherlands, at a gestational age of 32 weeks or less, were eligible 
for the study. Regular health care workers (residents, research-nursing staff, neonatologists) 
informed the women about the study. Enrolment took place immediately after delivery when 
the newborns were admitted to the neonatal intensive care unit. Women were excluded from the 
study if the placenta was not available for histological examination and, at a later stage, if no 
more placental tissue was available to test for C. trachomatis. Antenatal, perinatal and neonatal 
data were obtained from maternal and neonatal medical records and prospectively stored in a 
database. Follow-up of neonates was until a postnatal age of 28 days or postmenstrual age of 36 
weeks. Neonates, who were transferred to another hospital, were followed in order to complete 
the data. Placentas were examined for evidence of infection or other pathology. Retrospectively, 
the placentas were examined for the presence of C. trachomatis. 
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Histopathology
Immediately after delivery placentas and membranes were fixed in formalin for at least 16 hours. 
Sampling was performed according to a standard protocol with two membrane rolls, two cross 
sections of the cord and three representative blocks of the placental disk as a minimum. The 
tissues were thereafter, according to routine standard methodology for pathological specimens, 
embedded in paraffin until histopathological examination. To prevent inter-examiner variation, 
the same pathologist who was specialized in perinatal pathology examined all placentas for his-
tological evidence of inflammation. The pathologist was blinded to clinical information. Placental 
inflammation was categorized according to a maternal inflammatory response (MIR) and foetal 
inflammatory response (FIR) as suggested by the Amniotic Fluid Infection Nosology Committee 
[19], and was considered positive if there was any evidence of a MIR and/or FIR. The MIR was 
divided into three stages (acute subchorionitis or chorionitis, acute chorioamnionitis, necrotizing 
chorioamnionitis) representing progression of disease, and two grades representing intensity of 
disease; the FIR was similarly divided into three stages (chorionic vasculitis or umbilical phlebitis, 
umbilical vasculitis or umbilical panvasculitis, (subacute) necrotizing funisitis or concentric 
umbilical perivasculitis) and two grades [19]. 
After histopathological examination, the placentas were stored in paraffin blocks at room tem-
perature. Before testing for C. trachomatis, the paraffin blocks were cut on different days using 
the same microtome with single use disposable blades. Care was taken to clean materials between 
cases to avoid contamination. The paraffin blocks were cut until the surface was straight after 
which five samples per paraffin block each of 10-µm thickness were cut for further microbio-
logical analysis. 
Microbiology
DNA Isolation
The tissue samples were deparaffinized with xylene at room temperature, followed by washes in 
ethanol. Bacterial DNA was isolated using the QIA Amp Tissue Kit (QIAgen, Hilden, Germany). 
Briefly, after a first step of lysis with proteinase K, DNA was bound to a QIAamp spin column. 
The column was then washed twice and the purified DNA was eluded from the column in an 
elution buffer AE and preheated at 70ºC according to the manufacturer’s instructions.
DNA amplification and detection
Real-time PCR was carried out using the Lightcycler 2.0 system combined with the FastStart 
DNA Master SYBR Green I kit (Roche Diagnostics, Almere, The Netherlands). The primers 
NLO 5’-ATGAAAAAACTCTIGAAATCG-3’ (position 1-21) and NRO 5’-CTAACTG-
TAACTGCGTATTT-3’ (position 1128-1108) were used to amplify C. trachomatis plasmid 
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DNA [20]. Each PCR reaction contained 0.5 µM of each primer and 3 mM MgCl
2
. After an 
initial denaturation of 10 minutes at 95 ºC, the PCR reactions were subjected to 40 cycles of 15 
sec at 95 ºC, 10 sec at 60 ºC and 20 sec at 72 ºC. To check the specificity of the amplification 
products, a melting curve analysis was performed consisting of heating from 65 ºC to 95 ºC at 
a rate of 0.1 sec per step and holding for 20 sec at each step for data acquisition. The melting 
temperature for the specific amplicons was 82 ºC. For each sample, the PCR was done using a 
separate internal validation (β-globine PCR). For each run a negative control (water) and three 
positive controls (dilutions of purified C. trachomatis) were included. 
Ethical aspects
The study was approved by the Medical Ethics Committee for Research on Human Subjects of 
the Erasmus MC, Rotterdam, The Netherlands.
Statistics 
Statistical analysis was performed using the Statistical Package of Social Sciences version 11.0 
for Windows (SPSS Inc. Chicago, Illinois, USA). For comparison of categorical variables 
between groups the Fisher’s Exact test or Pearson’s Chi-square test was used. For comparison of 
the continuous variables the two-tailed Student’s T-test was used. The Mantel-Haenszel test was 
used to asses trends. Statistical significance was considered P<0.05.
Results
Three hundred and twenty three pregnant women were eligible for the study. Placental tissue 
and clinical data were available for 304 (94%) women and their newborns. 
C. trachomatis in relation to clinical characteristics
C. trachomatis was detected by PCR in 76/304 (25%) women. The demographic and antenatal 
clinical characteristics of women with and without C. trachomatis are compared in table 1. 
Maternal age, parity, gravidity, and ethnicity were similar in women with and without C. trachomatis 
infection. Clinical diagnoses of pre-eclampsia (P<0.01) and HELLP (haemolysis, elevated liver 
enzymes, low platelets) syndrome (P<0.01) were significantly more prevalent among chlamydia-
negative women whereas leucocytosis (P<0.05) and a clinical diagnosis of chorioamnionitis 
(P<0.01) were significantly more often prevalent among chlamydia-positive women. No sig-
nificant differences were observed regarding other symptoms and signs of disease at the time of 
delivery.  Eighty-four women received antibiotics for imminent premature delivery. Chlamydia-
positive women received more often antibiotics than chlamydia-negative women: 32/76 (42%) 
versus 52/228 (23%); (OR 2.5, 95% CI 1.4-4.4). Interestingly, erythromycin was prescribed 
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significantly more often to chlamydia-positive than to chlamydia-negative women: 14 (18%) 
versus 20 (9%); (OR 2.4, 95% CI 1.1-5.2). Prescription of amoxicillin-clavulanic acid and 
amoxicillin did not differ significantly between the two groups (data not shown). 
The delivery characteristics are presented in table 1. Chlamydia-positive women delivered sig-
nificantly less often by caesarean section than chlamydia-negative women (P<0.01), and delivered 
less often a newborn after foetal distress (P<0.05). Nine (27%) chlamydia-positive women who 
delivered by caesarean section had PROM and fifteen (35%) women who delivered vaginally. 
Neonates born to chlamydia-positive women were significantly less often small for their gestational 
Table 1 Clinical characteristics of pregnancies according to Chlamydia trachomatis status
C. trachomatis negative
n=228
C. trachomatis positive
n=76
OR (95% CI)
Antenatal characteristics Mean ± SD Mean ± SD
maternal age 30.9 ± 5.3 30.1 ± 5.0 NA
para 1.8 ± 1.3 1.9 ± 1.1 NA
gravida 2.2 ± 1.7 2.0 ± 1.2 NA
Symptoms and signs n (%) n (%)
abdominal pain 5 (2) 4 (5) 2.5 (0.6-9.4)
cervical discharge 18 (8) 8 (11) 1.4 (0.6-3.3)
PROM 63 (28) 24 (32) 1.3 (0.7-2.2)
temperature raised 38 (17) 19 (25) 1.7 (0.9-3.1)
CRP raised 50 (22) 20 (26) 1.3 (0.7-2.3)
leucocytosis 16 (7) 11 (15) 2.2 (1.0-5.1)
Clinical diagnosis
pre-eclampsia 91 (40) 17 (22) 0.4 (0.2-0.8)
HELLP syndrome 58 (25) 7 (9) 0.3 (0.1-0.7)
clinical chorioamnionitis 62 (27) 34 (45) 2.2 (1.3-3.7)
foetal distress 114 (50) 27 (36) 0.6 (0.3-1.0)
Delivery characteristics
caesarean section 146 (64) 33 (43) 0.4 (0.3-0.8)
gestational age 29.1 ± 1.9 29.1 ± 1.9 NA
small for gestational age 67 (29) 12 (16)  0.5 (0.2 - 0.9)
NA: not applicable, PROM: premature rupture of membranes, CRP: C-reactive protein, 
HELLP: haemolysis, elevated liver enzymes, low platelets
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age (P<0.05) (Table 1). Since these differences could also be due to group differences in maternal 
morbidity, we adjusted for the two major confounders pre-eclampsia and HELLP. After such 
adjustment the differences disappeared. 
Neonatal outcomes such as umbilical cord blood pH and base excess, Apgar scores, respiratory 
distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, periventricular 
Table 2 Risk of Chlamydia trachomatis infection according to progression and intensity of 
 inflammation in maternal and foetal placental tissues 
Placenta tissue
Total
n
C. trachomatis positive
n (%) OR (95% CI)*
no placenta inflammation 181 35 (19) 1.0 (reference)
placenta inflammation 123 41 (33) 2.1 (1.2-3.5)
Maternal tissue
no inflammation 190 38 (20) 1.0 (reference)
inflammation 114 38 (33) 2.0 (1.1-3.5)
progression**
stage 1 32 9 (28) 1.6 (0.6-3.9)
stage 2 55 17 (31) 1.8 (0.9-3.7)
stage 3 27 12 (44) 4.3 (1.7-11.2)
intensity***
grade 1 86 25 (29) 1.6 (0.9-3.1)
grade 2 28 13 (46) 4.7 (1.9-11.9)
Foetal tissue
no inflammation 236 53 (22) 1.0 (reference)
inflammation 68 23 (34) 1.8 (0.9-3.3)
progression
stage 1 15 3 (20) 0.8 (0.2-3.5)
stage 2 16 8 (50) 3.5 (1.1-10.7)
stage 3 37 12 (32) 1.7 (0.7-3.7)
intensity
grade 1 30 11 (37) 2.0 (0.8-4.8)
grade 2 38 12 (32) 1.6 (0.7-3.6)
*OR compared to placenta without inflammation, ** P=0.003 for trend, *** P=0.002 for trend
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leucomalacia, and neonatal mortality rate were not significantly different between neonates 
born to chlamydia-positive and chlamydia-negative women (data not shown). 
C. trachomatis in relation to histological signs of placental inflammation
Histological evidence of placental inflammation (PI) was present in 123/304 (40%) women of 
whom 64 (52%) had inflammation diagnosed in both maternal and foetal tissue, 50 (41%) in 
maternal tissue only, and four (3%) in foetal tissue only (Figure 1). Five (4%) placentas showed other 
specific features including peripheral funisitis, acute villitis, acute intervillositis with intervillous 
abscesses, or the presence of decidual plasma cells, but had no signs of a maternal or foetal 
inflammatory response. Chlamydia-positive women had significantly more often histopatho-
logical signs of placental inflammation than chlamydia-negative women: 41/76 (54%) versus 
82/228 (36%); (OR 2.1, 95% CI 1.2-3.5) (Table 2). 
The progression and intensity of inflammation of maternal and foetal tissues and its relation to 
C. trachomatis infection were assessed separately. Chlamydia-positive women had significantly 
more often signs of maternal progression stage 3 (Figure 1) and maternal intensity grade 2 in their 
placentas than chlamydia-negative women (Table 2). In addition, a significantly increasing 
trend towards more frequent detection of C. trachomatis was observed with increasingly higher 
scores for progression (P=0.003) and intensity (P=0.002) of inflammation (Table 2). On the 
foetal side, chlamydia-positive women had significantly more often foetal progression stage 2 in 
their placentas than chlamydia-negative women, but no trend was observed between the prevalence of 
C. trachomatis and the progression or intensity of inflammation in placental tissue (Table 2).
Discussion
Chlamydia trachomatis DNA was detected in a high proportion (25%) of placentas from women 
who had early preterm delivery (≤ 32 weeks), and C. trachomatis infection was associated with 
histopathological signs of placental inflammation. The presence of C. trachomatis did not appear 
to affect either delivery or neonatal outcomes. 
The strength of this study is the prospective, observational design during which the placentas 
and clinical data were obtained, the large number of well-described participants, a high follow-up 
rate, and the use of nucleic acid amplification technique (NAAT) for the detection of C. tracho-
matis. In order to prevent contamination of samples during the process of cutting, during DNA 
isolation or during the PCR test itself, precautions were taken. Paraffin blocks were cut in 
badges on different days by two different people using a similar microtome with single-use dis-
posable blades, and care was taken to clean materials between cases. In addition, the order of 
cutting was recorded and no clustering was observed in the detection of C. trachomatis in the 
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cuts. In addition, DNA isolation was done on different days by different laboratory technicians 
in different locations, and pipetting was performed using aerosol-resistant tips. Furthermore, 
the PCR was done using an internal validation (β-globine PCR) for each sample separately, and 
for each run using a negative control (water) and three positive controls (dilutions of purified C. 
trachomatis). None of the negative controls became positive. Therefore, contamination seems 
unlikely to have influenced the results of the study. A potential weakness of the study is that con-
founding as a result of co-infection by other pathogens was not tested as part of the study. Indeed, 
the finding of many cases of placental inflammation in the absence of C. trachomatis infection 
would support the role of other inflammation-inducing pathogens in this cohort of women. 
Another limitation was that C. trachomatis testing was done retrospectively and prospectively no 
specimens were collected from the infants, which made it impossible to study vertical transmission.
The PCR technique has been used previously to detect C. trachomatis in placentas [21-23], but 
reports focusing on the use of PCR to detect C. trachomatis in placentas of early preterm deliveries 
are very limited and from much smaller cohorts. One case report described a stillborn at 36 
weeks of gestation in whose placenta C. trachomatis was identified [21]. In a Chinese study 59 
specimens of chorionic villi were examined that had been collected from women attending an 
antenatal clinic for artificial abortion within the first trimester of pregnancy, of which three cases 
(5%) were found to be C. trachomatis positive [22]. In a Croatian study of women with a mis-
carriage between four and 19 weeks gestation, C. trachomatis was detected in only one of 108 
placental tissues examined [23]. 
A 25% prevalence of C. trachomatis in pregnant women is high. It is much higher than the C. 
trachomatis prevalence in the general population from which these pregnant women originated 
[24]. However, the current study population was a selected group of women who all delivered 
at 32 weeks gestation or earlier. The findings, though, suggest an association between C. tracho-
matis infection and preterm delivery. Indeed, the prevalence is similar to that found in one of 
our previous population-based studies among 4,055 pregnant women in the same region and 
during the same time as the present study, and for whom the referal centre is the hospital in 
which women and neonates were enrolled for the present study. In the latter study we found a 
C. trachomatis prevalence of 4% among all pregnant women and 18% among the women who 
delivered at 32 weeks gestation or less [25]. Others also reported an association between C. 
trachomatis infection and preterm delivery [16-18, 26-28]
We found no difference in maternal age, parity, gravidity, ethnicity, abdominal pain or cervical 
discharge between chlamydia-positive and chlamydia-negative women. One might have 
expected to find chlamydia-positive women to be younger than the control group. However, our 
findings are not surprising since chlamydia-positive women were not compared with a healthy 
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control group, but with another group of women with disease who had significant other risks 
for premature delivery such as pre-eclampsia and HELLP syndrome [29]. Individual symptoms 
and signs indicative of maternal infection were not significantly associated with C. trachomatis 
infection. However, symptoms and signs resulting in a clinical diagnosis of chorioamnionitis 
and leucocytosis, both of which are known to be related to infection, were significantly associated 
with the presence of C. trachomatis. 
The delivery characteristics and neonatal outcome did not differ between the chlamydia-positive 
and chlamydia-negative group, although C. trachomatis infected women seemed less likely to 
deliver by caesarean section for presumed foetal distress and their newborns were less often small 
for their gestational age. Again, these differences were due to comparison with another group of 
women with disease, pre-eclampsia and HELLP syndrome, instead of a healthy control group 
as shown by loss of these differences after adjustment for the latter confounders. We found no 
difference in acute or chronic respiratory pathology between neonates born to chlamydia-posi-
tive and chlamydia-negative women. However, since no respiratory specimens were obtained 
from the newborns and follow-up was done for only 28 days, we cannot ascribe any respiratory 
disease to C. trachomatis.  Neither were specimens collected to diagnose neonatal conjunctivitis.
Histologically proven chorioamnionitis is considered the gold standard against which other 
clinical predictors of inflammation should be measured [2, 30, 31]. Histological evidence of 
placental inflammation was present in 40% of the women of whom virtually all had signs of 
maternal inflammation whereas only half the time foetal inflammation was present. Only mater-
nal inflammation would be concordant with infection originating from the maternal side. 
Indeed, C. trachomatis was detected more often in placentas with maternal inflammation than 
in those with foetal inflammation. In addition, we found an association between the prevalence 
of C. trachomatis detection and progression and intensity of tissue inflammation only with 
maternal inflammation. Our findings, therefore, suggest that ascending C. trachomatis infection 
during pregnancy may extend into the placental tissues. Such invasion of placental tissue is 
likely to produce an inflammatory response that may trigger preterm labor and delivery [32].
C. trachomatis is transmitted from an infected mother to her newborn during passage through the 
birth canal. However, there are several, mostly anecdotal, reports of newborns delivered by caesarean 
section that were infected with C. trachomatis [33-37]. Ascending chlamydial infection in women 
undergoing caesarean section may be due to PROM, but the possibility of a transmembrane or 
transplacental route has also been suggested in the pathogenesis of neonatal chlamydial infection 
[34, 36]. In our study 43% of chlamydia-positive women gave birth by caesarean section of which 
27% had PROM. Unfortunately, we are unable to confirm the latter hypothesis since no specimens 
were collected from the newborns. The chorioamnionitis study was not designed as such.
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In conclusion C. trachomatis DNA was frequently detected in the placenta of women with early 
preterm delivery. C. trachomatis infection was associated with signs of maternal inflammation in 
the placenta, but not with any adverse outcome. Additional research is needed to study a trans-
membrane or transplacental route of transmission for chlamydial infection.
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Abstract
Background Chlamydia trachomatis is the most common sexually transmitted pathogen in 
adults, which at delivery may be transmitted from mother to child and cause conjunctivitis and 
pneumonia. In the Netherlands, prenatal chlamydial screening and treatment of pregnant 
women is not routine practice. The contribution of C. trachomatis to neonatal ophthalmic disease 
has not been studied in the Netherlands and remains unclear. 
Objective To asses whether Chlamydia trachomatis is a cause of neonatal conjunctivitis in a 
Dutch population and evaluate the clinical presentation and treatment.
Methods At the Erasmus MC-Sophia and Rotterdam Eye Hospital, two cohorts of infants less 
than three months of age presenting with conjunctivitis were studied, one retrospectively (July 
1996 to July 2001), and one prospectively (September 2001 to September 2002). Laboratory 
diagnosis was based on bacterial culture and PCR for C. trachomatis.
Results C. trachomatis was detected in 27 (64%) of 42 retrospectively studied infants and 14 
(61%) of 23 prospectively studied infants. Mucopurulent discharge was present in 35 (95%) of 
37, swelling of the eyes in 27 (73%) of 37, conjunctival erythema in 24 (65%) of 37, respiratory 
symptoms in 14 (38%) of 37 and feeding problems in five (14%) of 37 infants respectively. 
Before microbiological diagnosis, general practitioners prescribed anti-chlamydial antibiotics 
locally to five (12%) and systemically to four (10%) of 41 infants who tested positive for C. 
trachomatis, and ophthalmologists to 21 (51%) and seven (17%) of 41, respectively.
Conclusions C. trachomatis was the major cause of bacterial conjunctivitis in this population. 
Clinically, differentiation from other pathogens was not possible. Many infants who tested positive 
for C. trachomatis did not receive appropriate antibiotic treatment.
Neonatal Chlamydia trachomatis conjunctivitis, courtesy of MR Hammerschlag
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Introduction
The occurrence of Chlamydia trachomatis infection in infants is directly related to the prevalence 
of maternal urogenital infections and vertical transmission rates [1-4]. The overall risk for 
infants born to women with untreated chlamydial infection is approximately 50 to 75%, with 
infection occurring at one or more anatomic sites. Conjunctivitis may occur in 20 to 50% of 
infected infants, nasopharyngitis in up to 70% and pneumonia in 5 to 20% [5]. C. trachomatis 
has become the most frequent identifiable cause of neonatal conjunctivitis in many countries 
[6-9]. The majority of chlamydial conjunctivitis cases heal spontaneously during the first few 
months of life. However, untreated persistent infections can lead to acute discomfort and distress 
for both infant and mother, as well as to chronic eye disease. Simultaneous silent infection of 
the respiratory tract may cause acute or chronic respiratory disease [3, 10, 11]. 
Screening of pregnant women for C. trachomatis infection was recommended by the CDC more 
than a decade ago [12, 13]. In 2004 the Dutch National Health Council advised against routine 
chlamydial screening of Dutch pregnant women, because local data with respect to chlamydial 
infection in pregnant women and the contribution of C. trachomatis to neonatal disease (preg-
nancy outcome, conjunctivitis, respiratory tract infection) provided insufficient evidence to 
support screening [14, 15]. Recently we reported a prevalence of C. trachomatis infection in 
pregnant women of 6.4% [16]. Most of these infections had been missed in routine care, sug-
gesting that C. trachomatis transmission to infants may often remain unnoticed. 
The main objective of this study was to establish whether C. trachomatis was a cause of neonatal 
conjunctivitis in infants referred to hospital-based care in Rotterdam, the second largest city in 
the Netherlands. In addition, we evaluated the clinical presentation of and prescribed treatment 
for chlamydial conjunctivitis compared with other infections.
Materials and Methods
Study population
We conducted our study at the Rotterdam Eye Hospital (REH) and Erasmus MC-Sophia 
(SCH), Rotterdam, The Netherlands. Rotterdam has a multi-ethnic population. Chlamydial 
screening is not standard practice in pregnant women in the study area; testing is done on 
clinical suspicion. Neonatal ocular prophylaxis against chlamydia or gonorrhoea is not routinely 
provided. Most newborns with conjunctivitis are treated at mother and child health clinics or 
by general practitioners (GPs). Infants with persistent conjunctivitis are referred to the REH or 
SCH depending upon the parents’ or referring GP’s choice. We studied infants retrospectively 
between July 1996 and July 2001 and prospectively between September 2001 and September 
2002. Infants less than three months of age presenting to the REH or SCH with bacterial 
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(mostly persistent) conjunctivitis to the REH or SCH were eligible for the study. We defined 
bacterial conjunctivitis as having conjunctival erythema, swelling of the eyelids and/or mucopu-
rulent discharge. In the retrospective study, infants who were diagnosed by ophthalmologists with 
viral conjunctivitis (conjunctival erythema only) and who were neither microbiologically tested 
nor treated with antibiotics and improved spontaneously were excluded from the study. Similarly, 
infants with dacryostenosis (nasolacrimal duct obstruction) were excluded from the study. 
Infants diagnosed with chlamydial conjunctivitis in the REH were referred to the SCH for 
further investigation and systemic treatment. Infants diagnosed with C. trachomatis conjunctivitis 
in our prospective study were treated systemically with erythromycin suspension (ethylsuccinate), 
50 mg/kg/day in 3 to 4 oral doses for 10-14 days and were invited for a single follow-up visit. 
Parents were asked to return to the clinic if the infant had respiratory symptoms. Parents them-
selves were referred to the sexually transmitted disease clinic for investigation and treatment.
Microbiological diagnosis
Eye swabs were taken for routine bacterial culture, including gonococcal culture, and chlamydial 
and gonococcal polymerase chain reaction (PCR) (Cobas Amplicor, Roche Molecular Diagnostics, 
Pleasanton, USA). Specimens were obtained by swabbing the conjunctiva of the everted lower 
eyelid using a sterile Dacron swab. Bacteriologic cultures were processed according to standard 
procedures for aerobic bacteria in a clinical microbiology laboratory. Chlamydial and gonococcal 
PCRs were performed according to the manufacturer’s instructions.
Treatment
Antibiotics that were prescribed and considered to be effective against C. trachomatis were eryth-
romycin, azithromycin, clarithromycin, tetracycline and doxycyline, and chloramphenicol.
Data collection
We collected retrospective data through a systematic review of medical records. We used a stand-
ardised questionnaire and laboratory investigations to collect prospective data. Recorded variables 
included the following: age at presentation, gender, complaints (conjunctival erythema, swelling 
of the eyelids, mucopurulent discharge, unilateral/bilateral involvement, and respiratory or 
feeding problems), physical examination, diagnostic tests, diagnosis, and therapy by GPs and 
 ophthalmologists before microbiological diagnosis. 
Statistical analysis
We used SPSS 10.0.0 statistical software (SPSS Inc., Chicago, IL) for our analyses. We used 
uncorrected chi-square tests to compare categorical variables. We calculated risk ratios (with 95% 
confidence intervals) to examine factors associated with a diagnosis of chlamydia conjunctivitis.
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Results
Demographics
Retrospectively, 64 infants with conjunctivitis were identified; 36 (56%) were male. The median 
age was 2 weeks, with a range of 0 to 13 weeks. Prospectively, 23 infants were enrolled; 12 
(52%) were male. The median age was 1 week, with a range of 0 to 7 weeks.
Diagnostic tests
Five of 64 retrospectively studied infants were clinically diagnosed with bacterial conjunctivitis 
without performing a laboratory test. The remaining 59 infants had a bacterial culture done, 
including gonococcal culture; 42 infants also had a chlamydial PCR and 17 infants a gonococcal 
PCR. With inclusion of all tests, 50 (85%) of 59 tested infants had a positive result. All 23 of the 
prospectively studied infants had bacterial and gonococcal cultures done, as well as a chlamydial 
and gonococcal PCR. Nineteen infants (83%) had a pathogen detected. Table 1 shows the frequency 
of isolated species. Detection of C. trachomatis was significantly higher than of other pathogens 
(P<0.001), with similar rates in retrospectively and prospectively studied infants: 27 (64%) of 42 and 
Table 1 Identified pathogens among infants less 3 months of age with conjunctivitis
Pathogens detected
by test method
Retrospective
cohort
Prospective
cohort
Total
infants P-value*
RR
(95% CI)*
Bacterial culture, n 59 23 82
S. aureus, n (%) 11 (19) 0 (0) 11 (13)
H. influenzae, n (%) 5 (8) 2 (9) 7 (9)
S. pneumoniae, n (%) 4 (7) 0 (0) 4 (5)
N. gonorrhoeae, n (%) 2 (3) 0 (0) 2 (2)
other pathogens, n (%) 4 (7)† 3 (13)‡ 7 (9)
cultures with pathogens, n (%) # 24 (41) 5 (22) 29 (35)
PCR n = 17 n = 23 n = 40
N. gonorrhoeae, n (%) 1 (6) 0 (0) 1 (3)
PCR n = 42 n = 23 n = 65
C. trachomatis, n (%) 27 (64) 14 (61) 41 (63) <0.001 1.8 (1.3-2.5)
RR: risk ratio; CI: confidence interval
* P-value is for the difference in the yield between the non-chlamydia pathogen culture (29 of 82) and C. trachomatis 
PCR (41 of 65); RR reflects the higher likelihood of finding C. trachomatis than another pathogen in these infants
# Three co-infections included H. influenzae, twice with N. gonorrhoeae and once with S. pneumoniae
† Other pathogens included Moraxella catarrhalis, Escherichia coli, Stenotrophomonas maltophilia, haemolytic streptococcus
‡ Other pathogens included two M. catarrhalis and one N. meningitidis
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14 (61%) of 23, respectively. Three infants in the retrospective cohort with Haemophilus influenzae 
had a second pathogen diagnosed.
Clinical presentation
We examined the age of 69 infants with microbiologically confirmed conjunctivitis. Of these 
infants, 41 had chlamydial conjunctivitis and 28 had another infection (Table 2). Infants with 
chlamydial conjunctivitis were 2.3 times (95% CI 1.0-5.2 times) more likely than those with 
other infections to present between one and six weeks of age than within the first week of life. 
We were able to examine clinical information in 37 infants with chlamydial conjunctivitis (23 
diagnosed retrospectively and 14 prospectively) and 22 with another pathogen (17 diagnosed 
retrospectively and 5 prospectively). Because there was no significant difference between the 
retrospective and prospective study, and the number of infants in each study was small, the 
overall results of a total of 37 evaluable infants who tested positive for C. trachomatis and 22 
infants with another pathogen are shown in table 2. Mucopurulent discharge was the presenting 
Table 2 Clinical presentation of neonatal conjunctivitis by causative pathogen
C. trachomatis
n (%)
Other pathogens
n (%) P-value*
RR
(95% CI)
Age at presentation 41 28 0.03
< 1 week 4 (10) 9 (32) 1.0 (reference)
1-6 weeks 34 (83) 15 (54) 2.3 (1.0-5.2)
> 6 weeks 3 (7) 4 (14) 1.4 (0.4-4.5)
Number of symptoms 37 22 0.26
One symptom 8 (22) 9 (41) 1.0 (reference)
mp discharge 7 (19) 9 (41)
redness 1 (3) 0 (0)
Two symptoms 9 (24) 5 (23) 1.4 (0.7-2.6)
mp discharge + swelling 6 (16) 3 (14)
mp discharge + redness 2 (5) 2 (9)  
redness + swelling 1 (3) 0 (0)
Three symptoms 20 (54) 8 (36) 1.5 (0.9-2.7)
mp discharge + swelling + redness
Extra-ophthalmic symptoms 37 20
respiratory 14 (38) 6 (30) 0.55 1.3 (0.6-2.8)
feeding 5 (14) 2 (10) 0.70 1.4 (0.3-6.4)
RR: risk ratio; CI: confidence interval, mp: mucopurulent 
*P-value for the test of heterogeneity of age or number of symptom categories; P-value of extra-ophthalmic symptoms for 
the difference between pathogen categories
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symptom for 35 (95%) of 37 infants who tested positive for C. trachomatis, swelling of the 
eyelids for 27 (73%) of 37, and conjunctival erythema for 24 (65%) of 37 compared with 22 
(100%) of 22, 11 (50%) of 22, and 10 (45%) of 22, respectively, for infants with other pathogens; 
27 (73%) of 37 infants who tested positive for C. trachomatis had bilateral eye involvement 
compared with 17 (77%) of 22 of infants with other pathogens. The presence of extraophthalmic 
symptoms did not differ between infants with chlamydia and those with another pathogen 
(Table 2). Feeding difficulties corresponded with respiratory complications in infants who 
tested positive for C. trachomatis. In the other group, these were separate cases. Additional 
symptoms in infants who tested positive for chlamydia included rhinitis (12 of 37), cough (4 of 
37), excessive mucous (3 of 37), and wheezing or breathing difficulty (2 of 37). In the group of 
infants with other pathogens, 4 of 20 had rhinitis; one had cough, and one had wheezing and 
crepitations.
Therapy
Both GPs and ophthalmologists prescribed topical antibiotics as eye ointment, gel, or drops, 
including tetracycline, aminoglycosides with or without steroids (gentamicin, soframycin, or 
tobramycin), fusidic acid, polymyxin/trimethoprim, ofloxacin, and erythromycin. In addition, 
GPs also prescribed chloramphenicol. Both GPs and ophthalmologists prescribed systemic treatment, 
including penicillin, clarithromycin and erythromycin. In addition, GPs used co-trimoxazole 
and ophthalmologists used amoxicilin, augmentin, flucloxacillin, and cefotaxime.
Antibiotic treatment by diagnosis as prescribed by GPs and ophthalmologists is shown in table 3.
Comparison of treatment in the retrospective and prospective cohort showed that ophthalmologists 
gave empiric antibiotics to 17 (63%) of 27 infants who tested positive for C. trachomatis in the 
retrospective versus 14 (100%) of 14 in the prospective study, (P<0.01), anti-chlamydial antibiotics 
to 14 (52%) of 27 and 7 (50%) of 14 infants (P=0.9), and systemic treatment to 6 (22%) of 27 
and one (7%) of 14 infants, respectively (P=0.22).
Table 3 Antibiotic treatment prescribed by GPs and ophthalmologistss
Antibiotic treatment according to diagnosis
GPs
n/N (%)
Ophthalmologists
n/N (%) P-value *
Any confirmed bacterial conjunctivitis
any antibiotic 30/69 (43)  51/69 (74) <0.001
C. trachomatis conjunctivitis
any antibiotic 20/41 (49) 31/41 (76) 0.01
anti-chlamydial antibiotic 5/41 (12) 21/41 (51) <0.001
systemic anti-chlamydial antibiotic 4/41 (10) 7/41 (17) 0.33
* P-value for the difference in treatment choice between GPs and ophthalmologists
125
Chlamydia trachomatis conjunctivitis in Dutch infants
Binnenwerk Chlamydia trachomatis.indb   125 6/16/10   12:39 PM
Follow-up
At follow-up, no more conjunctivitis was observed, and no symptoms or signs of respiratory 
tract infection were present.
Discussion
This study demonstrated that C. trachomatis was the major cause of neonatal conjunctivitis in 
this population of infants referred to paediatric or eye hospitals in Rotterdam. On clinical presentation, 
no distinction could be made between chlamydial conjunctivitis and conjunctivitis caused by other 
pathogens. Empiric management to treat chlamydial conjunctivitis was frequently inappropriate. 
The main limitation of this study was that we could only include infants with conjunctivitis 
who were referred to specialist hospitals. Other limitations were the incomplete diagnostic 
work-up in the retrospective cohort and missing data on clinical symptoms in a few infants. 
Also, the number of children in analyses was relatively small, too small to draw firm conclusions. 
Although we cannot show what proportion of all neonatal conjunctivitis is caused by C. trachomatis, 
we have shown that it is an important cause of (persistent) conjunctivitis. Determining the 
incidence of chlamydial neonatal conjunctivitis and transmission rates would require a prospective 
study testing all pregnant women and their newborns. 
The identification rate of pathogenic bacteria in our study was 84%, which is higher than in 
most reports [17-20]. In addition, C. trachomatis was the organism isolated most often. This is 
likely to be related to our study design and to the Dutch referral system, in which mainly 
infants with persistent conjunctivitis are referred to ophthalmologists. However, we may even 
have underestimated the contribution of chlamydia to persistent neonatal conjunctivitis, 
because we excluded the infants with a clinical diagnosis of viral conjunctivitis. Underdiagnosis 
of C. trachomatis persistent conjunctivitis may also be suggested by the relatively low observed 
number of five cases per year in the retrospective study versus 14 in the prospective year. How-
ever, the latter increase may also reflect an actual increase of chlamydial infection in Dutch 
adults [21].
To put our results into context, we related the findings from our prospective study to obstetric 
data from the SCH in that year. There were 1,648 deliveries in total, of which 731 were in 
women under 30 years of age. With an antenatal prevalence of 6.4% [16], about 47 women 
would be expected to have C. trachomatis infection. With an estimated transmission rate of 50 
to 75% and 20 to 50% of these developing conjunctivitis [5], we would expect 9 to 24 infants 
with chlamydial conjunctivitis, which corresponds with our findings. This may suggest that all 
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of the infants with conjunctivitis were detected. However, not all studied infants were born to 
women delivering at the SCH, but also in other hospitals in Rotterdam or at home. 
The clinical presentation of chlamydial conjunctivitis has been extensively described by others 
and our study shows similar results to previous reports [3, 4, 9, 22-24]. Most infants who tested 
positive for C. trachomatis presented between the ages of one and six weeks (because of the slow 
reproductivity of the organism), and with all three of the symptoms (erythema, swelling, discharge).
Ophthalmologists more often prescribed antibiotics that were effective against chlamydial infec-
tion than GPs. Still, only half of the infants with chlamydial conjunctivitis received effective 
antibiotics before microbiological diagnosis, and less than 20% received systemic treatment. In 
the prospective study, even fewer infants received systemic treatment. This probably reflects the 
agreement made with ophthalmologists to refer infants to a paediatrician after diagnosis. We 
cannot draw any conclusions about chlamydial conjunctivitis in primary health care from our 
study. Acute conjunctivitis may be correctly treated by GPs with topical antibiotics according to 
Health Care Insurance Board guidelines. However, C. trachomatis is probably not being considered 
in the differential diagnosis by some GPs, because only 12% of infants with chlamydia had 
received antibiotics that were active against C. trachomatis.
Our results may suggest the need to institute eye prophylaxis for ophthalmia neonatorum, 
which is not practiced in the Netherlands. However, we do not want to advocate the application 
of neonatal eye prophylaxis, because prophylaxis does not prevent all chlamydial neonatal con-
junctivitis, and the absence of conjunctivitis as an indicator of chlamydial infection may delay 
the proper diagnosis of (silent) chlamydial infection at other sites. Another motivation against 
the decision to start routine eye prophylaxis is that this may lead to overtreatment of newborns 
in a country with easy access to medical care. We would rather like to use our findings to indicate 
the need for proper (systemic) antibiotic treatment of infants who test positive for C. trachomatis 
and screening of pregnant women.
Chlamydial screening for pregnant women is not standard practice in the study area or in the 
rest of the Netherlands. Testing is only done when clinically warranted. In the prospective year 
of the study, only 1% of 1,648 deliveries were tested for C. trachomatis, of which 4 tested positive. 
These figures may also reflect the underestimation of chlamydial infection in pregnant women. 
The value of screening may warrant further discussion [16]. To prevent one case of chlamydial 
conjunctivitis, 31 to 78 pregnant women need to be screened. Assuming a specificity of 99.8% 
or more [16], this could result in 0.06 to 0.16 false-positive mothers and 2 to 5 truly positive 
mothers (and their partners); furthermore, this could result in the prevention of 1.4 to 2.5 
nasopharyngitis cases and 0.2-1.0 pneumonia cases. Previously we described the costs for C. 
trachomatis screening of pregnant women by different DNA-isolation methods in individual 
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and pooled urine samples [16]. The cost per C. trachomatis case detected when using the Cobas 
Amplicor on individual urine samples was 275 euros and when using a combined method of 
isolation with the MagNA Pure bacterial DNA-isolation kit (Roche Molecular Diagnostics, 
Pleasanton, USA), and subsequent amplification and detection by Cobas Amplicor on pooled 
urine samples, as we did, was 108 euros. 
In the absence of a chlamydial screening program, we urge clinicians to have a higher index of 
suspicion for neonatal and maternal chlamydial infection. Furthermore, we recommend that in 
areas where prenatal chlamydial screening and treatment of pregnant women is not routine 
practice, infants with signs of conjunctivitis that persist for more than 72 hours while applying 
frequent normal saline eye irrigation should have a full microbiological evaluation including N. 
gonorrhoeae and C. trachomatis. While awaiting laboratory results, empiric treatment in this 
population should include erythromycin eye drops or ointment to both eyes. We recommend 
that confirmed chlamydial conjunctivitis should be treated systemically with erythromycin sus-
pension or alternatively azithromycin [13, 25]. 
Current national treatment guidelines for neonatal chlamydial conjunctivitis are from the 
Health Care Insurance Board and recommend tetracycline eye drops (with or without oral 
erythromycin or tetracycline) [26]. The current CDC recommendation, however, is to treat all 
neonatal chlamydial conjunctivitis systemically with a 14-day course of erythromycin suspension 
[13]. Systemic treatment has been demonstrated to be more effective than topical treatment, and 
infants with conjunctivitis are often infected at other sites as well [27].
In conclusion the high rate of C. trachomatis in infants with persistent conjunctivitis confirms 
the importance of this infection in the Netherlands. GPs and ophthalmologists need to consider 
C. trachomatis in the differential diagnosis of neonatal conjunctivitis and use appropriate antibiotics. 
Targeted screening for C. trachomatis prenatally to prevent infection and related complications in 
both mother and infants should again be considered in those countries where it is not routine practice.
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Abstract
Background Chlamydia trachomatis is the most common bacterial pathogen causing sexually 
transmitted infections in Dutch adults. As prenatal screening for C. trachomatis and treatment 
of pregnant women is not routine practice in the Netherlands, perinatal transmission of 
C. trachomatis may therefore occur. 
Methods We evaluated the presence of C. trachomatis in infants less than six months of age who 
presented with respiratory complaints to the Erasmus MC-Sophia. Respiratory specimens, primarily 
nasopharyngeal swabs, were tested for C. trachomatis, respiratory viruses and Mycoplasma pneumoniae 
using PCR, viral isolation in cell cultures and direct immunofluorescence. 
Results C. trachomatis respiratory tract infection was confirmed to be relatively common with 
detection in 10 (7%) of 148 infants tested. C. trachomatis had not been tested for by the attending 
physicians, but was the second most frequently detected respiratory pathogen after human Res-
piratory Syncitial Virus, which was found in 41 (28%) infants. 
Conclusion Perinatal respiratory infection with C. trachomatis was common and underesti-
mated in this population.
Chlamydia trachomatis pneumonia, courtesy of FJ Dijkstra [6]
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Introduction
Although Chlamydia trachomatis is currently the most prevalent sexually transmitted bacterial 
infection in the Netherlands, pregnant women are not screened for C. trachomatis infection in 
the Netherlands and neither is it a notifiable disease. The prevalence of C. trachomatis infection 
among pregnant women in Rotterdam, however, is approximately 6% [1]. Recently, we reported 
that C. trachomatis was a major cause of neonatal conjunctivitis in infants less than three months 
of age in our population in Rotterdam [2].
In the present study we evaluated the presence of C. trachomatis respiratory tract infection in 
infants presenting with respiratory complaints in the same region in Rotterdam, The Netherlands.
Methods
Design
The study was conducted at the Erasmus MC-Sophia, Rotterdam, The Netherlands. C. trachomatis 
screening is not standard practice in pregnant women in the study area; testing is done on 
clinical suspicion only. Respiratory specimens (nasopharyngeal aspirates or broncho-alveolar 
lavages) were collected from infants less than 6 months of age who presented with symptoms 
and signs compatible with respiratory tract infection to the hospital between January 2002 and 
January 2003. All specimens were prospectively tested for viral pathogens and Mycoplasma pneumoniae, 
and retrospectively tested for C. trachomatis. Clinical data, eosinophil count and chest X-ray 
results were collected through a systematic review of medical records. 
Microbiological diagnosis
Initially, the samples were sent to the virology laboratory specifically requesting a test for respiratory 
viruses. Routine virological testing for respiratory pathogens was performed using direct 
immunofluorescence on cells in respiratory specimens, virus isolation in cell cultures and 
immunofluorescence, and included human Respiratory Syncitial Virus (hRSV), influenza A, B 
and C viruses, human para-influenza virus types 1-4, adenovirus and rhinovirus. Following a 
diagnosis of picornavirus, nucleic acid amplification techniques were performed with specific 
primers. Detection of human Metapneumovirus (hMPV), M. pneumoniae and C. trachomatis 
was done by PCR. 
Satistical analysis
Data were analyzed using SPSS 10.0.0 (SPSS Inc, Chicago, IL). P value <0.05 was considered 
significant. 
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Results
A total of 157 infants were eligible for the study. From nine infants the specimens were consumed 
while testing for viral pathogens during admission. From 148 (94%) infants, 187 respiratory 
specimens (184 nasopharyngeal aspirates and three broncho-alveolar lavage fluids) were available 
for C. trachomatis testing. Mean age of the infants was 67 days ± 49 days (range 1 to 172 days), 
68 (46%) of 148 were female and 80 (54%) of 148 were male. 
Potential respiratory pathogens were identified in 67 (45%) of 148 infants. C. trachomatis was 
detected in 10 (7%) infants. Among the viral pathogens, hRSV was most frequently detected in 
41 (28%) infants, followed by rhinovirus (6 of 148 [4%]), influenza A virus (3 of 147 [2%]), 
adenovirus (2 of 147 [1%]), para-influenza 3 virus (2 of 147 [1%]) and para-influenza 1 virus 
(1 of 147 [1%]). Influenza B and C virus, para-influenza 2 and 4 virus, hMPV and M. pneumoniae 
were not detected. One (10%) C. trachomatis positive infant was also infected with hRSV. 
Comparison of C. trachomatis and viral pathogens by age group (less than three months versus 
three to six months) showed that both C. trachomatis and hRSV infections were more often 
observed in the younger group (Figure 1). Eight (80%) of 10 C. trachomatis infections occurred 
before three months of age. hRSV was the most common pathogen detected in 28% of infants 
in both age groups.
The underlying pathology and clinical characteristics of the 10 C. trachomatis positive infants 
and their mothers are shown in table 1. Most infants had significant underlying disease except 
for patient 4 and 5. Five infants had a history of conjunctivitis: patient 1 had Klebsiella pneumoniae 
cultured from a conjunctival specimen four days after birth and patient 3 had Haemophilus 
Figure 1 Cumulative incidence of Chlamydia trachomatis and hRSV infection in infants
 presenting with respiratory infection 
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Table 1 Characteristics of Chlamydia trachomatis positive infants and their mothers
Infant number 1 2 3 4 5 6 7 8 9 10
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Characteristics Mother
maternal age 32 31 26 24 28 31 27 23 35 21
gravidity 1 1 2 1 4 2 1 1 5 1
term delivery + + + + + + + + + +
vaginal delivery + + + + + C/S + + + +
Infant
AGA + + SGA + + + + + + +
age at testing (days) 11 17 26 32 33 45 48 65 147 168
rhinorrhoea/congestion + - - + + + + + + -
fever - - + - - - - + + -
cough - + - - + - + - - -
apnoea - - - - + - - - - -
cyanosis + + - - + + + - - -
retractions - - + - + + - - - +
wheezing - + - - + - - - - +
crepitations + - - - - - - - - -
dyspnoea + + + - + + + + - +
tachypnoea + + - + - + + + - +
oxygen requirement + + + - + + + - - -
feeding difficulties + + + + + + + + + +
X-ray chest
hyperinflation - - - - + - + - ND +
atelectasis + + - - + + - - ND -
interstitial infiltrates - - - - - - - - ND +
consolidation + - - - - - - - ND -
Laboratory
leucocytes (.109/l) 12.7 9.0 9.0 14.1 4.6 10.8 9.4 1.3 23.0 26.0
eosinophils (mm³) 889 720 90 1128 ND ND 752 0 ND 780
Viral pathogens
hRSV - - - - + - - - - -
IUGR: intra-uterine growth retardation, VLCAD: very long-chain acetyl coenzymeA dehydrogenase deficiency, C/S: 
caesarean section, AGA: appropriate for gestational age, SGA: small for gestational age, ND: not done 
135
Chlamydia trachomatis respiratory infection in Dutch infants
Binnenwerk Chlamydia trachomatis.indb   135 6/16/10   12:39 PM
influenzae at 22 days of age; eye cultures from the other infants showed no growth. None of the 
eye samples were tested for C. trachomatis. Seven infants had signs compatible with upper respiratory 
tract infection and most infants had signs compatible with lower respiratory tract infection. 
However, only one patient (#10) had a characteristic chest X-ray with hyperinflation and inter-
stitial infiltrates compatible with chlamydial pneumonia. Bacterial cultures of the nasopharynx, 
sputum and/or blood were negative for all infants except patient 3 and 5, who had H. influenzae 
and M. catarrhalis with K. oxytoca in the sputum. 
Two C. trachomatis positive nasopharyngeal specimens were obtained from patient 8: at the age 
of 65 days and 174 days. On both occasions she had rhinorrhea and congestion. 
Discussion
In this study C. trachomatis was detected in 7% of infants less than 6 months of age presenting 
to hospital with respiratory tract infection. The role of C. trachomatis as a causative pathogen for 
respiratory disease in young infants is well described in the literature [3, 4]. All respiratory 
specimens in our study were sent to the laboratory for viral tests, but none were sent for 
C. trachomatis. This suggests that the attending physicians have a low index of suspicion for 
C. trachomatis infection in these infants. 
The main limitations of the study are the retrospective design, lack of controls, and the fact that 
we only included infants who presented to the hospital. Therefore, this study cannot be regarded 
as a population-based study of the frequency of chlamydial infections. Neither can we be sure 
that C. trachomatis is the causative pathogen of the respiratory complaints in these infants 
instead of being coincidental finding. It does, however, demonstrate the relative importance of 
perinatally acquired C. trachomatis infection among infants with respiratory complaints in this 
population. 
The nasopharynx is the most frequent site for perinatally acquired C. trachomatis infection, but 
only about 20% of infants with nasopharyngeal infection go on to develop pneumonia. 
Nasopharyngeal infection is usually asymptomatic and self-limiting but may persist for periods 
of up to one year. C. trachomatis pneumonia has a characteristic presentation. Infants usually 
present between 3 and 12 weeks of age with tachypnoea, a distinctive (staccato paroxysmal) 
cough and are usually afebrile. Chest auscultation reveals crepitations, with no or minimal 
wheezing. Chest X-rays show hyper-expansion with bilateral, diffuse interstitial and patchy 
alveolar infiltrates. Peripheral eosinophilia and elevated anti-C. trachomatis IgM antibodies may 
be present [3, 4]. In our study, we found 10 infants with C. trachomatis nasopharyngeal infection 
and only one infant had the characteristic presentation of chlamydial pneumonia with infiltrates 
present on chest X-ray. Interestingly, more than half the infants were dyspnoeic, cyanotic or 
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required oxygen support. Respiratory failure has been described with chlamydial infection, but 
is relatively uncommon and mainly described in preterm infants with an early onset respiratory 
distress syndrome [5]. Therefore, the more severe, atypical course of chlamydial infection in our 
infants may rather be due to underlying pathology, which included significant cardiopulmonary 
disease, antenatal hypoxia, acute myeloid leukemia and intrauterine growth retardation with 
microcephaly and dysmorphic features. 
In conclusion, this study demonstrated that perinatal respiratory infection with C. trachomatis 
is common in the Netherlands. We recommend that in countries such as the Netherlands, where 
screening for C. trachomatis is not part of routine antenatal care, testing for C. trachomatis should 
be included in diagnostic and treatment protocols for respiratory disease in infants during the 
first six months of life.
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Abstract
Background The success of large-scale screening for Chlamydia trachomatis depends on the 
availability of non-invasive samples, low costs and high-quality testing. 
Objective This study was conducted to evaluate pooled testing for C. trachomatis in pregnant 
women while using urine specimens. 
Methods First void urine specimens from 750 consecutive asymptomatic pregnant women 
from the Rotterdam area, The Netherlands, were collected. Initially, we investigated the per-
formance of three different DNA isolation methods with 350 of these urines and 70 pools of 
five of the same subset of urine samples. The routinely used Cobas Amplicor test was compared 
to the Cobas Amplicor with prior DNA isolation by the MagNA Pure large-volume kit and 
with prior DNA isolation by the MagNA Pure bacterial DNA isolation kit. Next, using all 750 
urines, the Cobas Amplicor performance for individual testing was compared to pooled testing 
with the standard Cobas Amplicor procedure and subsequently to pooled testing with the 
Cobas Amplicor in combination with the MagNA Pure bacterial DNA isolation kit.
Results The combination of the Cobas Amplicor with prior DNA isolation by the MagNA Pure 
bacterial DNA isolation kit provided the best DNA test for pooled urines, with a sensitivity 
twice that of the other methods. The sensitivity of the Cobas Amplicor was 65% on individual 
and 42% on pooled urines, but improved to 92% on pooled urines with the MagNA Pure bac-
terial DNA isolation kit, making this combination the best screening method. The C. tracho-
matis prevalence in this population appeared to be 6.4%. Additionally, the cost of the combined 
MagNA Pure bacterial DNA isolation kit and Cobas Amplicor method on pooled urines was 
only 56% of the cost of the standard Cobas Amplicor test applied to individual urines. Costs 
per positive case detected in the combined method were 39% of standard costs.
Conclusion Pooled testing for C. trachomatis infection in asymptomatic pregnant women can 
be developed for large scale testing provided the Cobas Amplicor method is used together with 
prior chlamydial DNA isolation by the MagNA Pure Bacterial DNA Isolation Kit. This combi-
nation significantly improves sensitivity and decreases costs.
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Introduction
Chlamydia trachomatis is one of the major sexually transmitted pathogens, and high prevalences 
of chlamydial infection have been documented for asymptomatic women in many European 
countries [1]. Asymptomatic carriers are of substantial importance in the transmission of C. 
trachomatis infection within a community. Asymptomatic chlamydial infection in pregnant 
women imposes an additional risk for acute and chronic consequences for the women them-
selves and their (unborn) offspring [2-6]. In the Netherlands, C. trachomatis causes most sexu-
ally transmitted infections with approximately 60,000 new cases estimated for a total popula-
tion of 16 million in the year 2000. Studies in general practice have shown an increase in the 
incidence of chlamydial infections [7], but data covering other specific target groups outside of 
the sexually transmitted disease (STD) outpatient clinics are sparse [8]. Dutch population-
based screening for C. trachomatis is still under debate, with cost-effectiveness of screening, 
complexity of sampling, the reliability of test methods, and the nature of the target population 
as major issues of discussion [9]. 
In order to investigate the prevalence of chlamydial infection during pregnancy in Rotterdam, 
and the risk factors and consequences of chlamydial infection during pregnancy for women and 
newborns, a follow-up study was planned. We explored different methods for C. trachomatis 
testing with respect to sensitivity and cost-effectiveness. The preferred method for the detection 
of asymptomatic chlamydial infection with a low threshold should involve urine specimens in 
combination with nucleic acid amplification techniques (NAATs) [10]. However, bacterial 
loads in urine are generally low, which has an adverse effect on the sensitivity of NAATs [11]. 
Urines of asymptomatic women generate inferior NAAT results, sometimes 10% lower in sen-
sitivity than attained for male urines [12, 13]. To reduce the costs of chlamydial screening in 
low-prevalence populations, pooling of urine specimens has been suggested. Although some 
studies suggested 100% sensitivity of pooled testing compared to individual testing [14, 15], 
other studies showed a lower sensitivity [16, 17], which decreased most significantly when eight 
or more urines were pooled [16, 18]. Another important aspect is that large-scale screening 
programs require automation of test procedures, which should simultaneously improve the 
quality of testing and should reduce the costs. 
To date limited data are available concerning NAATs performed on urines from (asymptomatic) 
pregnant women as well as for NAATs for pooled urines. We present a study among 750 preg-
nant women in which the performance and costs of testing with both pooled urines and auto-
mated specimen preparation (using the MagNA Pure LC system and DNA amplification with 
the Cobas Amplicor system) for the detection of asymptomatic C. trachomatis infection were 
evaluated. 
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Materials and Methods
Patient population
Pregnant women and their offspring were enrolled in the Generation R study, a prospective 
multi-center, population-based cohort trial that includes 10,000 children and women in Rot-
terdam, The Netherlands. The study focuses on growth, development, and health of children 
from intra-uterine fetal life to adolescence [19]. Pregnant women before 24 weeks of gestational 
age who were Dutch residents and expected to deliver in the Rotterdam area were approached 
to take part in the study. After informed consent was obtained, women were asked for a fresh 
first-void urine specimen, preferably at a gestational age of 12 weeks. For the current study, 750 
urine specimens were tested anonymously. 
DNA amplification
Throughout the study, the automated C. trachomatis Cobas Amplicor PCR system (Roche 
Diagnostics, Almere, The Netherlands) was used according to the manufacturer’s instructions to 
detect chlamydial DNA in specimens processed by any of the methods described below [12]. 
Positive specimens were subjected to quantitative LightCycler PCR (version 3.5) to assess the 
bacterial load [20]. For this purpose, DNA was isolated from each specimen according to 
method IIIB (see below). The PCR protocol was based on the use of the FastStart DNA Mas-
terPLUS SYBR Green I kit (Roche), the primers 5’-GGACAAATCGTATCTCGG-3’ and 
5’-GAAACCAACTCTACGCTG-3’, and 40 amplification cycles. The same dilution range of 
C. trachomatis serovar E (100, 10-2, and 10-4 [relative C. trachomatis concentrations]) was 
included in each run and used to calculate the concentration of target DNA relative to the ini-
tial copy number in the undiluted control. Since this control was not subjected to titration, the 
absolute number of bacteria could not be determined. 
Processing of specimens
The 750 samples were analyzed in two separate batches. Initially, a group of 350 samples was 
tested according to six different protocols as outlined below and in figure 1 (methods IA to 
IIIB). Afterwards, all 750 samples were tested individually using the Cobas Amplicor, tested in 
pools of five according to the Cobas Amplicor procedure, and tested in pools of five with pre-
ceding DNA purification by use of the MagNa Pure bacterial DNA isolation kit III.
Method IA: Cobas Amplicor on individual urines
Single urine specimens were processed according to the instructions of the Cobas Amplicor 
manufacturer (Roche Diagnostics). In short, a 500 µl-urine specimen was diluted with 500 µl 
of washing buffer and centrifuged at 14,000 rpm. The pellet was resuspended in 250 µl lysis 
buffer and centrifuged again after addition of 250 µl diluent. The supernatant (50 µl) was used 
for PCR. The results were reported as negative or positive.
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Method IB: Cobas Amplicor on pooled urines 
Pools for the Cobas Amplicor were made by adding 100 µl of five different urines into one tube. 
The 500 µl-urine specimen was further processed as described above, and 50 µl of the superna-
tant was used for PCR. The urines from negative pools were reported as negative. Urines from 
positive pools were individually retested and reported as described for method IA. 
Method IIA: MagNA Pure large-volume kit on individual urines
The MagNA Pure LC DNA Isolation Kit-Large Volume (Roche Diagnostics) was used to isolate 
DNA from urines according to the manufacturer’s instructions. From individual urines a 1,000-
µl specimen was used. DNA was isolated in the automated MagNA Pure LC instrument using 
an elution volume of 100 µl, of which 25 µl was used for PCR. The results were reported as 
negative or positive.
Method IIB: MagNA Pure large-volume kit on pooled urines 
The MagNA Pure LC DNA Isolation Kit-Large Volume (Roche Diagnostics) was used accord-
ing to the manufacturer’s instructions. Pools were made of five urines by adding 200 µl of each 
of the five urines into one tube. From these pools the full 1,000-µl specimen was taken and used 
without further processing. DNA was isolated in the automated MagNA Pure LC instrument 
using an elution volume of 100 µl, of which 25 µl was used for PCR. The urines from negative 
pools were reported as negative. Urines from positive pools were individually retested and 
reported as described for method IIA.
Method IIIA: MagNA Pure bacterial DNA isolation kit on individual urines
The MagNA Pure LC Bacterial DNA Isolation Kit III (Roche Diagnostics) was used to isolate 
DNA from individual urines. From single urines 500 µl was taken and centrifuged for 10 min 
at 14,000 rpm. Subsequently 400 µl was removed and the pellet was resuspended in 100 µl of 
the remaining supernatant, mixed with 130 µl lysis buffer and 20 µl proteinase K, incubated for 
10 min at 65 °C, and denatured for 10 min at 95°C.  Finally, DNA was isolated in the auto-
mated MagNA Pure LC instrument using a sample volume of 250 µl and an elution volume of 
100 µl. Again, 25 µl was used for PCR. The results were reported as negative or positive.
Method IIIB: MagNA Pure bacterial DNA isolation kit on pooled urines
The MagNA Pure LC Bacterial DNA Isolation Kit III (Roche Diagnostics) was used to isolate 
DNA from pooled urines. Pools were made of five urines by adding 200 µl of each of the five 
urines into one tube. From each pool the full 1,000 µl was taken and centrifuged for 10 min at 
14,000 rpm. Subsequently 900 µl was removed, and the pellet was resuspended in 100 µl of the 
remaining supernatant, mixed with 130 µl lysis buffer and 20 µl proteinase K, incubated for 10 
min at 65°C, and thereafter denatured for 10 min at 95°C.  Finally, DNA was isolated in the 
automated MagNA Pure LC instrument using a sample volume of 250 µl and an elution vol-
ume of 100 µl. Again, 25 µl was used for PCR. The urines from negative pools were reported as 
negative. Urines from positive pools were individually retested and reported as described for 
method IIIA.
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Figure 1 summarizes the various volumes used in each test method. In method IIA, IIB, IIIA, 
and IIIB, the elution buffer did not contain MgCl
2
 and consequently could not be used directly 
in the PCR. Therefore, the eluate for amplification was mixed 1:1 with MgCl
2
- containing dilu-
ent from the Cobas Amplicor system. In the PCR 50 µl of this mixture was used.
Discrepancy analysis
A specimen was considered to be truly positive if one or more of the test methods described 
above gave results that were positive for individual samples. When a pool was positive, all indi-
vidual samples were retested according to the same procedure as used for the pool in order to 
identify the positive specimen(s). A positive pool result was considered to be truly positive when 
one or more individual samples within the pool appeared to be positive by either method. A 
positive pool result was considered to be false positive when none of the individual samples 
within the pool turned out positive. A negative pool result was considered true negative in the 
presence of a positive internal inhibition control as included in the commercial Cobas Amplicor 
kit. All individual samples and pooled samples were retested when results were discrepant. 
When the internal control was negative, the sample contained inhibitors. Retesting was per-
formed after diluting the specimen 10-fold and heating the sample for 10 min at 95°C.
Costs
We calculated the costs of materials and reagents for individual and pooled testing by the stand-
ard Cobas Amplicor method and by the Cobas Amplicor in combination with the MagNA Pure 
bacterial DNA isolation kit. We used list prices available at the time of the study. We assumed 
full runs for each test method, which consist of 20 specimens plus a positive and a negative 
control per run for the Cobas Amplicor and 32 MagNa Pure specimens. We calculated total 
costs and costs per positive case detected. We also calculated the costs per positive case using the 
standard Cobas Amplicor for individual urines versus the combination of the Cobas Amplicor 
with the MagNA Pure bacterial DNA isolation kit for pooled urines. This was done for hypo-
thetical prevalences in a population ranging between 1% and 10%. Calculations were based on 
full runs and pools of 5 urines and the sensitivity determined for the Cobas Amplicor method 
with individual urines and for the combined method with pooled urines.
Statistical analysis
Binomial 95% confidence intervals (CI) were calculated for the prevalences and sensitivities of 
the different DNA isolation methods. McNemar’s test was used to compare the two methods. 
The nonparametric Kruskal-Wallis H test was used to compare median results. 
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Results
Comparison of three different DNA isolation methods
Figure 1 summarizes the results of the analysis of the initial 350 urine specimens. Individual 
urines processed according to methods IA, IIA, or IIIA scored positive in 15, 14 and 27 cases, 
respectively. This equals sensitivities of 51.7%, 48.3% and 93.1% when calculated on the basis 
of the number of true positives (n=29). The specificity was 100% for all tests.
Nine pools were positive with the standard Cobas Amplicor test method (method IB). The use 
of the MagNA Pure large-volume DNA Isolation Kit also yielded nine positive pools and the 
use of the MagNA Pure bacterial DNA isolation kit resulted in 19 positive pools, which included 
the 9 pools that were positive by the standard Cobas Amplicor test as well as by the MagNA 
Pure large-volume DNA Isolation Kit. Including the MagNa Pure bacterial DNA isolation kit 
clearly provided the most sensitive test method (McNemar’s test, P<0.01), with equal sensitivi-
ties when testing pooled urines compared to individual urines.
Comparison of the Cobas Amplicor method for individual urines with pooled urines 
Pooling of urines was compared to individual testing with the Cobas Amplicor method on all 
750 urines; results are summarized in table 1. Testing individual urines by the Cobas Amplicor 
method yielded 31 positive test results out of 750 specimens, resulting in an estimated preva-
lence for C. trachomatis of 4.1% among these pregnant women. Testing of pooled urines by the 
Cobas Amplicor method resulted in 15 positive pools out of 150 pools. Subsequent individual 
testing of the 75 urines from these 15 pools by the Cobas Amplicor yielded 20 positive tests, 
which with a total of 750 urines resulted in an estimated prevalence of 2.7%. Eleven specimens 
would have been reported falsely negative when using the Cobas Amplicor test only on pooled 
urines (11/730 = 1.5%), which proved the sensitivity of standard processing of pooled urines by 
the Cobas Amplicor method to be 65% compared to individual testing of urines by the Cobas 
Amplicor method. The number of truly positive samples was 48.
Performance of the MagNA Pure bacterial DNA isolation kit with pooled urines
Pooled urines were tested using the standard Cobas Amplicor method as described above, and 
results were compared to the performance of the combination of the Cobas Amplicor method 
with the MagNA Pure bacterial DNA isolation kit (Table 1). All 750 urines were tested in pools 
of five urines. A total of 34 pools tested positive by the Cobas Amplicor after DNA isolation was 
done with the MagNA Pure bacterial DNA isolation kit. Subsequent testing of the 170 indi-
vidual urine specimens yielded 44 positive urines compared to 20 urines by the standard Cobas 
Amplicor method (McNemar’s test, P<0.001). 
Two pools which were positive after DNA isolation with the MagNA Pure bacterial DNA isola-
tion kit could not be confirmed by individual testing of urines in either isolation method and 
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Figure 1 Methods and results of individual and pooled testing by different DNA isolation
 methods
 Sensitivity values marked * indicate that the MagNA Pure bacterial DNA isolation kit provided the best 
method for DNA processing, P<0.01 (McNemar’s test), with equal levels of sensitivity and specificity for pooled 
urines and individual urines. NR: not relevant
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were considered false positive. One other pool was positive after DNA isolation by the MagNA 
Pure bacterial DNA isolation kit, but the individual urines were negative. However, one urine 
from this pool was positive in the standard Cobas Amplicor assay for individual urines. There-
fore, the pool/urine result was considered to be a true positive. 
Altogether, 48 urines were positive for C. trachomatis after individual testing by the Cobas 
Amplicor method with or without the prior use of the MagNA Pure bacterial DNA isolation 
kit, revealing a prevalence of C. trachomatis infection of 6.4% in this population.
When positive individual testing in either method is considered as the gold standard, routine 
individual testing of urines with the Cobas Amplicor method proved to have a sensitivity of 
65%. This sensitivity dropped to 42% when the Cobas Amplicor method on pooled urines was 
used. However, when using pooled urines with the combination of the Cobas Amplicor method 
after initial DNA isolation was done with the MagNA Pure bacterial DNA isolation kit, the 
sensitivity was 92% (see Table 1 for exact figures). 
Inhibition
The Cobas Amplicor procedure showed inhibition for one (0.7%) of the pools and for 37 
(4.9%) of the individually tested urines. After DNA isolation by MagNA Pure LC procedures, 
no (0%) inhibition was found among pooled urines and only once (0.6%) while testing indi-
vidual urines.
Bacterial load in pools
Positive urine specimens were subjected to quantitative LightCycler PCR to assess the bacterial 
load. Figure 2 illustrates the relative Chlamydia trachomatis DNA concentrations of pooled 
urines observed with the use of the LightCycler PCR in relation to the standard Cobas Amplicor 
Table 1 Test results and costs of individual and pooled urines by different DNA isolation methods
Procedure No. of 
positive
tests/no.
tested
No. of 
positive-
women/ 
no.tested
Estimated
prevalence
% 
(95% CI)
Estimated
sensitivity
% 
(95% CI)
Total
costs
(euro)
Cost per
case
detected
(euro)
Cobas Amplicor 4.1 65
individual urines 31/750 31/750 (2.8-5.8) (49-78) 8,522 275
Cobas Amplicor 2.7 42
pooled urines 15/150 20/750 (1.6-4.1) (28-57) 2,562 128
MagNA Pure Bacterial DNA Kit 5.9 92
pooled urines 34/150 44/750 (4.3-7.8) (80-98) 4,770 108
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test results. True positive pools, which tested negative by the standard Cobas Amplicor method, 
had significantly lower relative C. trachomatis concentrations than positive pools (Kruskal-Wallis 
H test, P<0.001), confirming that bacterial titres do contribute significantly to the sensitivity of 
testing. Figure 3 illustrates the relative frequency distributions of the bacterial loads established 
in the urine samples obtained from these essentially symptom-free females. Note that most of 
the loads are relatively low but that no correlation with the bacterial load in urine samples from 
symptomatic patients has been made.
Figure 2 Relative Chlamydia trachomatis (CT) concentrations of pooled urines observed via 
 LightCycler in relation to standard Cobas Amplicor test results
 Horizontal lines represent the medians of the relative C. trachomatis concentration of pooled urines 
*P-value (Kruskal-Wallis H test) 
Figure 3 Relative Chlamydia trachomatis (CT) concentrations versus number of patients falling 
 in different titer classes
 Note that most patients fall within the low-titer classes 
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Costs
The Dutch costs for a Cobas Amplicor test was 10.33 euros per sample (isolation 0.82 euro, 
amplification 4.71 euro, detection 4.80 euros) and for the MagNA Pure isolation 4.04 euros per 
sample with a full run. The cost of the combined method (isolation with the MagNA Pure and 
subsequent amplification plus detection by the Cobas Amplicor) was 13.55 euros. The total 
costs for 750 specimens were, therefore, 8,522 euros for the Cobas Amplicor method with indi-
vidual urines (750 tested with 75 controls) and 2,562 euros when pooled testing by the Cobas 
Amplicor was followed by individual testing (150 pools with 15 controls plus 15 positive pools 
times 5 individual tests with 8 controls, making 248 tests). The costs for pooled and individual 
urines with the prior use of the MagNA Pure bacterial DNA isolation kit were 4,770 euros (150 
pools with 15 controls plus 34 positive pools times 5 individual urines with 17 controls, making 
352 tests). The calculation of screening costs per positive detected case of C. trachomatis infec-
tion incorporated the sensitivities found in this study: 65% for the Cobas Amplicor test for 
individual urines, 42% for the Cobas Amplicor for pooled urines, and 92% for the use of the 
MagNA Pure bacterial DNA isolation kit in combination with the Cobas Amplicor PCR test 
for pooled urines. Screening costs per positive detected case were lowest with the use of the lat-
ter combination (Table 1). 
Figure 4 illustrates the difference in costs between the standard Cobas Amplicor used for individual 
urines compared to the use of the MagNA Pure bacterial DNA isolation kit in combination with 
the Cobas Amplicor PCR test for pooled urines for hypothetical prevalences ranging from 1% to 10%.
Figure 4 Costs per positive Chlamydia trachomatis case detected in relation to population 
 prevalences
 • Cobas Amplicor results for individual urines ■ pooled MagNA Pure plus Cobas Amplicor results 
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Discussion
Technological aspects
We analyzed 750 individual urine samples by several methods. Overall, 31 samples tested posi-
tive upon individual testing using the Cobas Amplicor platform. When pooled urines were used 
without prior DNA purification the sensitivity of the test dropped significantly, only 20 women 
tested positive. However, upon usage of the MagNa Pure DNA isolation system, an overall 
number of 48 women tested truly positive (see Table 1 for a summary). So this study shows that 
pooling of urines combined with prior DNA isolation by use of the MagNA Pure bacterial 
DNA isolation kit is a reliable and cost-effective way to both increase the sensitivity of testing 
(by 27%) and decrease the costs per detected case (by 62%) during large scale-testing for asymp-
tomatic C. trachomatis infection among pregnant women. Furthermore, we show a 6.4% preva-
lence of C. trachomatis carriership in apparently healthy pregnant women in this Dutch area. 
We used the Cobas Amplicor test in our study because it is fully automated and its performance 
is good [12, 13, 21, 22], being less prone to experimental variation than the Amplicor test [23, 
24]. However, the sensitivity of the Cobas Amplicor for female urines is in the range of 80 to 
90%, as has been shown in STD outpatient populations [12, 13]. A major problem with the use 
of urine specimens is inhibition. Urinalysis has shown that various substances are responsible for 
inhibition [25], and that between 2% and 4% of urine specimens contain inhibitors [21, 26]. 
The sensitivity, however, could be improved by using a modified specimen-processing proce-
dure [27]. In our study the inhibition was slightly higher when using the Cobas Amplicor 
method for individual urines (4.9%), but much lower when using the same method for pooled 
urines (0.7%). However, automated DNA isolation from urines by use of the MagNA Pure 
bacterial DNA isolation kit prior to the Cobas Amplicor reduced the inhibition significantly in 
both individual and pooled testing. This significantly improved the sensitivity of C. trachomatis 
detection. In addition, the use of the MagNA Pure bacterial DNA isolation kit prior to the 
Cobas Amplicor resulted in a higher sensitivity than automated DNA isolation with the MagNA 
Pure large-volume kit, which may be explained by the additional use of proteinase K prior to 
DNA isolation in the bacterial DNA kit.  
Sample pooling and cost aspects
Pooling of urine specimens is important to reduce the costs of screening. However, some 
describe a significant reduction of the sensitivity [14, 15], whereas others reported a similar 
sensitivity with pooling [16-18]. In our study, pooling with the Cobas Amplicor method 
resulted in a significant reduction of the sensitivity, which is probably due to the dilution of 
positive specimens and –as shown- not to the introduction of inhibitors from other urines in a 
pool. However, the use of the MagNA Pure bacterial DNA isolation kit restored and even 
improved the sensitivity. The combined procedure was the only method producing acceptable 
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results with pooled urines. Therefore, pooling of urines in large screening programs for the 
detection of asymptomatic C. trachomatis infections should only be used in conjunction with 
DNA isolation methods that yield highly purified DNA. It should be noted that the sensitivity 
of our procedure was 92% and not 100%. A low copy number of chlamydial targets in positive 
urine specimens in our population of asymptomatic women- as shown in figure 2- can explain 
this. Other variables influencing the sensitivity are the quality of specimens and the timing of 
sampling [28]. The sensitivity of screening could be improved by testing multiple specimens 
obtained at various time points, but this would compromise the cost-benefit ratio of screening 
programs. 
C. trachomatis screening among pregnant women
Pregnant women could be a specific target group for C. trachomatis screening. Antenatal screen-
ing, as recommended by the Centers for Disease Control [29], may be beneficial for decreasing 
morbidity amongst women themselves, but also to prevent vertical (infant) and horizontal 
(partner) transmission [2-5, 30]. Screening of pregnant women usually yields prevalences simi-
lar to those of non-pregnant women. In Europe, the prevalence of C. trachomatis infection 
among asymptomatic women was recently estimated to range from 1.7% to 17%, depending 
on setting, context and country [1]. The prevalence of 6.4% in apparently healthy pregnant 
Dutch women is much higher than previously reported in asymptomatic women in general 
practices (2,9% and 4,9% in 1996 and 1997) or in a general obstetric and gynecological popu-
lation (4.5% in 2002) [8, 31, 32], and approaches the chlamydial prevalence of 7.3% that was 
found in 1998 amongst women consulting the STD outpatient clinic in Rotterdam [33]. How-
ever, these figures must be interpreted with caution since test format is clearly important. Test-
ing of individual urines by the Cobas Amplicor method without prior DNA isolation by the 
MagNA Pure bacterial DNA isolation kit yielded a much lower prevalence of 4.1%.
Screening programs are considered to be cost-effective when the prevalence of C. trachomatis 
infection is higher than 3% to 6% [9, 10, 34, 35]. The introduction of improved technology for 
screening may reveal higher prevalences, rendering screening programs cost-effective. It was 
shown that Cobas Amplicor testing was more cost-effective with pooled urines compared to 
individual urines, but pooling reduced sensitivity. However, usage of the MagNA Pure bacterial 
DNA isolation kit increased sensitivity and appeared to be more cost-effective: the calculated 
costs per detected case in the combined method with pooling were a mere 39% of the costs of 
individual testing with the Cobas Amplicor.
In conclusion, we show that pooled testing for C. trachomatis infection in asymptomatic preg-
nant women can be developed for large-scale testing provided that the Cobas Amplicor method 
is used together with prior chlamydial DNA isolation by use of the MagNA Pure bacterial DNA 
isolation kit. This combination significantly improves sensitivity and decreases costs. 
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Abstract
Background Chlamydia trachomatis infections are largely asymptomatic. In pregnancy chlamy-
dial infections may influence pregnancy outcomes and its prevention is based on screening. The 
success of large-scale screening for C. trachomatis depends on the target population (prevalence, 
participation), availability of non-invasive sampling, high-quality testing, effective treatment, 
and the cost-effectiveness of screening.
Objective Cost-effectiveness analysis of C. trachomatis screening during pregnancy.
Methods We designed a pharmaco-economic decision analysis model, which included potential 
health outcomes of C. trachomatis infection such as PID, infertility and chronic abdominal pain 
as well as ectopic pregnancy, premature delivery and neonatal disease. We estimated the cost-
effectiveness from a societal perspective using the most recent prevalence data from a popula-
tion-based prospective cohort study among pregnant women in the Netherlands. We calculated 
the prevented costs by linking health outcomes with health care costs and productivity losses. 
Cost-effectiveness was estimated in base-case-, sensitivity- and scenario analysis.  
Results In the base-case analysis the costs to detect 1,000 pregnant women with C. trachomatis 
were estimated at e378,300. Cost savings on complications were estimated at e814,400 resulting 
in net cost savings. Sensitivity analysis showed that net cost savings remained with a test price 
up to e28, an averted proportion of complications of only 25% and a risk for PID of only 
0,4%. Scenario analysis showed even more cost savings with targeted screening for women less 
than 30 years of age or with first pregnancies.
Conclusions C. trachomatis screening of pregnant women in the Netherlands is cost-saving.
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Introduction
Chlamydia trachomatis is one of the major sexually transmitted pathogens in industrialized 
countries [1]. Treacherously, about 80% of infected women remain asymptomatic. Asymptomatic 
chlamydial infection during pregnancy poses risks for women due to PID and ectopic preg-
nancy [2-5], and may, due to vertical transmission, lead to neonatal chlamydial conjunctivitis 
and respiratory tract infection [6-9]. These complications may lead to major health costs, which 
can only be prevented by active case finding and early treatment of C. trachomatis infection. 
C. trachomatis screening, however, is not part of routine antenatal care in all countries, because 
little is known about the cost-effectiveness of such screening. Recently we found C. trachomatis 
infection during pregnancy to increase the risk for early premature delivery in chlamydia-positive 
women four-fold [10]. This finding implies that screening for C. trachomatis may be more cost-
effective than previously estimated. 
In this study we estimate the cost-effectiveness of C. trachomatis screening in pregnant women 
in the Netherlands based on a static model. Our approach builds on recently reported local data 
and a decision tree of possible complications.
Materials and Methods
General Model Design
Preferably, we used data from local studies, but if unavailable we used international results. The 
model we used for the cost-effectiveness analysis (CEA) of screening consists of an epidemiologic 
part and an economic part. We used the epidemiologic part to estimate the impact of screening 
on the prevalence of C. trachomatis in the population. The economic part we used to evaluate 
the prevented complications and costs, and the costing of a screening program. We linked the 
two models by using the output of the epidemiologic part as input for the economic part resulting 
in a formal cost-effectiveness ratio (CER). 
Epidemiologic model
To analyze the cost-effectiveness, we used a recent update of a health-economic model that was 
previously developed for C. trachomatis screening in the Dutch setting [11-15]. 
For the epidemiologic part of the model we could use a dynamic or a static version. The dynamic 
model version includes explicitly the transmission dynamics of C. trachomatis infection in the 
population, i.e. “a force of infection that varies” with the changing prevalence of C. trachomatis 
infection in the population [14-17]. A screening program will have a decreasing effect on the 
chlamydial prevalence in a population with a subsequent decrease in the overall probability to 
encounter an infected partner and indirectly protection for future sex partners. Dynamic models 
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are especially warranted to screen populations with frequently changing sexual partners [18]. 
The static model version, on the contrary, includes “a constant force of infection” or a constant 
probability to encounter an infected partner. In the static model only the cures are taken into 
account that are directly related to screening and subsequent treatment, but not to the changing 
prevalence or risk due to averted chlamydial infections. Static models suffice to assess popula-
tions in which frequent change of sexual partners is not common [18]. We have applied this 
static version of our model to evaluate screening for C. trachomatis infection in pregnancy before 
[11]. However, at that time, actual data concerning pregnant women and pregnancy outcomes 
were not available in the Netherlands. In the current study we applied the static model version to 
large-scale observational data on the prevalence and outcome of C. trachomatis infection in Dutch 
pregnant women [10].
Epidemiologic Data
We used the prevalence data from a prospective multi-center, population-based C. trachomatis 
study among 4,055 pregnant women aged 15 to 46 years in Rotterdam, The Netherlands, 
which were gathered between 2003 and 2005 [10]. This collection represents the start of the 
Generation R study [19, 20]. Pooled fresh first void urine specimens were tested by a nucleic 
acid amplification technique [21], and showed that 157 women (3.9%) tested positive for 
C. trachomatis. Age-specific prevalences were 13.5% in women 20 years and younger, 6.7% 
between 21 and 25 years, 3.3% between 26 and 30 years, and 1.6% in women over 30 years. 
The women were followed regarding their pregnancy outcomes. Pregnancy-specific prevalences 
were 4.5% in women with a first pregnancy, 3.1% in women with a second pregnancy and 
3.6% for next pregnancies. Adverse pregnancy outcomes such as miscarriage, low birth weight 
and perinatal death were not found to be associated with C. trachomatis infection of the women 
in this population, but chlamydia-positive women had an increased risk for premature delivery 
before 35 weeks and 32 weeks gestation [10]. This risk was inserted in our model. (see below)
Figures with respect to maternal complications were used from previous international studies [14]. 
Data regarding the outcome of premature delivery, e.g. the duration of admission to a neonatal inten-
sive care unit in the Netherlands, were obtained from The Netherlands Perinatal Registry [22]. 
Risks, Disease Costs and QALYs
Figure 1 shows the medical decision-tree we used for our analysis and reflects the progression of 
asymptomatic C. trachomatis infection in pregnant women in a screening and no-screening 
scenario, thereby combining the acute disease and long-term complications of chlamydial infection 
for the women themselves, and complications in their newborns and partners (reduced by 50% 
due to screening and treatment) [14]. 
Table 1 shows the risks we used in the CEA-model for screening of C. trachomatis infection during 
pregnancy, which were previously reported [14]. In the current analysis, we added the elevated 
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risk for preterm delivery before 35 weeks gestation, which was directly calculated from the study 
on pregnancy outcomes [10]. We calculated the risks for preterm delivery for chlamydia-positive 
women (4.6%) and chlamydia-negative women (1.5%). The 3.1% difference between groups 
reflects the elevated risk for preterm delivery in women with C. trachomatis infection compared 
to the base-case risk in the absence of infection (Table 1). 
The probabilities for neonatal conjunctivitis and pneumonia as well as preterm delivery were 
based on live-born neonates only and were adjusted taking into account that 1.5% of pregnan-
cies result in miscarriages and perinatal death [10, 23]. The probabilities for ectopic pregnancy 
and tubal infertility after (post-partum) PID were interpreted as referring to the next pregnancy 
and were only applied in the model if a next pregnancy wish was expected to occur. The prob-
ability for a next pregnancy wish was based on Dutch data for having a second, third or next 
pregnancy, and was estimated at 78%, 50%, and 45% respectively [22]. We made calculations 
for these pregnancy rates individually in the sensitivity analysis (below), which analyses were 
aggregated for reporting the base-case analysis (see below). 
Besides maternal and neonatal complications, we included symptomatic and asymptomatic dis-
ease of male partners according to our previous approach [12]. We assumed that pregnant 
Figure 1 Medical decision tree for Chlamydia trachomatis screening during pregnancy based on 
 complications in women, newborns and partners
 *Percentages may add up over 100% as complications can be in different individuals: pregnant women, 
newborns and partners
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women have a 68% probability of having infected partners [24]. The infected male partners 
have 50% probability of becoming symptomatic with urethritis and 50% probability of remaining 
asymptomatic. However, of the latter group another 2% will develop epididymitis [12]. 
The costs include the direct medical costs of treatment for C. trachomatis infection and compli-
cations, and the indirect costs of production losses. Previously reported costs were updated 
using appropriate deflators to achieve 2007 price levels [14, 25](www.cbs.nl). According to the 
Dutch guidelines for pharmacoeconomic practice we discounted the costs of chronic pelvic pain 
(CPP), ectopic pregnancy and infertility at 4% per year [26], taking into account that CPP costs 
occur during 5 subsequent years and that the average duration between two pregnancies is 2.5 
years [25]. The costs for prematurity were based on data from the St Radboud UMC, Nijmegen 
(personal communication L. Collee).
The assumed quality-adjusted life year (QALY) losses that we applied in the model are also listed 
in table 1 [15, 27, 28]. Given the lack of valid studies regarding the quality of life impact fol-
lowing prematurity, no such QALYs were included for either the newborns or the parents. As 
for the costs, the QALY gains were similarly discounted, but at a rate of 1.5% per annum [26].
Intervention Costs
The costs of testing were assumed at e12 [14], which included the discounts that would pre-
sumably be achieved in a large-scale use of PCR-kits as would be the case in a screening program. 
If a woman would test positive for C. trachomatis, she and her partner would be treated or 
referred to a General Practitioner (GP) for treatment: costs at e20.4 per GP-visit. We included 
a prescription for amoxicillin for pregnant women, azithromycin for partners and erythromycin 
for infants in the model. Internationally, single-dose azithromycin is often the preferred treat-
ment for C. trachomatis. However, current Dutch guidelines recommend amoxicillin during preg-
nancy [29]. The costs were rated at e10.77 for amoxicillin and at e12.02 for azithromycin, which 
both included the pharmacist’s fee [14, 29]. The effectiveness of the antibiotics was inserted in 
the model at 95% [13]. Reinfection in the absence of partner treatment was not included in the 
model. 
Cost-effectiveness Analysis
The risks, costs and QALY losses were linked within the static cost-effectiveness model as previ-
ously described [11]. We calculated the cost-effectiveness ratio (CER) using the formula: 
CER = (C
S&T 
– S
C
)/QALYs gained, in which the costs for screening and treatment (C
S&T
) minus 
the savings on complications (S
C
) are divided by the QALY losses averted (QALYs gained) [30]. 
These calculations were consistently done for various age groups and screening in first pregnancies, 
second and subsequent pregnancies.
In the cost-effectiveness framework, we assumed a 100% specificity of testing and a crude 50% 
of complications that could be averted by screening and subsequent effective treatment [14]. 
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The latter reflects the possibility that C. trachomatis infection may already have caused irreversible 
damage. 
The calculations were performed in a base-case analysis, sensitivity analyses and in scenario 
analyses [30]. We did a base-case analysis using the above-mentioned assumptions on risks, 
costs, QALYs, discount rates and effectiveness of C. trachomatis screening for all pregnant 
women based on the medical decision tree (figure 1). Next, we performed a sensitivity analysis 
directed towards the test price (ranging from e5 up to the official price of e35), towards the 
assumed 50% of complications being averted (ranging from 25% to 75%) and towards the risk 
for PID to develop after C. trachomatis infection (ranging from 0,43 to 40%) [31]. PID has 
been consistently found to be the most sensitive parameter for the cost-effectiveness of screening 
for C. trachomatis in a general population [13, 32], but has also been criticized to be overesti-
mated [31]. Eventually, we performed a scenario analysis on possible target groups for screening 
based on age (cut-offs at 20, 25 and 30 years) and pregnancy rate (first, second or next pregnancies) 
as well as on the discount rate (ranging from 0 to 4%) for the costs and the QALYs. 
Table 1 Complications of Chlamydia trachomatis infection with risks, costs and QALY losses  
 per case
Complication Risk Risk base Costs (e) QALY
Current pregnancy
Mothers
asymptomatic PID 12% CT-infection* na na
symptomatic PID 8% CT-infection* 1,621 0.35
CPP 18% any PID 2,072 1.94
Infants**
neonatal conjunctivitis 30% CT-infection*** 45 0.02
neonatal pneumonia 15% CT-infection*** 1,944 0.06
preterm delivery <35 weeks 3.1% CT-infection*** 32,000 ni
Next pregnancy
ectopic pregnancy 8% any PID 3,982 0.04
tubal infertility 11% any PID 2,107 2.74
Male partners
symptomatic urethritis 34% CT-infection 83 0.01
epididymitis 0.68% CT-infection 940 0.01
*All C. trachomatis infected pregnant women 
**Risks adjusted for 1.5% of pregnancies resulting in miscarriages and stillbirths
***C. trachomatis infected women delivering a live-born baby 
QALY: quality-adjusted life year, PID: pelvic inflammatory disease, CT: C. trachomatis, 
na: not applicable, CPP: chronic pelvic pain, ni: not included 
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Results
Base-case Analysis 
In the base-case analysis, we estimated an investment of e378,300 in order to detect C. tracho-
matis infection for 1,000 pregnant women and subsequently treat them and their respective 
partners. This estimate consisted of e312,800 for testing and e65,500 for (partner) treatment. 
The cost savings on complications were estimated at e814,400. A distribution of the savings is 
shown in figure 2a: the major savings were due to the prevention of preterm delivery (65%), 
followed by neonatal pneumonia (17%) and PID (8%). Eventually, the resulting net costs were 
negative indicating overall net cost savings. 
Regarding major outcomes, per 1,000 pregnancies identified 73 cases of symptomatic PID, 
CPP, ectopic pregnancy and infertility would be averted in addition to 225 cases of neonatal 
conjunctivitis, pneumonia and preterm delivery, and 162 male complications. Correspondingly, 
we estimated that over the various complications in total 59 QALYs were to be gained per 1,000 
pregnancies detected, which distribution is shown in figure 2b: the major QALY gains were due 
to CPP (61%), infertility (26%) and neonatal pneumonia (8%). In the absence of any data, no 
QALY gains were included for prematurity.
Sensitivity Analysis
The sensitivity analysis of the test price is shown in figure 3, which clearly demonstrates that the 
net cost savings remain as long as test costs are below approximately e30. The exact break-even 
test costs (rendering net costs equaling e0) were estimated at e28. 
Figure 2a Distribution of cost-savings on complications
 PID: pelvic inflammatory disease, CPP: chronic pelvic pain, EP: ectopic pregnancy, TI: tubal infertility, 
PREM: preterm delivery, NP: neonatal pneumonia, NC: neonatal conjunctivitis, GUTI: genito-urinary 
tract infection
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 Varying the proportion of complications that can be averted between 25% and 75% (50% in 
the base-case), rendered estimated cost savings over the whole range for the base-case test costs 
at e12. Break-even test costs were estimated at e13 and e44, respectively. For the low propor-
tion of only 25% averted complications, cost-effectiveness remained below e20,000 per QALY 
until test costs were raised to e35, at which test price the cost-effectiveness was still only 
e19,400 per QALY. 
Varying the risk for PID from 0.4% to 40% (20% in the base-case), again rendered savings over 
the whole range for the base-case test costs. Break-even test costs were estimated at e26 and 
e30, respectively. For a PID risk at 0.4%, the cost-effectiveness still remained below e4,000 
per QALY when test costs were raised up to e35.
Scenario Analysis
The results of a cost-effectiveness analysis may vary by the prevalence in any given population; 
by age and by pregnancy rate. 
For age-specific screening at base-case test costs, results indicated cost savings for screening 
pregnant women ≤ 20 years of age (break-even test costs > e35), women aged 21-25 years 
(break-even test costs > e35) and women aged 26-30 years (break-even test costs e30 and CER 
e2,400 per QALY for test costs at e35). For women > 30 years of age, the screening program 
did not exhibit cost savings anymore with a CER of e1,300 per QALY (break-even test costs at 
e10, e28,800 per QALY at test costs of e35). 
For screening by pregnancy rate, the most favorable estimate was derived for screening in first 
pregnancies with cost savings of e7,800 additional to any QALY gained. The cost savings for 
second pregnancies were e6,500 and e7,600 for next pregnancies. 
Figure 2b Distribution of QALYs gained on complications
 CPP: chronic pelvic pain, TI: tubal infertility, PID: pelvic inflammatory disease, EP: ectopic pregnancy, 
NP: neonatal pneumonia, NC: neonatal conjunctivitis, PREM: preterm delivery, GUTI: genito-urinary 
tract infection. No QALYs included for preterm delivery
165
Cost-effectiveness of Chlamydia trachomatis screening in Dutch pregnant women
Binnenwerk Chlamydia trachomatis.indb   165 6/16/10   12:39 PM
Figure 4 shows the costs per QALY gained for screening in pregnant populations with a C. trachomatis 
prevalence from 0% onwards, illustrated for second pregnancy rates (curves for first and next 
pregnancies not shown as these are almost identical and nearly overlapping). At base-case costs 
(e12), the results indicated cost savings for screening of pregnant women in populations with 
a C. trachomatis prevalence beyond 1.7%. At the extremes, if test costs would be as low as e5 
cost savings would already occur beyond a prevalence of 0.7% and with test costs as high as e35 
cost savings would occur beyond a prevalence of 5%. However, for the latter high test costs, the 
cost-effectiveness would still be below e20,000 per QALY gained for prevalences above 2%.
In addition, figure 4 can also be used to estimate the cost-effectiveness for age-specific screening 
during pregnancy at varying test costs. With prevalences, as in our population, of 13.5% in women 
20 years and younger, or 6.7% in women between 21 and 25 years the net costs per QALY gained 
remained negative even at the extreme of e35 test costs. When screening women between 26 and 
30 years with a prevalence of 3.3%, the net costs per QALY gained remained negative at a test price 
below e20. The net costs per QALY gained would only be cost saving if screening of women over 
30 years - with a prevalence of 1.6% - would be done at a test price below e12.
At base-case test costs, the cost savings remained if discount rates were multi-variately ranged 
from 0 to 4% for both costs and QALYs. At the extreme, the cost-effectiveness worsened only 
slightly from e2,800 when discounting according to Dutch guidelines (costs at 4% and QALYs 
at 1.5%) to e2,900 when discounting both the costs and QALYs at 4% and the test costs at 
e35 [26].
Figure 3 Sensitivity analysis on the test price
  Base-case assumption at test price of €12
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Discussion
The present health-economic analysis clearly shows that screening for C. trachomatis would be 
cost-saving if all pregnant women would be included in a screening program in the Netherlands 
at a test price up to e28, despite the conservative approach we used throughout our design. 
Subsequent sensitivity analysis shows that a screening program remains cost saving, or at least 
highly cost-effective, if relevant parameters such as test price, complication rate and PID are 
varied within plausible ranges. Furthermore, the scenario analysis shows that the health economic 
gain can be further increased if a screening program would take aim at specific groups of pregnant 
women including women below thirty years of age or women with first pregnancies only.
C. trachomatis infection during pregnancy may lead to serious complications like ectopic preg-
nancy and premature delivery, vertical transmission with subsequent neonatal conjunctivitis 
and respiratory tract infection [2, 6-9], and post-partum pelvic inflammatory disease (PID), 
chronic pelvic pain (CPP) and infertility [33-35]. Pregnant women may, therefore, be a specific 
target group for C. trachomatis screening. Antenatal screening, as recommended by the CDC 
[36], would be beneficial to decrease morbidity amongst women themselves, but also to prevent 
vertical (infant) and horizontal (partner) transmission. At present seven of 25 member states of 
the European Union have included C. trachomatis screening in their guidelines for antenatal 
care in normal pregnancies [37]. In the Netherlands, however, chlamydial testing is not part of 
routine antenatal care since local data regarding C. trachomatis infection in pregnant women 
and perinatal transmission were lacking and the cost-effectiveness of a national screening pro-
gram remained largely hypothetical. 
Figure 4 Costs per QALY gained by prevalence when screening for Chlamydia trachomatis in 
 pregnant women using different test costs
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In the current cost-effectiveness study of a screening program for C. trachomatis we have chosen 
to use a static model approach since the absence of frequently changing sexual partners is likely 
to be a reasonable assumption in relationships during pregnancy. We included the use of NAATs 
on pooled urine specimens to test for C. trachomatis in a screening program, because of the non-
invasive nature of sampling, a high sensitivity and specificity of testing and a reduction of the 
total amount and subsequent costs of testing [21]. We worked with the recently reported C. 
trachomatis prevalence of 3.9% that was found in apparently healthy Dutch pregnant women 
and took into account the increased risk for preterm delivery [10]. The latter finding has recently 
been reported to occur in C. trachomatis infected pregnant women in other countries as well 
[3-5, 38]. Including preterm delivery in the model increased the public healthcare costs dra-
matically [39]. Since women were already pregnant in this model, we included the probability 
for ectopic pregnancy and tubal infertility only for a possible second or third pregnancy. Higher 
pregnancy rates are not common in the Netherlands and were conservatively not included in the 
model. Furthermore, we worked with 50% of complications being avertable since treatment may 
occur at a moment that infection may already have caused irreversible damage. We discounted 
the costs of CPP, ectopic pregnancy and infertility as well as the QALYs per year according to 
standard practice in correcting for time preference in health-economic modeling. Reinfection in 
the absence of partner treatment was not included in the model. We assumed that women who 
were married or living in registered partnership (85%) [10], and single women with a steady 
relationship, would take medication at the same time as their partners and have no sexual contact 
outside the relationship during the time of the current pregnancy. Similarly, for the single 
women without a steady relationship, we assumed that they would take medication with or 
without the partner when test findings were positive and that they had no further new sexual 
contacts during the current pregnancy. 
Our results indicate that the benefits of averted direct and indirect costs are much higher than 
the investment costs for C. trachomatis screening of pregnant women despite the conservative 
approach we used throughout our design. In the current approach for cost-effectiveness analysis 
we did not include the potentially high costs of long term complications due to premature birth 
such as lifelong impairments, disability or handicap in hearing, vision, language and speech, 
neuromotor dysfunction, mental development, musculoskeletal and respiratory tract complications. 
We also didn’t calculate the extra costs and production losses of parents of premature newborns 
directly after birth and in the years to follow, which may be expected to extend into adolescence 
or possibly even into adulthood, nor the potential production losses of the prematurely born 
individuals themselves during their lives [40-46]. Furthermore, we didn’t include QALY losses 
due to premature birth for both the infants and their parents. Despite this conservative approach, 
both the base-case analysis and sensitivity analysis demonstrated that C. trachomatis screening 
would be highly cost-effective. While varying the proportion of averted complications to as little 
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as 25% and calculating with a risk for PID as low as 0.4%, the cost-effectiveness remained 
below e20,000 per QALY. In the Netherlands, a cost-effectiveness below e20,000 per QALY 
gained is informally taken as a threshold for accepting preventive programs from a health-economic 
point of view. Our results also demonstrate that screening of pregnant women for C. trachomatis 
in the Netherlands would be cost-saving if screening would be based on either pregnancy rate or 
age, with the exception of screening women over 30 years of age. However, screening of women 
over 30 years of age would still be considered cost-effective in the Dutch population.
If we would extrapolate our CEA of C. trachomatis screening to all pregnant women in the 
Netherlands, approximately 200,000 pregnancies per year, the total costs for screening and 
treatment could be estimated at e2,737,000 annually. Nationally, this would be counterbal-
anced by savings on costs related to the complications of C. trachomatis infection that would 
mount to e5,893,000, which means net savings of more than e3 million each year. In addition 
to this economic gain, 426 QALYs would be gained nationwide. 
Our conclusion is that screening pregnant women for C. trachomatis is highly cost-effective and, 
in most cases, cost-saving in the Netherlands. 
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Summary
The studies described in this thesis aimed to assess the health-related importance of Chlamydia 
trachomatis infection during pregnancy for women and their newborns in order to provide informa-
tion for future decision making regarding the need for C. trachomatis screening in pregnant women. 
In chapter 1 we presented the research questions, and related studies, that we addressed in this 
thesis. Main topics included:
1) What is the prevalence of C. trachomatis infection during pregnancy?
2) What are risk factors for C. trachomatis infection in pregnant women? 
3) Is C. trachomatis infection during pregnancy associated with increased risk for adverse preg-
nancy outcomes such as stillbirth, premature birth and low birth weight? 
4) What is the rate of C. trachomatis transmission from women to neonates? 
5) Can we find evidence of vertical transmission by detection of C. trachomatis in infants with 
neonatal conjunctivitis and respiratory disease?
6) Is pooling of urine specimens a good method to improve cost-effectiveness of C. trachomatis 
testing during pregnancy? 
7) Is routine screening for C. trachomatis a cost-effective approach during pregnancy?
In chapter 2 we reviewed the literature regarding C. trachomatis infection in relation to pregnant 
women and infants. Chlamydial infection is characterized by invasion of the host cell, intra-
cellular reproduction, and an inflammatory response that may persist and cause chronic inflam-
mation and fibrotic changes. C. trachomatis infection, however, is most often asymptomatic. 
Due to its latent, insidious and potentially chronic character the severity of infection may range 
from asymptomatic and selflimiting disease to infection with severe complications such as pelvic 
inflammatory disease, infertility, and chronic pelvic pain. Moreover, C. trachomatis infection in 
pregnant women may lead to adverse pregnancy outcome and neonatal disease. Different test 
methods can be used to diagnose (latent) C. trachomatis infection of which NAATs are the gold 
standard at present. NAATs are highly sensitive and can be used with most specimens including 
urine and vaginal swabs. Various antibiotic treatment options for C. trachomatis infection are 
discussed. Single-dose treatment with azithromycin is recommended, because of high compliance, 
treatment succes, and less adverse events. Pregnant women were proposed as a significant target 
population for C. trachomatis screening. Prenatal chlamydial screening was contemplated according 
to the Wilson and Jung criteria. Some of these had not yet been explored in the Netherlands. 
In chapter 3 we asessed the prevalence of sexually transmitted infections in 766 pregnant urban 
South African women at the time they presented for delivery. In addition, associations of sexu-
ally transmitted infections with demographic and socio-economic characteristics and with clin-
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ical symptoms were determined. Overall, 48% carried one or more sexually transmitted agents 
during their pregnancy. Infection with HIV, Treponema pallidum, C. trachomatis and Neisseria 
gonorrhoeae was detected in 18%, 23%, 12% and 9% of women. Predictive factors for infection 
included lack of antenatal care (OR 1.7, 95% CI 1.0-3.0), multiple pregnancies (OR 2.2, 95% 
CI 1.5-3.3), being unmarried (OR 1.8, 95% CI 1.3-2.5), and being unemployed (OR 1.4, 95% 
CI 1.0-1.9). HIV seropositivity was significantly higher among women under 30 years of age 
(21%) than among women 30 years and older (12%). For syphilis a significant trend was noted 
with the lowest prevalence among the youngest women (14%) and a higher rate in the older 
group (30%). For C. trachomatis infection a trend was observed with the highest prevalence in 
the younger women (22%) and the lowest among the older women (5%). We concluded that 
nearly half of the pregnant women carried one or more of the common sexually transmitted 
pathogens, and that chlamydial and gonococcal infections remained undetected and untreated 
during pregnancy. Furthermore, that infection was not associated with symptoms, but with dif-
ferences in demographic and socio-economic characteristics.
In chapter 4 we studied the rate of transmission of C. trachomatis infection from 77 pregnant 
South African women (described in chapter 3) to their newborns in a setting where tetracycline 
eye prophylaxis is routinely provided to prevent neonatal conjunctivitis. Furthermore, we evalu-
ated the postnatal consequences of chlamydial carriage during pregnancy for women and 
infants. LCR and/or culture for C. trachomatis were positive in 23 of their infants reflecting a 
transmission rate of 30%. Nineteen (83%) of these 23 infants had a positive nasopharyngeal test 
and nine (39%) had a positive conjunctival test; five infants (22%) were colonised at both sites. 
All conjunctival cultures were negative. Nasopharyngeal specimens were positive in 13 (57%) of 
23 infants by LCR and in 9 (45%) of 20 infants by culture. Infants of chlamydia-positive 
women were reported to have significantly more often nasal problems than infants of chlamy-
dia-negative women (32 (49%) of 65 infants versus 15 (23%)) of 65 infants, which were also 
found on physical examination (37 (57%) versus 7 (11%)), as were higher respiratory rates and 
intercostal recession. 
Postnatal genitourinary symptoms and signs were found in 34 (52%) and 51 (78%) of chlamy-
dia-positive women, with 12 women (18%) developing post-partum pelvic inflammatory dis-
ease. We concluded that chlamydial infection in pregnant women places the newborn at risk 
and that topical tetracycline prophylaxis at birth is insufficient to prevent chlamydial infection 
in the infant. Furthermore, we suggested that the finding of postnatal maternal genitourinary 
symptoms and signs, in combination with symptoms and signs in the infant, should alert clini-
cians to the possibility of neonatal and maternal complications of chlamydial infection. 
In chapter 5 we studied the prevalence of and risk factors for C. trachomatis infection during 
pregnancy in 4,055 Dutch pregnant women who attended one of the midwifery practices or 
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antenatal clinics that participated in the Generation R study in Rotterdam, The Netherlands. 
Furthermore, we assessed the effect of chlamydial infection during pregnancy on premature 
delivery and birthweight. C. trachomatis infection was detected in 157 (4%) women. The prev-
alence was inversely correlated with age with the highest prevalence in women age 20 years or 
less (14%) and lowest in women over 30 years (2%). The prevalence was highest in Antillean 
(16%), Cape Verdean (11%) or Surinamese (9%) women, and in women with low-level educa-
tion (6%), single marital status (12%), first pregnancies (5%), multiple sexual partners in the 
past year (8%) or a history of an STI (6%). In the unadjusted analysis the latter risk factors, 
except for pregnancy rate, were significantly associated with C. trachomatis infection. In the 
adjusted analysis age below 21 years (OR 1.8, 95% CI 1.2-2.6), Antillean ethnicity (OR 2.3, 
95% CI 1.4-3.7) and single marital status (OR 1.6, 95% CI 1.3-2.0) remained risk factors for 
C. trachomatis infection; other maternal factors were not independently associated. For the sec-
ond part of the study, pregnancy outcomes (gestational ages and birth weights) were analysed 
for 3,913 newborns. We found that 18% (95% CI 0.7-36.7) of women who delivered before 32 
weeks and and 11% (95% CI 3.1-18.8) of women who delivered before 35 weeks gestation 
tested positive for C. trachomatis infection. Chlamydial infection was, after adjustment for 
potential confounders, associated with preterm delivery before 32 weeks (OR 4.4, 95% CI 1.3-
15.2) and 35 weeks gestation (OR 2.7, 95% CI 1.1-6.5), but not with low birth weight. Of all 
deliveries before 32 weeks and 35 weeks gestation 15% (95% CI 4.5-39.5) and 7% (95% CI 
2.5-20.1) were attributable to C. trachomatis infection. We concluded that C. trachomatis con-
tributes significantly to early premature delivery which should be considered a public health 
problem, especially in young women and others at increased risk of C. trachomatis infection. 
In chapter 6 we evaluated the relationship between the presence of C. trachomatis and signs of 
placental inflammation in the placentas of 304 women who delivered before 32 weeks of gesta-
tion at the Erasmus MC-Sophia, Rotterdam. C. trachomatis was detected in 76 (25%) placentas. 
Histological evidence of placental inflammation was present in 123 (40%) placentas: in 41 
(54%) of 76 placentas with C. trachomatis versus 82 (36%) of 228 placentas without C. trachomatis 
infection (OR 2.1, 95% CI 1.2-3.5). A significant increase towards more frequent detection of 
C. trachomatis infection was observed with increasing progression (P=0.003) and intensity 
(P=0.002) of placental inflammation on the maternal side, but not on the fetal side. We con-
cluded that C. trachomatis was frequently detected in women with early premature delivery, and 
that C. trachomatis infection was associated with histopathological signs of placental inflammation. 
In chapter 7 we evaluated whether C. trachomatis was a cause of neonatal conjunctivitis in 
infants less than three months of age presented to the Erasmus MC-Sophia and the Rotterdam 
Eye Hospital, Rotterdam. In addition, we evaluated the clinical presentation of and prescribed 
treatment for chlamydial conjunctivitis compared with other infections. C. trachomatis was 
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detected in 27 (64%) of 42 retrospectively studied infants and 14 (61%) of 23 prospectively 
studied infants. Mucopurulent discharge was present in 35 (95%) of 37 infants, swelling of the 
eyes in 27 (73%) of 37, and conjunctival erythema in 24 (65%) of 37 infants. Respiratory 
symptoms occurred in 14 (38%) of 37 and feeding problems in five (14%) of 37 infants. Before 
microbiological diagnosis, general practitioners prescribed anti-chlamydial antibiotics to five 
(12%) and systemic antibiotics to four (10%) of 41 infants who tested positive for C. trachomatis. 
Ophthalmologists prescribed anti-chlamydial antibiotics to 21 (51%) and systemic antibiotics 
to seven (17%) of 41 infants, respectively. We concluded that C. trachomatis was the major cause 
of bacterial conjunctivitis in this population and that clinical differentiation from other pathogens 
was not possible. Many infants who tested positive for C. trachomatis did not receive appropriate 
antibiotic treatment.
In chapter 8 we evaluated the presence of C. trachomatis in infants less than six months of age 
who presented with respiratory complaints to the Erasmus MC-Sophia during a one-year 
period. Respiratory specimens, primarily nasopharyngeal swabs, were tested for C. trachomatis, 
respiratory viruses and Mycoplasma pneumoniae using PCR, viral cell cultures and direct immu-
nofluorescence. C. trachomatis respiratory tract infection was detected in 10 (7%) of 148 infants 
tested. Eight (80%) of 10 C. trachomatis infections occurred before three months of age. C. 
trachomatis had not been tested for by the attending physicians, but was the second most fre-
quently detected respiratory pathogen after hRSV, which was found in 41 (28%) infants. We 
concluded that perinatal respiratory infection with C. trachomatis was relatively common and 
underdiagnosed in this population of infants less than six months of age.
In chapter 9 we evaluated C. trachomatis testing in pregnant women. First void urine specimens 
were collected from 750 asymptomatic pregnant women in Rotterdam. Initially, we investigated 
the performance of three different DNA isolation methods with 350 of these urines and 70 
pools of five individual urines of the same subset. The routinely used Cobas Amplicor test was 
compared to the Cobas Amplicor with prior DNA isolation by the MagNA Pure large-volume 
kit and the MagNA Pure bacterial DNA isolation kit. We found that 15, 14 and 27 urine 
specimens tested positive resulting in sensitivities of 52%, 48% and 93%, respectively. Subse-
quently, using all 750 urines, the Cobas Amplicor performance for individual testing (32 posi-
tive tests) was compared to pooled testing with the standard Cobas Amplicor procedure (20 
positive tests) and to pooled testing with the Cobas Amplicor in combination with the MagNA 
Pure bacterial DNA isolation kit (44 positive tests), resulting in a sensitivity of 65%, 42% and 
92% respectively (P<0.001). The prevalence of C. trachomatis in this population appeared to be 
6%. In addition, we demonstrated that with pooling of urine specimens the costs of the com-
bined MagNA Pure Bacterial DNA Isolation Kit and Cobas Amplicor method were only 56% 
of the costs of the standard Cobas Amplicor test applied to individual urines. The costs per 
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positive case detected in the combined method were only 39% of the standard test costs. We 
concluded that pooled testing for C. trachomatis infection in pregnant women could be devel-
oped for large-scale testing when the Cobas Amplicor test was used in combination with the 
MagNA Pure Bacterial DNA Isolation Kit. This combination significantly improved the sensi-
tivity and decreased the costs.
In chapter 10 we performed a cost-effectiveness analysis of C. trachomatis screening in pregnant 
women in the Netherlands based on a static model. We designed a pharmaco-economic decision 
analysis model, which included potential health outcomes of C. trachomatis infection in preg-
nant women such as PID, infertility and chronic abdominal pain as well as ectopic pregnancy, 
premature delivery and neonatal disease, and disease of the partner. We estimated the cost-
effectiveness from a societal perspective using the prevalence data we found in chapter 5. We 
calculated the prevented costs by linking health outcomes with health care costs and productivity 
losses. Cost-effectiveness was estimated in base-case-, sensitivity- and scenario analysis. In the 
base-case analysis the costs to detect 1,000 pregnant women with C. trachomatis were estimated 
at e383,000. Cost savings on complications were estimated at e805,300 resulting in extensive 
net cost savings. A sensitivity analysis showed that net cost savings remained with a test price up 
to e28, an averted proportion of complications of only 25% and a risk for PID of only 0,4%. 
A scenario analysis showed even more cost savings with targeted screening for women less than 
30 years of age or with first pregnancies. We concluded that C. trachomatis screening of pregnant 
women is highly cost-effective, and in most cases, cost-saving in the Netherlands.
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Methodological considerations
The specific methodological considerations of each study in this thesis have been presented in 
the separate chapters. In this paragraph selection bias, information bias and confounding as well 
as ethical issues are discussed in general for the Dutch and South African follow-up study.
Selection bias
Of all eligible children at birth, 61% participated in the Dutch Generation R Study. National and 
regional registries do not have the subject characteristics for all eligible children and their parents 
to enable a detailed non-response analysis [1]. However, the percentages of women from different 
ethnicity, lower socio-economic status and the percentages of women or children with medical 
complications were lower among the participants than expected from the population figures in 
Rotterdam [1, 2]. This selection towards a more affluent and healthy study population may have 
an impact on some determinants and outcome analyses separately, affecting the frequency rates 
and, as a consequence, the statistical power and generalizibility of the results. The prevalences 
found in the study should therefore be interpreted against the background of potential selection 
mechanisms. This selection bias leads only to bias in aetiological studies if the selection mecha-
nisms are both related to the determinant and outcome. Not all women who were initially enrolled 
in the generation R study could be tested for C. trachomatis. We had a non-response of 9.5% (491 
women) for the Chlamydia study. This may in part be a true non-response, but is more likely due 
to a change in the routine of the overall Generation R study when urine specimens had to be col-
lected. Another 12.0% (621 women) had to be excluded because their urines could not be matched 
to the respective questionnaires in the database due to logistical problems in the pilot phase of the 
Chlamydia study. However, all risk factors were similarly distributed among tested and untested 
women and no differences were found in median gestational age and mean birth weight (39.8 
weeks versus 39.8 weeks; P=0.84, 3408 grams versus 3407 grams; P=0.92). Also, no differences 
were found in the proportion of C. trachomatis infections between women included and not 
included in the analyses of gestation age and birth weight. Therefore, selection bias seems unlikely. 
Finally, our numbers were too small to properly assess the association of C. trachomatis infection 
with low incidence outcomes, including miscarriage and perinatal death. Of all women enrolled 
in the study and with information about C. trachomatis infection, only 62 (1.5%) had a miscar-
riage or perinatal death. Data on gestational age and birth weight were not available for women 
with the latter adverse pregnancy outcomes, but it is likely that these women had premature deliv-
eries relatively more often. None of these women had a C. trachomatis infection. Theoretically, our 
effect estimates for the associations of chlamydial infection with gestational age and birth weight 
could be biased and exaggerated when these associations would differ between all foetuses and 
foetal ‘survivors’. This would be the case if C. trachomatis infection would have a ‘protective’ effect 
on early foetal death. However, this is unlikely [3, 4]. 
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In the South African study, all consecutive pregnant black women delivering at the Johannes-
burg Hospital were included in the study. The hospital serves a population covering all socio-
economic classes and races, but most obstetric patients are of lower socio-economic status. This 
may cause a selection towards a less healthy study population, which may influence some deter-
minants, outcome and frequency rates. On the other hand, women who required an emergency 
caesarean section after presentation to the obstetric ward, and women who had an (incomplete) 
abortion or who were fully dilated upon arrival in the hospital were not included in the study. 
Non-inclusion of these women and newborns with medical complications caused a selection 
towards a more healthy study population, which may influence some determinants and out-
comes, frequency rates, and the statistical power and generalizibility of the results. The preva-
lences found in this study should therefore be interpreted carefully considering the role of 
potential selection mechanisms. 
Information bias
In the Dutch Chlamydia study information about socio-economic and life style risk factors of 
women was collected using self-administered questionnaires. The use of such self-reported ques-
tionnaires may be better than in-person interviews to obtain information. However, younger 
women may lack self-confidence and subsequently underreport certain risk factors such as 
number of sexual partners, history of sexually transmitted infections, and the use of alcohol or 
drugs, which may cause an underestimation of effects. 
In the South African study information about socio-economic and life style risk factors of 
women was obtained through questionnaires administered by a nurse or docter. The choice for 
this method was made, because many women were illiterate and would not have been able to 
provide any or reliable information. To minimise underreporting of certain risk factors due to 
sense of shame, a female doctor or nurse did the questionnaires. However, underreporting of 
certain risk factors such as number of sexual partners or history of sexually transmitted infections 
may still have occurred and may cause an underestimation of effects. Most women spoke English. 
Otherwise the study was explained and the questionnaire obtained in their home language in 
order to prevent misunderstanding of questions and subsequent information bias due to linguistic 
problems. Privacy was always striven for. However, the questionnaires sometimes had to be done 
behind curtains in the presence of one up to three more women in the room. Again, this may 
have lead to underreporting of certain risk factors, which may subsequently have caused an 
underestimation of effects. 
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Confounding
One of the strengths of the Dutch Chlamydia study was that we were able to adjust for many 
potential confounders. However, regarding the number and proportion of early and late premature 
deliveries attributable to chlamydial infection some confounding as a result of co-infection by 
other genital pathogens could not be excluded. Furthermore, we did not correct for a previous 
history of termination of pregnancy in these women since this potential confounder was only 
recently established [5]. Finally, we had no information concerning the use of (macrolide) anti-
biotics during pregnancy. However, pregnant women are not routinely tested and treated for 
Ureaplasma urealyticum or Mycoplasma genitalium in the Netherlands; neither are women with 
premature rupture routinely treated with antibiotics. Regarding the use of (macrolide) antibiotics, 
it is most likely that such use would mitigate the detrimental effect of C. trachomatis infection 
on pregnancy outcome rather than exaggerate it. 
At the time of the study 96% of all deliveries in the South African study was by black women. 
To avoid confounding by white, coloured, or Indian women we focused on black women. In 
this study none of the women reported specific treatment for C. trachomatis infection in the 
three months prior to delivery, but chlamydia-negative women reported more often to have 
received antibiotics for other reasons than C. trachomatis infection that may have affected their 
chlamydial status. However, this difference was not statistically significant. A previous history of 
termination of pregnancy was also not corrected for in this study. Furthermore, regarding the 
number and proportion of respiratory tract infection in infants that may have been attributable 
to chlamydial infection confounding as a result of (co-) infection by other pathogens could not 
be excluded since we did not test for other respiratory pathogens.
Ethical considerations
One may question the ethics of the Dutch C. trachomatis study since we did not treat the 
women who were screened and found to be positive for C. trachomatis. Prospective studies 
regarding C. trachomatis infection in pregnant women and pregnancy outcome or perinatal 
transmission would face ethical barriers in countries that have national guidelines or directives 
advocating C. trachomatis screening and treatment in routine antenatal care and would be 
impossible to carry out [6, 7]. However, in most countries of the European Union, including 
the Netherlands, screening and treatment of chlamydial infection during pregnancy remains 
controversial and routine antenatal screening for C. trachomatis is currently not recommended 
[8]. One of the reasons for the Dutch health Council to advise against screening for C. trachomatis 
was the lack of local data [9]. A large prospective study like ours would also be very difficult to 
perform in the Netherlands because of financial recources and logistics. Therefore it was a 
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unique opportunity to participate in the Generation R study, which is a population-based, non-
interventional, prospective cohort study designed to identify early environmental and genetic 
determinants of growth, development and health of children, starting from foetal life until ado-
lescence [1, 10]. We were allowed to insert our C. trachomatis study into the Generation R Study 
provided that the study would remain non-interventional. Furthermore, the data would be 
provided anonymously in order to protect the privacy of the participants. Both the Generation 
R Study and the C. trachomatis study were approved by the Medical Ethical Committee for 
Research on Human Subjects of the Erasmus University Medical Centre, Rotterdam. Written 
informed consent was obtained from all participants. Since we had to conform to the overall 
study design of the Generation R study and had no access to names or addresses we were not 
able to treat chlamydia-positive women or refer them to regular health care providers. However, 
the study did not interfere with current Dutch standard medical practice. Standard medical 
practice does not include screening for C. trachomatis antenatally. Pregnant women are only 
tested and treated for C. trachomatis during their pregnancy if they are identified as being at risk 
of infection due to clinical signs or via contact tracing from a chlamydia-positive partner. 
In the chorioamnionitis study and respiratory study, samples were tested retrospectively with a 
few years in between specimen collection and testing, after which period we did not trace the 
women or infants.
In the retrospective part of the conjunctivitis study chlamydia-positive infants had been treated 
according to standard practice of the ophthalmologists at that time. In the prospective part of 
the conjunctivis study chlamydia-positive infants were treated with erythromycin and parents 
were referred to their general practitioner, the municipal public health service or a sexually 
transmitted disease clinic. 
In the South-African study, great effort was made to invite participants to return for follow-up. 
At inclusion, the women were given a copy of the consent form, an information letter about the 
study, and a follow-up appointment. Chlamydia-positive women and infants who did not 
return for their follow-up appointment were traced by phone calls, by letters in English, Zulu, 
Sotho and Xhosa, and by home visits. This way, a much higher follow-up rate was achieved than 
is generally known from African follow-up clinics [11]. At their follow-up visit, all infants born 
to chlamydia-positive women were treated with erythromycin. All chlamydia-positive women 
and their partners were also given a prescription for treatment with erythromycin. In addition 
they were counseled and referred to the sexually transmitted disease clinic for further follow-up 
of C. trachomatis or other infections for which they had tested positive.
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Conclusion
In this thesis we endeavoured to provide information for future studies, discussions and decision 
making about the need for routine C. trachomatis screening in pregnant women in the Netherlands. 
The presented studies were performed with the aim to answer specific research questions.
1: The assessment of the prevalence and risk factors during pregnancy
The prevalence of C. trachomatis infection was found to be 12.0% in South African pregnant 
women and 3.9% in Dutch pregnant women with the highest prevalence in young women: 
22.0% and 13.5%, respectively. In the Dutch study, age below 30 years, Antillean, Cape Verdean 
and Surinamese ethnicity, lower education, single marital status, multiple sexual partners in the 
year prior to the pregnancy and history of an STI were associated with C. trachomatis infection. 
Young age, single marital status and Antillean ethnic status appeared independent risk factors 
for infection. Determination of the typical symptoms for chlamydial urogenital infection was 
insufficiently sensitive and specific to estimate the risk. The willingness to participate in screening 
was good in both studies. We also had a high follow-up rate in both studies, although it must 
be stated that the follow-up rate in the South African study would have been much lower without 
the continuous effort to trace the women. 
2: The evaluation of complications of C. trachomatis infection during pregnancy
The extent of morbidity associated with C. trachomatis infection during pregnancy was demon-
strated for chorioamnionitis, adverse pregnancy outcome in terms of preterm delivery, and vertical 
transmission as evidenced by neonatal conjunctivitis and respiratory tract infection, and post-
partum PID. A population attributable risk of C. trachomatis infection for preterm delivery 
before 32 weeks and 35 weeks of gestation was found to be 15% and 7% in our population. A 
vertical transmission rate of 30% was found even in the presence of tetracycline eye prophylaxis. 
3: The assessment of the feasibility of screening
Screening pregnant women for C. trachomatis infection by means of nucleic acid amplification 
techniques on pooled urine specimens was shown to have a good sensitivity and to decrease the 
costs for a screening program. An estimation of the cost-effectiveness of a screening program in 
pregnant women, while using the data of our study and international data in a pharmaco-eco-
nomic decision analysis model, showed that such a screening program would be highly cost-
effective in the Netherlands. 
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Previously we stated that the success of a large-scale screening program depends on proper selection 
of the target population, non-invasive sampling, high-quality testing, the availability of effective 
treatment, and the cost-effectiveness of screening. We addressed these items and effective treatment 
is readily available in the Netherlands. Based on this thesis we can conclude that C. trachomatis 
infections in pregnant women and infants are highly underdiagnosed and, hence, not treated, 
and that that there is an association between C. trachomatis infection during pregnancy and 
early premature delivery. But, since we did not adjust for potential confounding as a result of 
co-infection by other genital pathogens and a previous history of termination of pregnancy, we 
did not prove a causal relation beween C. trachomatis infection during pregnancy and premature 
delivery and that treatment of pregnant women for C. trachomatis infection will prevent premature 
delivery. However, considering the high rate of C. trachomatis detection in women with premature 
deliveries less than 32 and 35 weeks of gestational age in the outcome study as well as the high 
rate of C. trachomatis detection in the placentas of women with preterm delivery before 32 
weeks in the placenta study in association with histopathological signs of inflammation, the fact 
that it is biologically plausible that C. trachomatis is involved in preterm delivery, and other 
studies have shown a decrease in preterm deliveries with antibiotic treatment that is effective 
against C. trachomatis, we think it is very likely that the relation between C. trachomatis infec-
tion and premature delivery is causal. We think that all conditions are met for pregnant women 
to be a good target population for C. trachomatis screening in the Netherlands, but while imple-
menting a screening program the latter considerations should still be explored.
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Recommendations
• C. trachomatis infection in pregnant women must be considered an important public health 
problem in the Netherlands. 
• We strongly recommend further study into the implementation of an antenatal C. trachomatis 
screening program for pregnant women in the Netherlands with emphasis on the effects of 
treatment of chlamydia-positive women (and their partners) on pregnancy outcomes. 
• In the absence of a screening program we urge clinicians -general practitioners, midwives, 
obstetricians, gynaecologists, neonatologists, paediatricians and ophthalmologists- to have a 
higher index of suspicion for maternal and neonatal C. trachomatis infection. 
• Women with (imminent) premature delivery should be tested for C. trachomatis.
• Infants less than three months of age with signs of conjunctivitis that persist for more than 72 
hours should have a microbiological evaluation that includes C. trachomatis diagnostics. 
• Likewise, infants less than six months of age with signs of respiratory tract infection that 
require microbiological evaluation should be tested for C. trachomatis. 
• Chlamydia-positive infants should be treated appropriately, which implies the systemic application 
of appropriate antibiotics.
• Last but not least, we emphasize the importance of primary prevention through continuous 
education about antenatal care, sexual health, and relationship education as well as awareness 
campaigns and promotion of condom use both in the Netherlands and in South Africa.
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Future research and perspectives
We did a literature search for evidence of an evaluation of the cost-effectiveness of an already 
implemented screening program for C. trachomatis among pregnant women, but found no 
reports. We advocate an implementation study in the Netherlands with respect to the cost-
effectiveness of screening for C. trachomatis infection during pregnancy. We recommend a stepwise 
implementation of such antenatal screening program, suggesting a start in the major cities and, 
if appearing cost-effective, to be extended to the rest of the Netherlands with careful evaluation 
at regular intervals. 
Chlamydia trachomatis screening for pregnant women in the context of routine antenatal care in the 
Netherlands
Most pregnant women in the Netherlands seek antenatal care in early pregnancy spontaneously. 
This affords a propitious opportunity for relatively uniform and efficient C. trachomatis screening 
since inclusion would not require much extra organisational effort in the already existing struc-
ture of routine antenatal care that is being delivered by midwives and general practitioners 
(75%-80%), and by gynaecologists (20%) [1]. Women are routinely screened for infections 
such as HIV, syphilis, Hepatitis B and rubella [2]. Conveniently, screening for C. trachomatis 
could be included at this time for which the logistics already exist. Likewise, the notification of 
test results and provision of treatment could be included in the existing logistics. Retesting of 
chlamydia-positive women after they received treatment would require some extra effort, but 
could be included at a regular follow-up visit. Annually, around 200.000 women are pregnant 
in the Netherlands. Extrapolation of our figures would mean that on a yearly basis 7.800 preg-
nant women may test positive for C. trachomatis, who are at increased risk for developing PID, 
chronic pelvic pain, tubal infertility, and ectopic pregnancies as well as, assumed, for preterm 
delivery before 35 weeks of gestation and all subsequent complications for their newborns such 
as respiratory distress syndrome, intraventricular haemorrhage, periventricular leucomalacia, 
persistent ductus arteriosus, necrotizing enterocolitis, sepsis, and others. Transmission will put 
the newborns at risk of conjunctival or respiratory chlamydial infection and the partners for 
symptomatic urethritis and epididymitis. These complications together with the resulting soci-
etal costs and loss of quality of life may be prevented by incorporation of C. trachomatis screen-
ing in the existing routine antenatal care.
Chlamydia trachomatis screening for pregnant women in the context of routine antenatal care in 
South Africa
We had insufficient data to evaluate the cost-effectiveness of an antenatal screening program for 
C. trachomatis in South Africa. Theoretically, such screening program would be even more 
rewarding in South Africa and in other developing countries. However, logistically a screening 
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program would be much more difficult to realise in South Africa because of the lack of financial 
resources, the fact that not all pregnant women seek antenatal care – especially the younger 
ones-, late antenatal clinic booking, the use of different antenatal clinics during a single preg-
nancy, and difficulties in follow-up. At present, routine screening for HIV and syphilis is offered 
at most South African antenatal clinics, and it may be suggested to include rapid onsite testing 
for C. trachomatis at the same time. However, recent studies in developing countries have 
reported rather poor sensitivities of rapid C. trachomatis tests and many positive women would 
still be missed despite a great effort and costs [3, 4]. Another approach might be to offer on site 
single dose treatment with azithromycin to all pregnant women. However, many women would 
be treated without being infected, costs would be unnecessarily high, and emergence of antimi-
crobial resistance may aggrevate rather than help eradicate C. trachomatis infections in this sus-
ceptible group of women. We showed that a syndromic approach for C. trachomatis infection 
during pregnancy was not useful, but that demographic and socio-economic characteristics 
could be helpful to treat sexually transmitted infections in this population. Therefore, we pro-
pose on site single dose treatment with azithromycin for pregnant women at increased risk for 
infection in South Africa, with additional provision of single dose treatment for partners. 
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Samenvatting
De doelstelling van de in dit proefschrift beschreven studies was om het gezondheidsgerelateerde 
belang van Chlamydia trachomatis infecties tijdens de zwangerschap voor vrouwen en pasge-
borenen te evalueren om zodoende een bijdrage te leveren aan een toekomstige besluitvorming 
over C. trachomatis screening tijdens de zwangerschap.
In hoofdstuk 1 presenteren we de onderzoeksvragen en de studies die in dit proefschrift beschreven 
zijn. De belangrijkste vragen waren:
1) Wat is de prevalentie van C. trachomatis infectie tijdens de zwangerschap?
2) Wat zijn risicofactoren voor C. trachomatis infectie tijdens de zwangerschap?
3) Is C. trachomatis infectie tijdens de zwangerschap geassocieerd met een verhoogd risico voor 
ongunstige zwangerschapsuitkomsten zoals doodgeboorte, vroeggeboorte en laag geboortegewicht?
4) Wat is het risico van C. trachomatis transmissie van vrouwen naar pasgeborenen?
5) Kunnen we bewijs vinden van verticale transmissie door het aantonen van C. trachomatis bij 
zuigelingen met conjunctivitis en luchtweginfecties?
6) Is samenvoegen van urine monsters een goede methode om de kosten-effektiviteit van testen 
voor C. trachomatis tijdens de zwangerschap te verbeteren?
7) Is routinematige screening voor C. trachomatis een kosten-effectieve benadering tijdens de 
zwangerschap?
In hoofdstuk 2 hebben we een literatuur overzicht gegeven over de rol en het belang van C. trachomatis 
infectie bij zwangere vrouwen en zuigelingen. Chlamydia infectie wordt gekarakteriseerd door invasie 
van gastheercellen, intracellulaire reproductie en ontstekingsprocessen, welke kunnen persisteren en 
chronisch inflammatoire en fibrotische veranderingen kunnen veroorzaken. C. trachomatis infectie 
verloopt echter meestal asymptomatisch. Door het latente, sluimerende en mogelijk chronische 
karakter van de infectie kan het beloop asymptomatisch en zelfherstellend zijn, maar kan het ook 
leiden tot ernstige complicaties zoals ‘pelvic inflammatory disease’ (PID), infertiliteit en chronische 
buikpijn. Tevens kan C. trachomatis infectie tijdens de zwangerschap leiden tot een ongunstige 
zwangerschapsuitkomst en ziekte bij de pasgeborene. Verschillende test methoden kunnen worden 
gebruikt om (latente) C. trachomatis infecties aan te tonen, waarvan de NAATs momenteel de 
gouden standaard zijn. NAATs hebben een hoge sensitiviteit en kunnen gebruikt worden met de 
meeste materialen waaronder ook urine en vaginale uitstrijkjes. De mogelijkheden voor antibi-
otische behandeling van infecties door C. trachomatis worden besproken. Eenmalige behandeling 
met azithromycine wordt aanbevolen in verband met de goede compliantie, het succes van de 
behandeling en de geringe bijwerkingen. Zwangere vrouwen worden voorgesteld als een belangrijke 
doelgroep screening op C. trachomatis. Prenatale C. trachomatis screening wordt daarbij beschouwd 
aan de hand van de Wilson en Jung criteria, waarvan sommige nog niet uitgezocht zijn in Nederland.
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In hoofstuk 3 rapporteren we de prevalentie van sexueel overdraagbare infecties in 766 zwangere 
vrouwen in stedelijk Zuid-Afrika op het moment dat zij kwamen bevallen, en de associaties van 
sexueel overdraagbare infecties met demografische en socio-economische karakteristieken en 
klinische symptomen. In totaal hadden 48% van de vrouwen een of meer sexueel overdraagbare 
infecties tijdens hun zwangerschap, waarvan 18% geinfecteerd was met HIV, 23% met 
Treponema pallidum, 12% met C. trachomatis en 9% Neisseria gonorrhoeae. Voorspellende factoren 
voor infectie waren het ontbreken van prenatale zorg (OR 1.7, 95% CI 1.0-3.0), multigra-
viditeit (OR 2.2, 95% CI 1.5-3.3), en alleenstaand (OR 1.8, 95% CI 1.3-2.5) en niet werkzaam 
zijn (OR 1.4, 95% CI 1.0-1.9). HIV seropositiviteit was significant hoger onder vrouwen 
jonger dan 30 jaar (21%) dan onder vrouwen van 30 jaar en ouder (12%). Voor Syphilis was 
een significante trend waarneembaar met de laagste prevalentie onder de jongste vrouwen (14%) 
en de hoogste in de oudere groep (30%). Voor C. trachomatis infectie was een trend waarneembaar 
met de hoogste prevalentie in de jonge (22%) en de laagste in de oudere vrouwen (5%). We 
concluderen dat bijna de helft van de zwangere vrouwen één of meerdere sexueel overdraagbare 
pathogenen droeg, en dat chlamydia en gonorrhoea niet gediagnosticeerd en behandeld werden 
tijdens de zwangerschap. Tevens dat infectie niet geassocieerd was met symptomen, maar met 
verschillen in demografische en socio-economische karakteristieken. 
In hoofdstuk 4 tonen we de resultaten van een studie over de overdracht van C. trachomatis 
infectie van 77 zwangere Zuid-Afrikaanse vrouwen (beschreven in hoofdstuk3) naar hun pasge-
borenen in een setting waar tetracycline oog profylaxe routinematig wordt gegeven ter preventie 
van neonatale conjunctivitis. Tevens evalueren we de postnatale gevolgen van C. trachomatis 
dragerschap tijdens de zwangerschap voor moeder en kind. LCR en/of kweek voor C. trachomatis 
was positief in 23 kinderen resulterend in een transmissiepercentage van 30%. Hiervan hadden 
19 (83%) kinderen een positieve nasopharynx test en 9 (39%) een positieve conjunctiva test; 
vijf (22%) kinderen testten positief voor beiden. Alle conjunctiva kweken waren negatief. 
Nasopharynx materiaal was positief in 13/23 (57%) zuigelingen met LCR en in 9/20 (45%) 
zuigelingen met kweek. Zuigelingen van chlamydia-positieve vrouwen hadden significant vaker 
nasale klachten dan die van chlamydia-negatieve vrouwen (32/65 (49%) versus 15/65 (23%)), 
hetgeen ook bij lichamelijk onderzoek werd gevonden (37 (57%) versus 7 (11%)), als ook 
hogere ademhalingsfrekwenties en intercostaal intrekken. Postnatale urogenitale klachten en 
symptomen werden gevonden bij 34 (52%) en 51 (78%) van de chlamydia-positieve vrouwen, 
waarvan 12 vrouwen (18%) PID ontwikkelden. We concluderen dat C. trachomatis infectie 
tijdens de zwangerschap een risico vormt voor de pasgeborene en dat locale tetracycline profy-
laxe onvoldoende is om infectie bij de zuigeling te voorkomen. Tevens stellen we dat het vinden 
van postnatale maternale urogenitale klachten en symptomen in combinatie met klachten en 
symptomen van de zuigeling, de arts bedachtzaam moeten maken op de mogelijkheid van neo-
natale en maternale complicaties van C. trachomatis infectie. 
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In hoofdstuk 5 rapporteren we de prevalentie en risicofactoren van C. trachomatis infectie 
tijdens de zwangerschap in 4,055 zwangere Nederlandse vrouwen die naar een van de ver-
loskundige praktijken of prenatale klinieken gingen die meededen aan de Generation R studie 
in Rotterdam, Nederland, en het gevolg van C. trachomatis infectie tijdens de zwangerschap 
voor premature partus en geboortegewicht. C. trachomatis werd gevonden bij 157 (4%) van de 
vrouwen. De prevalentie was omgekeerd evenredig met leeftijd met een prevalentie van 14% in 
vrouwen van 20 jaar en jonger en 2% in vrouwen ouder dan 30 jaar. De prevalentie was het 
hoogst onder Antilliaanse (16%), Kaap Verdiaanse (11%) of Surinaamse (9%) vrouwen, alleen-
staande vrouwen (12%), en vrouwen met een laag opleidingsniveau (6%), primigraviditeit 
(5%), meerdere sexuele partners in het afgelopen jaar (8%) of een sexueel overdraagbare infectie 
in de voorgeschiedenis (6%). In de ongeadjusteerde analyse waren deze risicofactoren, met uit-
zondering van graviditeit, significant geassocieerd met C. trachomatis infectie. In de geadjusteerde 
analyse bleven leeftijd jonger dan 21 jaar (OR 1.8, 95% CI 1.2-2.6), Antilliaanse etniciteit (OR 
2.3, 95% CI  1.4-3.7) en alleenstaand zijn (OR 1.6, 95% CI 1.3-2.0) risicofactoren voor infectie 
met C. trachomatis; andere maternale factoren waren niet onafhankelijk geassocieerd. In het 
tweede deel van het onderzoek werden de zwangerschapsuitkomsten (zwangerschapsduur en 
geboortegewicht) van 3,913 pasgeborenen geanalyseerd. We vonden dat 18% (95% CI 0.7-
36.7) van de vrouwen die voor een zwangerschapsduur van 32 weken en 11% (95% CI 3.1-
18.8) van de vrouwen die voor 35 weken bevielen positief waren voor C. trachomatis. Na adjusteren 
voor mogelijke confounders was C. trachomatis infectie geassocieerd met vroeggeboorte vóór 32 
weken (OR 4.4, 95% CI 1.3-15.2) en 35 weken (OR 2.7, 95% CI 1.1-6.5) zwangerschapsduur, 
maar niet met laag geboortegewicht. Van alle partussen voor een zwangerschapsduur van 32 
weken en 35 weken waren 15% (95% CI 4.5-39.5) en 7% (95% CI 2.5-20.1) toe te schrijven 
aan C. trachomatis infectie. We concluderen dat C. trachomatis significant bijdraagt aan het 
optreden van vroege prematuriteit, hetgeen als een algemeen gezondheidsprobleem beschouwd 
zou moeten worden, vooral in jonge vrouwen en andere vrouwen met verhoogd risico op C. 
trachomatis infectie. 
In hoofdstuk 6 bestuderen we de relatie tussen de aanwezigheid van C. trachomatis en tekenen 
van placentaire ontsteking in de placentas van 304 vrouwen die vóór een zwangerschapsduur 
van 32 weken bevielen in het Erasmus MC-Sophia, Rotterdam. C. trachomatis werd in 76 
(25%) placentas aangetoond. Histologische tekenen van placentaire ontsteking werden in 123 
(40%) placentas gevonden: in 41/76 (54%) placentas met C. trachomatis versus 82/228 (36%) 
placentas zonder C. trachomatis infectie (OR 2.1, 95% CI 1.2-3.5). C. trachomatis werd signifi-
cant vaker waargenomen met toenemende progressie (P=0.003) en intensiteit (P=0.002) van 
placentaire ontsteking aan maternale zijde, maar niet aan foetale zijde. We concluderen dat C. 
trachomatis vaak gevonden werd in de placentas van vrouwen met vroege prematuriteit, en dat 
C. trachomatis infectie geassocieerd was met histopathologische tekenen van placentaire ontsteking. 
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In hoofdstuk 7 hebben we onderzocht of C. trachomatis een oorzaak was van neonatale conjunc-
tivitis in zuigelingen onder de drie maanden die gepresenteerd werden in het Erasmus MC-
Sophia en Rotterdam Oogziekenhuis, Rotterdam. Tevens evalueren we de klinische presentatie 
en voorgeschreven behandeling voor C. trachomatis conjunctivitis vergeleken met conjunctivitis 
ten gevolge van andere infecties. C. trachomatis werd vastgesteld in 27/42 (64%) retrospectief 
bestudeerde zuigelingen en 14/23 (61%) prospectief bestudeerde zuigelingen. Mucopurulente 
afscheiding werd gezien in 35/37 (95%) zuigelingen, zwelling van de ogen in 27/37 (73%), en 
erytheem van de conjunctivae in 24/37 (65%) zuigelingen. Respiratoire klachten waren aan-
wezig in 14/37 (38%) en voedingsproblemen in vijf (14%) van de 37 zuigelingen. Vóór het 
stellen van de microbiologische diagnose, schreven huisartsen anti-chlamydia antibiotica voor 
aan vijf (12%) en systemische antibiotica aan vier (10%) van de 41 zuigelingen die positief 
waren voor C. trachomatis. Oogartsen schreven anti-chlamydia antibiotica voor aan 21 (51%) 
en systemische antibiotica aan zeven (17%) van de 41 zuigelingen. We concluderen dat C. tra-
chomatis de belangrijkste verwekker was van bacteriele conjunctivitis in deze populatie en dat 
klinisch onderscheid van andere pathogenen niet mogelijk was. Veel zuigelingen die positief 
waren voor C. trachomatis kregen niet de juiste behandeling met antibiotica. 
In hoofdstuk 8 bestuderen we de aanwezigheid van C. trachomatis in zuigelingen jonger dan zes 
maanden die gedurende een jaar met respiratoire klachten gepresenteerd werden aan het Erasmus 
MC-Sophia. Respiratoire materialen, vooral nasopharynx watten, werden getest voor C. tracho-
matis, respiratoire virussen en Mycoplasma pneumoniae met PCR, virale celkweken en directe 
immunofluorescentie. C. trachomatis respiratoire infectie werd gevonden in 10/148 (7%) geteste 
zuigelingen. Acht (80%) van de 10 C. trachomatis infecties werden gezien bij zuigelingen onder 
de leeftijd van drie maanden. Er werden door de betrokken artsen geen testen voor C. tracho-
matis aangevraagd, maar het was het tweede meest gevonden respiratoire pathogeen na hRSV 
dat gevonden werd in 41 (28%) zuigelingen. We concluderen dat perinatale respiratoire infecties 
met C. trachomatis relatief vaak voorkomen en ondergediagnosticeerd worden in deze groep 
zuigelingen jonger dan zes maanden.
In hoofdstuk 9 hebben we diverse test methoden voor C. trachomatis onderzocht in verband 
met de kosten-effektiviteit van screening tijdens de zwangerschap. Van 750 asymptomatische 
zwangeren vrouwen in Rotterdam werden urines verzameld. Aanvankelijk onderzochten we de 
kwaliteit van drie verschillende DNA isolatie methoden met 350 van deze urines en 70 pools 
van vijf urines van dezelfde subset. De gewone Cobas Amplicor test werd vergeleken met de 
Cobas Amplicor in combinatie met voorafgaande DNA isolatie met de MagNA Pure large-
volume kit en de MagNA Pure bacterial DNA isolation kit. We vonden dat 15, 14 en 27 urines 
positief testten, hetgeen resulteerde in een sensitiviteit van 52%, 48% en 93%, respectievelijk. 
Vervolgens, met gebruik van alle 750 urines, werd de kwaliteit van de Cobas Amplicor voor 
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individuele testen (32 positieve testen) vergeleken met gepoolde testen met de standaard Cobas 
Amplicor procedure (20 positieve testen) en met gepoolde testen met de Cobas Amplicor in 
combinatie met de MagNA Pure bacterial DNA isolation kit (44 positive testen), resulterend in 
een sensitiviteit van 65%, 42% en 92% respectievelijk (P<0.001). De prevalentie van C. tracho-
matis was 6% in deze populatie. Tevens toonden we aan dat met pooling van urines de kosten 
van de gecombineerde MagNA Pure Bacterial DNA Isolation Kit en Cobas Amplicor methode 
slechts 56% waren van de kosten van de standaard Cobas Amplicor test voor individuele urines. 
De kosten per positief vastgestelde casus waren in de gecombineerde methode slechts 39% van 
de standaard kosten. We concluderen dat gepooled testen voor C. trachomatis infectie tijdens de 
zwangerschap bruikbaar is voor grootschalig onderzoek door gebruik te maken van de Cobas 
Amplicor test in combinatie met de MagNA Pure Bacterial DNA Isolation Kit. Deze combinatie 
verbeterde de sensitiviteit significant en verlaagde de kosten. 
In hoofdstuk 10 hebben we een kosten-effektiviteits analyse gemaakt van C. trachomatis screenen 
onder zwangere vrouwen in Nederland op basis van een statisch model. We ontwikkelden een 
pharmaco-economisch beslismodel, waarin mogelijke gezondheidsuitkomsten van C. trachoma-
tis infectie tijdens de zwangerschap opgenomen werden zoals PID, infertiliteit and chronische 
buikpijn als ook ectopische zwangerschap, premature partus en neonatale ziekte, en ziekte van 
de partner. We begrootten de Kosten-effectiviteit vanuit een maatschappelijk perspectief waarbij 
we de gevonden prevalentie uit hoofdstuk 5 gebruikten. We berekenden de kosten die voorkomen 
zouden kunnen worden door de gezondheidsuitkomsten te koppelen aan gezondheidskosten en 
productiviteitsverlies. Kosten-efektiviteit werd geschat in base-case-, sensitiviteits- en scenario 
analyses. In de base-case analyse werden de kosten om 1,000 zwangere vrouwen met C. tracho-
matis te diagnosticeren op e378,300 geschat. Kosten-besparingen betreffende complicaties 
werden geschat op e814,400, hetgeen resulteerde in omvangrijke netto kostenbesparingen. Een 
sensitiviteits analyse liet zien dat netto kostenbesparingen bleven bestaan bij een test prijs tot 
e28, met een preventie van complicaties van slechts 25% en een risico voor PID van slechts 
0,4%. Een scenario analyse toonde zelfs meer kostenbesparingen met gerichte screening voor 
vrouwen onder 30 jaar en primigravida. We concluderen dat C. trachomatis screening van zwangere 
vrouwen in Nederland zeer kosten-effectief is en in de meeste gevallen zelfs kostenbesparend is.
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